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ABSTRACT 
 
The major challenge in cancer therapy is to selectively destroy cancer cells in the 
presence of healthy tissue. One viable strategy relies on targeting the function of an enzyme 
which is overexpressed in cancer cells relative to healthy cells. NQO1 is a cytoprotective enzyme 
which is overexpressed in most solid tumors and which detoxifies quinone-containing substrates. 
However, a few quinones are rendered more toxic by the action of NQO1. We discovered that 
deoxynyboquinone (DNQ) is a potent cytotoxin through a high-throughput screen, and we 
designed a concise and flexible synthesis of this molecule which enabled study of its mode of 
action. We found that DNQ generates toxic levels of reactive oxygen species (ROS) selectively 
in cancer cells through a bioreduction/oxidation process mediated exclusively by NQO1. 
Excitingly, DNQ is effective at reducing the size of tumors in a mouse model of cancer. 
Unfortunately, DNQ must be delivered at concentrations near the maximum tolerated dose in 
mice to achieve maximal efficacy. In addition, the poor aqueous solubility of DNQ necessitated 
the use of a formulation containing a high concentration of 2-hydroxypropyl-β-cyclodextrin 
(HPβCD) which would complicate treatment in human patients. Thus, we set out to discover 
derivatives of DNQ which are more soluble than, and equipotent to, the parent compound.  
We synthesized and evaluated a library of DNQ derivatives and determined the structure-
activity and structure-solubility relationships derived therefrom. We showed that a subset of 
these derivatives are equipotent to DNQ and are up to 4-fold more soluble in water, 250-fold 
more soluble in organic solvents, and 9-fold more soluble in an aqueous solution of HPβCD. 
Furthermore, we showed that the most promising of these derivatives are tolerated by mice at 
doses up to 4-fold higher than DNQ. We predict that derivatives of DNQ will exhibit a broad 
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therapeutic window in murine tumor models of cancer and will progress rapidly toward human 
clinical trials. 
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Chapter 1. Elevated Expression of NQO1 as a Target for the Personalized Treatment of 
Cancer 
 
1.1 Personalized medicine approach to cancer treatment 
The fundamental challenge in the treatment of cancer is to discover compounds which are 
toxic to cancer cells but not healthy cells. The most salient feature of cancer is rapid and 
unrestricted cell division. The vast majority of traditional chemotherapeutics target rapidly 
dividing cells by disrupting the cell cycle, causing cell death.1 Because some healthy tissues 
require cell division as part of their function, these antiproliferative cytotoxins also kill healthy 
cells, resulting in severe, dose-limiting side effects. New drugs and new cellular targets must be 
identified that better differentiate healthy and cancerous cells. These targets may be present in 
only a small fraction of cancer patients, making this a personalized strategy to treat cancer. 
There are at least three types of personalized anticancer targets: translocations, mutations, 
and protein dysregulations. Translocations that result in oncoproteins unique to cancers are 
perhaps the best type of target, but are extremely rare. In the celebrated example of targeting a 
translocation, Gleevec inhibits the fusion protein BCR-ABL, transforming CML from a fatal 
disease into a manageable condition.2,3 Mutations of enzymes that regulate growth pathways 
have been identified as crucial to the progression of some cancers and excellent targets for 
personalized therapy. Recently PLX4032, a small molecule that selectively inhibits the V600E 
mutant of BRAF kinase was hailed as a breakthrough in the treatment of one of the most 
refractory cancer types, malignant melanoma.4,5 
In the above examples, unique or mutated proteins drive cancer growth in a process 
termed oncogene addiction.6,7 Inhibiting such proteins directly prevents the growth of tumors. 
Exploiting the third personalized target, protein dysregulation, is much more subtle. While 
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dysregulated expression of proteins in cancers is extremely common, cancers have not been 
shown to be addicted to these protein-expression alterations. Furthermore, whereas some 
overexpressed proteins, such as HER2/neu,7,8 are involved in promoting growth signaling, altered 
expression of other proteins does not seem to convey a specific advantage to tumors. However, 
the function of these proteins can be exploited to provide drugs with selectivity for cancer or 
healthy cells. In this work we describe a small molecule, deoxynyboquinone (DNQ, 1-1, Figure 
1.1), the cytotoxicity of which depends predominately on the elevated expression of the enzyme 
NQO1, which is overexpressed in the majority of solid tumors.    
 
 
Figure 1.1. The structure of DNQ. 
 
1.2. NQO1 
 NAD(P)H quinone oxidoreductase (NQO1, DT diaphorase) is an FAD-dependent 2-
electron reductase whose primary function is to protect the cell from cytotoxins, especially 
quinones.9-15 It is a member of the Phase II detoxifying enzymes, the expression of which is 
regulated by NRF-2 and the antioxidant response element (ARE) in response to electrophilic or 
oxidative stress.16-18 Although generally identified as a cytosolic protein, NQO1 has been 
identified in subcellular compartments such as the mitochonia and nucleus.15 
 Quinone-containing molecules are frequently cytotoxic and harm cells through two 
mechanisms.18-23 Many quinones are conjugate addition acceptors and readily alkylate 
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nucleophilic species such as DNA and cysteine residues. Quinones are also substrates for 1-
electron reductases, such as cytochrome P450s, cytochrome b5, xanthine oxidase, and 
glutathione reductase (Figure 1.2). Reduction of quinones by these enzymes generates a highly 
reactive semiquinone that can damage biomolecules directly, or can be oxidized by dissolved 
oxygen resulting in the formation of an equivalent of superoxide anion radical and the parent 
quinone. Thus, 1-electron reduction of quinones can catalytically create reactive oxygen species 
(ROS) that damage the cell. By reducing quinones in a 2-electron process, NQO1 bypasses the 
toxic semiquinone and forms hydroquinones, which are commonly unreactive toward oxygen. 
Hydroquinones are then conjugated with molecules such as glutathione, glucose, or sulfate, and 
excreted by the cell. However, as shown in Figure 1.2, some hydroquinone-containing molecules 
are unstable and react with oxygen in two 1-electron oxidations back to the quinone, generating 
ROS.24 The relative stability of hydroquinones towards air oxidation cannot be predicted based 
on molecular structure and it does not correlate with reduction potential.14,25 
 Between 4-20% of the human population express inactive variants of NQO1.26 The most 
common of these, referred to as the NQO1*2 polymorph, arises from a C609T substitution 
resulting in serine replacing proline at codon 187.27 This substitution is thought to result in a 
conformation of NQO1 that binds NAD poorly and is more susceptible to enzymatic 
degradation. Lack of functional NQO1 has been shown to correlate with increased susceptibility 
to cancer in mice28 and humans,29-31 as well as poor prognosis for breast cancer patients.32 
NQO1 is the most important, but not the only obligate 2-electron reductase. NQO2 is a 
cytosolic quinone oxidoreductase that is 43 amino acids shorter than NQO1, but otherwise very 
similar (49% identity).33-35 Although both enzymes catalyze the 2-electron reduction of quinones 
in vitro, the role and significance of NQO2 in vivo is unclear. Instead of utilizing NAD(P)H, 
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NQO2 requires nicotinamide riboside (NRH) as an electron source.36 NRH has been referred to 
as nonbiogenic,37 although its actual concentrations in vivo appear to be unknown. It is, perhaps, 
the low availability of NRH which reduces the utility of NQO2 as a reductase in vivo relative to 
NQO1.  
  
 
Figure 1.2. Enzymatic reduction and subsequent reaction of quinone-containing molecules. 
 
1.3. Prodrugs that are activated by NQO1 
 NQO1 has attracted much attention as a potential target for the treatment of cancer 
because it has been shown to be frequently expressed at much higher levels in tumors relative to 
adjacent healthy tissue,15,38-48 particularly in the case of lung cancer.43-48 In addition, NQO1 
activity appears to increase during tumor progression.42 Other than for lung, breast, and colon 
tissues, relatively little data on the levels of NQO1 in normal tissues has been reported. Whereas 
low levels of NQO1 are reported in bone marrow49 and liver cells39,50 – two tissues frequently 
NQO1
cytochrome
P450s
Stable
Unstable
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damaged by chemotherapeutics – high levels of NQO1 have been noted in stomach and kidney 
cells.43,50 
The prospect of discovering toxins that are activated, instead of deactivated, by NQO1 
has attracted researchers for many years.51 Such molecules would turn this normally 
cytoprotective enzyme into a liability for the cell. Two general classes of molecules have been 
discovered that fit this description: DNA alkylators whose electrophilicity is increased after 
bioreduction, and redox cycling molecules that generate ROS catalytically after reduction (Chart 
1.1).15,20,52 These classes of molecules are composed almost exclusively of quinone-containing 
compounds, and we will limit our discussion to these.  
To qualify as a bioreductively-activated DNA alkylator, and to properly exploit the 
elevated expression of NQO1 in tumors, a molecule must possess three fundamental qualities: 1) 
Its ability to alkylate DNA must be increased many fold after bioreduction. 2) It must be 
selectively bioreduced by NQO1, to the exclusion of other reductases. 3) The hydroquinone 
species must not be easily oxidized by dissolved oxygen, which would destroy the alkylating 
species before it diffuses from NQO1 to the DNA. 
There is a caveat to the 3rd point relating to tumor hypoxia.53,54 Because the centers of 
solid tumors are poorly vascularized, they are frequently oxygen-starved, containing only 5-10% 
the amount of oxygen of a normal cell. The hypoxic cores of tumors are difficult to target with 
standard chemo- and radiotherapy, and much effort has been expended to discover drugs that are 
selectively toxic to hypoxic over oxic cells. If an NQO1-dependent bioreductively-activated 
alkylator can penetrate the hypoxic cells at the center of a tumor, and if the reduced quinone 
species is oxidized in well-oxygenated cells but not in hypoxic cells, and if the ROS produced in 
oxic cells during reoxidation is much less toxic than the reduced DNA-alkylating species that 
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persists in hypoxic cells, then the compound may be selectively toxic to hypoxic tumor cells over 
oxic cells in vivo.55 
As for alkylators described above, effective NQO1-dependent, ROS-producing 
cytotoxins must: 1) be relatively nontoxic in their quinone form, and 2) be selectively reduced by 
NQO1 over other reductases. Unlike the alkylators, the hydroquinone form of ROS-producing 
compounds must be highly reactive towards oxidation by dissolved oxygen, which would both 
produce ROS and regenerate the quinone, completing the catalytic cycle (Figure 1.2). 
To validate or invalidate NQO1 as an anticancer target in humans, compounds meeting 
the above criteria must also display good drug-like pharmacokinetic properties (eg. chemical 
stability in vivo, bioavailability, circulation half-life, tissue penetration, etc.) Below, the most 
studied alkylators and ROS generators that have been shown to be dependent on NQO1 for their 
function are examined. The conclusion is that none of these compounds possess all of the ideal 
qualities of an NQO1-dependent cytotoxin, suffering either from poor selectivity for NQO1 or 
insufficient stability in vivo. Thus, we consider that the clinical success or failure of these 
compounds has neither validated nor invalidated NQO1 as a target for cancer therapy. 
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Chart 1.1. Antitumor quinones that have NQO1-mediated bioreduction as part of their cytotoxic 
mechanism. 
 
1.3.1. Mitomycin C 
Mitomycin C (MMC) is the prototypical bioreductive drug and the only one clinically 
approved for the treatment of cancer.19,20,51,56-58 It is an antibiotic natural product isolated by 
Wakaki and co workers in 1958 from Streptomyces caespitosus.59 Its utility as an anticancer 
compound was quickly recognized, as it was used clinically in Japan just a few years later.58 
Despite serious side effects, including unpredictable and cumulative bone marrow suppression, 
and gastrointestinal toxicity, it continues to be used as a front-line therapy for several solid 
tumors.57-59 As MMC has been thoroughly reviewed numerous times19,20,51,56-58 only a brief 
overview is presented here.  
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It is generally accepted that bioreduction of MMC initiates a cascade of structural 
modifications resulting in the formation of highly electrophilic species that alkylate or crosslink 
biomolecules such as DNA (Scheme 1.1).55 Experiments in vitro have demonstrated that MMC 
is a substrate for NQO1, albeit a poor one, and that the resulting hydroquinone alkylates 
DNA.57,60 Numerous attempts to elucidate the role of NQO1 in the cytotoxic mechanism of 
MMC in cell culture have produced widely conflicting results.42,61-67 In fact, cytochrome P450 
has been identified as the most relevant reductase for MMC activation in cell culture.51 
Furthermore, MMC was not found to preferentially kill tumors expressing NQO1 in a mouse 
model of cancer relative to tumors derived from an isogenic cell line lacking active NQO1.68 
Because MMC can be activated by a variety of reductases, and because its reliance on NQO1-
activity appears minimal, its clinical relevance does not reflect on the viability of an NQO1-
based anticancer strategy. 
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Scheme 1.1. DNA crosslinking by Mitomycin C after bioreduction by a 1- or 2-electron (shown) 
process. Adapted from Colucci et al.69 
 
1.3.2 EO9  
As a result of the success of MMC, its mechanism and structure have been the inspiration 
for a host of synthetic analogs. The most successful of these is EO9 (EOquin).19,51,55,70-72 It was 
synthesized in 1984 as part of a study of MMC-like bioreducible alkylators. In vitro experiments 
revealed that EO9 could alkylate DNA crosslinking after reduction by NQO1, P450, or xanthine 
oxidase (Scheme 1.2).73-76 EO9 has been shown to be a 10- to 100-fold better substrate for NQO1 
than was MMC.57,73,74 
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Scheme 1.2. DNA alkylation by EO9 after 2-electron bioreduction. 
  
Although a positive correlation between NQO1 activity and sensitivity to EO9 has been 
shown in a number of cell lines,61,68,70,77 this relationship was lost in hypoxia,78,79 indicating that 
enzymes other than NQO1 may also be responsible for activation of EO9. Indeed, cells lacking 
NQO1 were more sensitive to EO9 in hypoxia.67,75 These results suggest that the semiquinone 
form of EO9 – presumably the toxic species present in NQO1-deficient cells in hypoxia, is more 
cytotoxic than the hydroquinone form. A possible scenario is that the semiquinone, but not the 
hydroquinone, form of EO9 is efficiently oxidized by O2 in low oxygen environments and that 
ROS thus produced causes cell death. In an oxic environment the hydroquinone might also be 
sensitive to oxidation, which would explain the positive correlation between NQO1 activity and 
EO9 cytotoxicity in oxia. Alternatively, the semiquinone may be more stable than the 
hydroquinone to oxidation. Thus, after being reduced by NQO1 in oxia, a single 1-electron 
oxidation of the hydroquinone results in the formation of the toxic semiquinone. The potential 
11 
 
role of ROS in the cytotoxic mechanism of EO9 is supported by evidence that the antioxidant 
tempol protects cells from the effects of EO9 in both oxia and hypoxia.80 
Despite its potency in cell culture, EO9 was shown to be only moderately effective in 
reducing murine tumor volumes,71,81,82 and no efficacy was observed in Phase II clinical trials.83-
85
 The dose-limiting toxicity was due to kidney damage,55 which was not observed in mice, even 
though NQO1 levels are higher in mice than in humans.81 This lack of success can be firmly 
attributed to two factors: its remarkable instability in vivo,71 and its poor tissue penetration.86,87 
The plasma half-life (t1/2) in human patients was measured to be as short as 48 seconds.71 
Support for the premise that short in vivo t1/2 resulted in a lack of tumor efficacy is that 
intratumoral injection of EO9 results in a far superior antitumor effect in mice than systemic 
administration.71 EO9 is moderately stable in isolated whole blood, with a t1/2 of 80 minutes.71,88 
Because the t1/2 of EO9 is too short to be explained solely by chemical degradation or 
elimination in the kidneys, and because EO9 penetrates tissues poorly, other unknown factors 
must be involved in the instability of EO9. Although EO9 is reasonably selective for NQO1-
mediated activation in cell culture, its failure in human trials must be ascribed to its poor 
pharmacokinetic (PK) properties, and not to NQO1 as an anticancer target. 
 
1.3.3. RH1 
RH1 is the latest in a series of diaziridinyl quinones to be promoted as NQO1-dependent 
DNA alkylating agents.15,19,71,89,90 Its immediate predecessor, MeDZQ possessed a promising 
preclinical profile and a strong correlation with NQO1 activity, but its poor aqueous solubility 
hampered its administration in vivo. RH1 was synthesized as a more soluble derivative of 
MeDZQ. RH1 was shown to be an excellent substrate for NQO1 in vitro, although it was 
12 
 
reduced by P450s as well.24,91,92 Experiments in cell culture strongly supported a dominant role 
for NQO1 in the activation of RH1 in normoxia.77,93-97 As was the case with EO9, NQO1 activity 
correlates negatively with sensitivity of cells to RH1 under hypoxia, leading to similar doubts 
about its cytotoxic mechanism.96 Indeed, assessment of RH1 in the NCI 60-cell line panel did not 
reveal any correlation with NQO1, leading to speculation about other enzymes that could be 
involved in activating RH1.98 Yan et al. subsequently showed that RH1 is also a substrate for the 
enzyme NQO2, which may have elevated levels in cell lines which are NQO1-poor, such as 
leukemias and lymphomas.99 The same study showed that other reductases, such as xanthine 
oxidase, P450, and b5r, do not affect the toxicity of RH1 in cell culture. A recent study of the 
sensitivity of pediatric cell lines failed to show a correlation between NQO1 and NQO2 levels 
and sensitivity to RH1, indicating that still more enzymes might be involved in RH1 
activation.100  
 As with EO9, RH1 suffers from poor metabolic stability and short in vivo half-life. The 
t1/2 of RH1 is human whole blood was measured to be 70 minutes; 10 minutes shorter than EO9. 
Both RH1 and EO9 were metabolized by liver and kidney cytosolic isolates too rapidly to be 
reliably measured.88 These properties correlate with a very short circulation half-life in mice of 
2.9 minutes. Despite these poor PK properties, RH1 successfully reduced tumor volumes in 
murine xenografts.93,101 In one study, Dehn and coworkers inoculated mice with either MDA-
MB-231 cells (NQO1*2), or the same cell line stably transfected with the wild-type NQO1 gene. 
RH1 significantly reduced tumor volumes in both models but was slightly more effective against 
the NQO1-expressing tumors.93 
 The results of a Phase I clinical trial of RH1 were recently disclosed.102 At a dose of 1.43 
mg/m2/day patients experienced dose-limiting bone marrow suppression. The circulation half-life 
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was only 12.3 minutes. Tumor samples showed evidence of DNA cross-linking by TUNEL 
assay, indicating that, despite the short lifetime of RH1, some of the compound was reaching 
tumors. Phase II studies have not been initiated. 
 
1.3.4 Streptonigrin 
 Streptonigrin was isolated from Streptomyces flocculus in 1959 and its potential as an 
anticancer compound was immediately recognized.103 Clinical trials were initiated, but severe 
bone marrow suppression was observed and was the major factor for discontinuing use of the 
compound.104-106 
 Streptonigrin is a metal chelator and it has been shown that metal chelation is required for 
its cytotoxic effect.107-110 This antibiotic has been suggested to work through a number of 
mechanisms, most notably involving either TOPO II inhibition or ROS generation.19,111,112 Both 
mechanisms are dependent on bioreduction by either a 1- or 2-electron process. 
 Streptonigrin has been shown to be an excellent substrate for NQO1 in vitro,57,109 
although it can be processed by other reductases as well.113 Oxygen consumption and NADH 
depletion experiments with purified NQO1 reveal that streptonigrin redox cycles efficiently, 
generating ROS. Incubation with a metal chelator, deferoxamine, did not affect redox cycling, 
however it did significantly protect cells from streptonigrin-mediated toxicity. This could either 
indicate that redox cycling does not directly cause cell death, or, more likely, that the 
deferoxamine sequesters Fe2+ necessary to generate the toxic hydroxyl radical from hydrogen 
peroxide which results from redox cycling. The semiquinone form of streptonigrin is relatively 
stable and may be a toxic species in its own right.114 
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A strong link between NQO1 activity and sensitivity to streptonigrin has been 
established.68,77,93,109 In fact, the IC50 ratios for isogenic cell line pair expressing or not 
expressing NQO1, and also between cell types, is routinely higher for streptonigrin than MMC, 
EO9, MeDZQ, or RH1. Because streptonigrin has not been studied in a clinical setting since the 
1970s, no PK data appears to exist that can be compared to EO9 and RH1 to ascertain if this drug 
was a reliable indicator of the effect of targeting NQO1 in cancer.115 
 
1.3.5. β-lapachone 
Beta-lapachone (β-lap) is an ortho-quinone originally isolated from the wood of the 
lapacho tree. It has garnered increasing attention over the past 2 decades because of its broad 
range of bioactivities.19,116,117 However, its cytotoxic mechanism is still the subject of debate. β-
lap was originally identified as an unorthodox inhibitor of topoisomerase I.118 Whereas most topo 
I inhibitors stabilize the TOPO I/DNA complex, β-lap appeared to bind the enzyme directly, 
preventing it from interacting with DNA.119 β-lap also induces G1 arrest and apoptosis in a 
variety of cell lines.120-122 Research based on cell cycle arrest led to the theory that β-lap kills 
cells through direct activation of checkpoint proteins without damaging DNA.123  
In 1999, Shiah and coworkers reported that, unlike other TOPO I inhibitors, β-lap 
induced the formation of ROS in HL60 cells.124,125 They showed that ROS caused DNA damage 
that was prevented by coincubation with ascorbic acid, which can display antioxidant properties. 
The following year, the Boothman group provided evidence that β-lap killed cells primarily 
though a NQO1-dependent mechanism.126 They have subsequently shown that the sensitivity of 
a wide variety of cell lines correlates strongly with NQO1 activity.47,126-129 They proposed that β-
lap undergoes a futile redox cycle initiated by NQO1-mediated bioreduction to the hydroquinone 
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with subsequent reoxidation and concomitant ROS formation.125,130 While they have noted rapid 
elevation of ROS levels in β-lap treated cells,47 they have not presented evidence that ROS is 
actually killing the cells.131 HL60 cells do not have detectable NQO1 activity so the origin of the 
ROS in the report by Shiah et al. is still unexplained.124 As a final consideration, the 
concentration of β-lap delivered to cells may induce different forms of cell death, with lower 
concentrations inducing apoptosis and higher concentrations initiating calcium-dependent 
necroptosis.132-135 
 Similar to EO9 and RH1, β-lap suffers from short half-life in vivo (~24 minutes)136and 
poor stability in isolated blood (t1/2 = 15 minutes).137 The poor stability of β-lap in blood appears 
to be due to enzymatic degradation.137-139 These degradation products appear to damage the red 
blood cells (RBCs), causing ROS generation and a spectral shift in the hemoglobin UV-visible 
absorption spectrum, indicative of an unknown reaction with the iron-heme complex.136,140 
Although murine RBCs have detectible NQO1 activity,71 human RBCs do not.141 It has been 
proposed that ROS formation following 1-electron reduction in RBCs caused anemia in animals 
treated with naphthoquinones unrelated to β-lap.14 In addition to ROS generation in RBCs, the 
poor aqueous solubility of β-lap necessitates the use of hydroxypropyl-β-cyclodextrin (HPβCD) 
as a solubility aid, high concentrations of which cause hemolysis of RBCs in vitro.136 To address 
the issues of compound instability and damage to RBCs, the Boothman and Gao groups have 
designed a micellar formulation of β-lap which demonstrates greatly improved PK properties and 
efficacy in murine tumor models.136 
 Whereas the core of β-lap is degraded by enzymes in RBCs, the majority of metabolites 
isolated from cultured hepatocytes and other mammalian cells are glucose-based conjugates of 
the hydroquinone form of β-lap.142 This argues against a highly unstable hydroquinone form that 
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should be too transient to be conjugated by other Phase II detoxifying enzymes. Alternatively, an 
enzyme complex composed of NQO1 and a glucosyl transferase might exist which shuttles the 
β-lap hydroquinone between the enzymes without exposing the reactive molecule to the cytosol. 
 As might be predicted from the poor PK properties of β-lap, its efficacy against 
subcutaneous tumor xenografts in mice was poor, unless injected intratumorally.127,128,143 
However, β-lap did effectively treat orthotopic tumors in mice where the drug must diffuse 
through much less tissue to reach the tumor.144 As previously mentioned, the micellar 
formulation of β-lap dramatically increased the half-life of the drug in vivo, enabling β-lap to 
reach subcutaneous xenografts and exert an antitumor effect.136 
 β-lap entered human clinical trials as a formulation in HPβCD; the micellar formulation 
has yet to be approved for Phase I trials. Although a few partial responses were observed in both 
Phase I and Phase II trials either alone145-147 or in combination with docetaxel148 or 
gemcitabine,149 the compound was dropped from development presumably due to lack of 
efficacy. The regimens were well tolerated, with anemia and hemolysis being dose-limiting.  
 The failure of β-lap in clinical trials appears to be the result of compound instability and 
damage to RBCs, either by the compound itself or potentially by the HPβCD formulation. It is 
yet to be determined if the micellar formulation will resolve these issues and permit β-lap to be 
dosed at levels high enough to see efficacy in humans. Because the mode of action of β-lap may 
be dose dependent and because of its poor PK properties, the clinical failure of β-lap cannot be 
ascribed to the utility of NQO1 as an anticancer target. 
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1.4. Conclusion 
While personalized medicine strategies have produced life-saving anticancer drugs, they 
affect only a small percentage of cancer patients. Because NQO1 levels are highly elevated in a 
large number of solid tumors, a treatment that successfully exploits NQO1 levels could benefit a 
significant fraction of all cancer patients. Despite the extensive efforts expended in discovering 
and developing NQO1-dependent cytotoxins, none of these compounds are both sufficiently 
selective for NQO1 and sufficiently stable in vivo to prove whether or not targeting NQO1 
overexpression is a viable anticancer strategy. In the following chapters, we provide evidence 
that DNQ possesses the selectivity and stability required to validate NQO1 as a target for the 
treatment of cancer. 
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Chapter 2. Total Syntheses of DNQ, SCH 538415, and Deoxynybomycin 
 
Portions of this Chapter are reprinted with permission from Bair, J. S.; Palchaudhuri, R.; and 
Hergenrother, P. J. J. Am. Chem. Soc. 2010, 132, 5469-5478. Copyright 2010 American 
Chemical Society. Contributions from R. P. are noted in the Figures.  
 
2.1. Background of DNQ 
 
2.1.1. Rediscovery of DNQ  
DNQ was discovered to be a potent cytotoxin through a high-throughput screen of the in-
house UIUC Heritage library. This library was assembled from compounds synthesized and 
stored in this department over the last century. In 2003, the library was screened for cytotoxicity 
against HL-60 cells in culture.1 DNQ was identified as the most potent cytotoxin in the library 
with 72 hour IC50 values in follow-up assays of 40 nM against HL-60 cells and 1.1 nM against 
MCF-7 cells. The sample of DNQ in the Marvel library originated in the laboratory of Prof. 
Kenneth L. Rinehart Jr. around 19612 and was impure, likely having degraded during storage.  
 
2.1.2. Origin of DNQ 
In 1955, Frieda et al. isolated a small molecule metabolite from a strain of Streptomyces 
possessing antibacterial properties; they named this molecule nybomycin (2-1, Scheme 2.1).3 In 
1961, Renfroe and Rinehart published their first report on the structure of nybomycin.2 As part of 
their structure-elucidation studies they found that treatment of nybomycin with hot concentrated 
hydroiodic acid resulted in dehydroxylation to deoxynybomycin (2-2) – itself identified as a 
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natural product in 1970.4 Oxidation of deoxynybomycin with hot concentrated nitric acid 
produced a red anthraquinone that they identified as 1-1, which we dubbed deoxynyboquinone, 
or DNQ (Figure 2-1). The experimental protocol for transforming nybomycin to DNQ was not 
reported. The Rinehart group subsequently reported the first and only total syntheses of both 
nybomycin (14 steps, 0.16% yield) and deoxynybomycin (10 steps, 0.83% yield, Scheme 2.2).5-7 
 
 
Scheme 2.1. Original synthesis of DNQ during studies of the structure of nybomycin.2 
 
 
Scheme 2.2. Summary of Rinehart’s syntheses of nybomycin and deoxynybomycin.7 
 
2.1.3. Previous research on DNQ 
Prof. Rinehart submitted a sample of DNQ to the National Cancer Institute for analysis in 
the NCI-60 cell line panel. DNQ was tested and found to be a potent cytotoxin with an average 
IC50 of 540 nM. Leukemia cell lines were not sensitive to the compound (IC50 >10 µM), whereas 
melanoma cell lines were highly sensitive. 
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In 2003, researchers at the NCI published a study of the mechanisms of action of a 
number of quinone-containing molecules, including DNQ.8 In this study, DNQ proved difficult 
to classify as it was far more cytotoxic than other molecules in its class. No mechanism of action 
was assigned to DNQ. Additionally, the researchers were using a stock of DNQ of similar age to 
that of the sample in the Marvel library. We considered the results of such experiments based on 
presumably impure compound to be questionable. Thus we required a synthetic route to DNQ in 
order to produce pure material to study. In addition, the route must be sufficiently flexible and 
modular to facilitate the synthesis of derivatives of DNQ. Two total syntheses of a structurally-
similar natural product, diazaquinomycin, have been reported and will be described briefly 
below.  
 
2.2. Structurally related compounds 
 
2.2.1. Diazaquinomycin 
Diazaquinomycin (2-3, Scheme 2.3) was isolated in 1982 from the fermentation broth of 
a streptomycete.9-11 It was identified during a screen of bacterial broths against Enterococcus 
faecium for thymidine-reversible toxicity, which is indicative of thymidylate synthase (TS) 
inhibition. Cell culture and in vitro experiments provided further evidence for this mode of 
action.12 Diazaquinomycin was found to be generally toxic to gram-positive bacteria with 
minimum inhibitory concentrations as low as 25 µM, but it was inactive against gram-negative 
bacteria. As TS inhibition has been validated as an anticancer as well as an antibiotic strategy, 
further work was done to assess the potency of 2-3 against cancerous mammalian cells. The 
concentration of 2-3 required to achieve total growth inhibition of HeLa cells was on the order of 
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1 µM, which is approximately equal to its maximum aqueous solubility. An attempt to treat mice 
infected with L-1210 leukemia and Ehrlich ascites carcinoma with 2-3 was unsuccessful.12 This 
poor in vivo performance is presumably due at least in part to its extremely poor solubility in 
water, which is likely the result of intermolecular hydrogen bonding, its planar structure, and the 
hydrophobicity imparted by its alkyl appendages. 
Two total syntheses of 2-3 have been reported. Kelly and coworkers reported an 
intramolecular double Knorr cyclization of hydroquinone 2-4 to form 2-3 in high yield (Scheme 
2.3, Equation 1).13 Unfortunately 2-4 was the only substrate demonstrated for this cyclization and 
previous work in our lab determined that the process was not repeatable with other substrates.14 
Pérez and coworkers developed a route based on a double hetero-Diels-Alder cycloaddition 
followed by oxidative removal of dimethylamine to produce diazaanthraquinone 2-5 (Scheme 
2.3, Equation 2).15,16 Double N-oxidation was followed by tosyl chloride-mediated 
rearrangement to give the diazaanthracene skeleton. Once again, however, we found the reported 
protocol to be unreliable as both the double N-oxidation and rearrangement produced less than 
5% of the desired products.14 Because published routes to structurally-related compounds could 
not be repeated in our hands, we set out to develop a new synthetic route to DNQ. 
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Scheme 2.3. Published total syntheses of 2.3. 
 
2.2.2. SCH 538415 
As we began work towards the synthesis of DNQ we became aware of a natural product 
with a nearly identical structure, SCH 538415 (2-10, Scheme 2.4). Two teams of researchers 
independently isolated SCH 538415 from the broth of a strain of streptomyces.17,18 It was first 
identified during a screen of bacterial broths for acyl carrier protein synthase inhibition in vitro, 
though no further research has been published on its mode of action. The salient structural 
difference between 2-10 and DNQ is the N-methylation of the ring nitrogens. SCH 538415 is far 
more soluble than its N-normethyl relatives presumably due to disrupted intermolecular 
hydrogen bonding. Compound 2-10 was shown to be toxic to S. aureus, S. pneumoniae, and N. 
gonorrheae as well as a variety of cancerous mammalian cell lines (GI50 = 1-5 µM). No 
synthesis of SCH 538415 had been reported. Because of its symmetric structure, we chose SCH 
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538415 as our initial synthetic target. After successfully devising a route for its synthesis, a 
related approach would be applied for the non-symmetrical DNQ. 
 
2.3. Total synthesis of SCH 538415 
 
2.3.1 Retrosynthesis 
Since the development of the synthetic routes to diazaquinomycin (section 2.b.i), 
palladium-catalyzed cross-coupling methods have come to be one of the most versatile and 
frequently employed of all synthetic methods. Recognizing that hydroquinones can be 
manipulated using these Pd-catalyzed protocols, and that a large number of mild conditions exist 
for oxidizing hydroquinones to the respective quinone, we devised the retrosynthesis of SCH 
538415 shown in Scheme 2.4. 
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Scheme 2.4. Retrosynthetic plan for the total synthesis of SCH 538415. 
 
The bis-protected hydroquinone form of SCH 538415 (2-11) was envisioned to arise 
from a double intramolecular Buchwald-Hartwig type aryl amidation. Double ortho-aryl 
bromination of phenols is well precedented using a wide range of conditions and was predicted 
to deliver 2-12 from 2-13. Di-amide 2-13 was to be formed by a double aryl-vinyl Suzuki 
coupling between 2-14 and two equivalents of 2-17. Although neither of these exact substrates 
had at the time been used previously in a Suzuki coupling,19 they bear strong resemblance to 
known substrates. Compound 2-17 was expected to be easily synthesized from 2-18 according to 
protocols for similar substrates.20 It was anticipated that 2-14 would be accessible by a double 
Miyaura-type borylation of a dihalohydroquinone, such as 2-15 or 2-16, and not by a double 
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lithiation/borylation procedure because of the difficulty of using lithiation-based techniques on 
bifunctional substrates. 
 
2.3.2 Unsuccessful routes to SCH 538415 
Despite the simplicity of its structure, no synthesis of 2-18 had been reported. It was 
readily synthesized by direct amidation of ethyl 2-butynoate with methylamine in methanol in 
87% yield as a mixture of amide rotamers (Scheme 2.5). (Z)-iodoolefin 2-17 was produced from 
2-18 as a single isomer by the action of sodium iodide in acetic acid20 in 96% yield.  
Both 2-15 and 2-16 are commercially available, but are prohibitively expensive 
(>$300/gram). We found that 2-15 was readily synthesizable via two separate routes. In the first 
method, a Dakin reaction produced 2-15 from 3,5-dibromo-4-hydroxybenzaldehyde (2-20) in 
72% yield on gram scale (Scheme 2.6, Equation 1). 
The second method involved bromination of hydroquinone monoacetate (2-21) (Scheme 
2.6, Equation 2). This differential protection affords an electronic desymmetrization of the ring 
in 2-21.21 Bromination with NBS in cold CH2Cl2 provided 2-22 in 76% yield. This bromination 
was completely regioselective, in part because it was mild enough to retain the unstable ester 
during the course of the reaction. Hydrolysis of the ester of 2-22 with sodium hydroxide 
provided 2-15, in 96% yield. The hydroxyls of 2-15 were protected as acetate esters and as 
benzyl, silyl, and methyl ethers (2-23, 2-24, 2-25, and 2-26, respectively, Scheme 2.7, Equation 
1).  
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Scheme 2.5. Synthesis of iodoamide 2.17. 
 
  
Scheme 2.6. Two synthetic routes to dibromohydroquinone 2-15. 
 
Unfortunately, borylation was unsuccessful, presumably because of the slow rate of 
oxidative addition of the palladium species to the electron-rich and sterically hindered C-Br 
bonds (Scheme 2.7, Equation 2).22,23 Palladium-catalyzed bis-stannylation of 2-23 or 2-25 using 
bis(tributyltin) was also unsuccessful (Scheme 2.7, Equation 3). Efforts were then directed 
toward formation of the more reactive 2,6-diiodohydroquinone 2-16 (Scheme 2.8).  
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Scheme 2.7. Attempts to synthesize Suzuki or Stille coupling partners for 2-17. 
 
Mimicking the route to 2-15 (Scheme 2.6, Equation 1) to make the analogous diiodo 
compound 2-16 by the Dakin reaction met with failure (Scheme 2.8, Equation 1). It is likely that 
that oxidation of the iodides of 2-32 to hypervalent iodine was the major competitive pathway. 
Attempts to mimic the second route to 2-16 were ultimately successful (Scheme 2.8, Equation 2). 
Screening reagents and conditions, and subsequent reaction optimization, revealed a method of 
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iodination using ICl which provided diiodide compound 2-33 in 73% yield from 2-21. 
Hydrolysis of the acetate ester produced 2-16 in 96% yield. The hydroxyls of 2-16 were 
protected as acetate esters and as benzyl, silyl, and methyl ethers (2-34, 2-35, 2-36, and 2-37, 
respectively, Scheme 2.8, Equation 2). The majority of efforts were focused on 2-35 because of 
the crystallinity imparted by the benzyl groups.  
Suzuki coupling was found to be possible with 2-35 (Scheme 2.8, Equation 2). 
Bispinacolborylation of 2-35 was accomplished most satisfactorily using Miyaura’s method.23 
Because 2-38 was found to be unstable to silica gel chromatography, it was submitted crude to 
the double Suzuki cross-coupling.  
Standard conditions for Suzuki coupling were examined for the synthesis of 2-40 and we 
found that a system based on PdCl2(dppf) produced the desired product in 25% yield over two 
steps from 2-35. Although the yield of 2-40 from 2-35 is low, and catalyst loadings are high, this 
procedure involves four individual cross-coupling reactions. In addition, the Suzuki coupling 
brings together an electron-rich and sterically hindered aryl boronate and a base sensitive vinyl 
iodide. Indeed, highly variable amounts of butynamides and protodeborylated materials were 
isolated from the reaction mixture. 
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Scheme 2.8. Synthesis of diamides 2-40 and 2-41 through diiodohydroquinone 2-16. 
 
The literature precedent for intramolecular aryl-amidation is strong when the aryl 
position is activated as the aryl halide.24-27 Unfortunately we were not able dibrominate 
compound 2-40 (Scheme 2.9, Equation 1). Under a variety of conditions 2-40 appeared to 
monobrominate rapidly and cleanly, but reaction at the alkenes was competitive with 
dibromination. Attention was then turned to reports of intramolecular amidation through C-H 
activation.28,29 A trimetallic system reported by Inamoto et al.29 successfully formed one ring, but 
even with stoichiometric catalyst loadings and increased time and temperature the other ring 
refused to close (Scheme 2.9, Equation 2). Resubjection of monocyclized material to the reaction 
conditions did not result in further reaction. 
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 It is hypothesized that, because the electronics of the ring should change only slightly, 
the ring-closed side of 2-44 must communicate with the unreacted side through steric 
interactions. Strong repulsion between the benzyl group and the fixed N-methyl might be 
expected to block the approach of the other appendage. Based on this hypothesis, 2-41 was 
synthesized to determine if a smaller protecting group would allow for better conversion. Here 
again, however, only monocyclization was observed (Scheme 2.9, Equation 2). 
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Scheme 2.9. Attempts to synthesize tricyclic precursors to SCH 538415. 
 
Continuing under the assumption that steric constraints prevented the second cyclization, 
2-46, which lacks the southern hydroxyl group, was synthesized. Once again, only 
monocyclization occurred (Scheme 2.9, Equation 3). Compound 2-48 and 2-50, which lack the 
northern hydroxyl, or both hydroxyls, respectively (see Supporting Information for synthesis of 
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2-46, 2-48, and 2-50), were also constructed. Neither of these substrates proceeded to even the 
bicyclic products under the same conditions (Scheme 2.9, Equation 4 and 5). 
With the failure of C-H activation attempts it was concluded that preactivation of the site 
with a halogen would be required to successfully perform the second amidation. An attempt to 
halogenate mono-cyclized product 2-44 was unsuccessful. It was reasoned that the halogens 
would have to be installed earlier in the synthesis and be inert to the borylation and Suzuki 
coupling conditions. Thus, the revised retrosyntheses outlined in Scheme 2.10 were proposed. 
The synthesis of SCH 538415 by oxidation of diazaanthracenols 2-52 or 2-53 is expected to be 
more facile than from diazaanthracene 2-51, but potential tetrahaloarene precursors to 2-51 are 
known, whereas phenol precursors to 2-52 and 2-53 are not known. Thus, the synthesis of 
diazaanthracene 2-51 was pursued first. 
 
 
Scheme 2.10. Revised retrosynthesis of SCH 538415: Early installation of halides to facilitate 
aryl amidation. 
 
Diiododibromobenzene 2-55 was synthesized according to the literature procedure.30 
Miyaura borylation did not generate any of the desired bis-boryl species 2-56 (Scheme 2.11, 
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Equation 1). This result was not surprising as there is a lack of precedent for palladium-catalyzed 
aryl borylations ortho to a bromide. Assuming that the reactivity of the bromide was the reason 
for the reaction’s failure, the less reactive dichlorodiiodo compound 2-57 (Scheme 2.11) was 
explored. This was readily synthesized from 1,3-dichlorobenzene using the same iodination 
procedure. Miyaura borylation conditions provided cross-coupling partner 2-59 in reasonable 
yield, but contaminated with as much as 15% bis(pincolato)diboron. Because 2-59 is not stable 
to chromatography, the crude mixture was used directly in the subsequent reaction. The Suzuki 
coupling between 2-59 and 2.17 (Scheme 2.11, Equation 2) generated 2-60 in 35% yield from 2-
57.  
A brief survey of known conditions for aryl chloride coupling with amides revealed a Pd 
(OAc)2/X-Phos system31 that quantitatively converted 2-60 to diazaanthracene 2-51. The 
generation of the active catalyst in situ by the addition of Pd(OAc)2 and X-phos in the presence 
of substrates was initially effective but upon purchase of another lot of X-phos a dependence on 
ligand batch was discovered. This inconsistency was not overcome by catalyst formation prior to 
the addition of reagents.32 Consistent results were finally found using a Pd/X-phos precatalyst 
described by Fors and Buchwald.33 
Despite a significant effort, no oxidative conditions were found that would perform the 
desired final oxidation (Scheme 2.11). Each attempt either returned starting material or generated 
complex mixtures of products. An exploration of the literature revealed that 2-51 is among the 
most electron poor of known substrates for arene oxidation to quinone, and is unique in its 
incorporation of alkene moieties. It was determined that the more electron-rich phenolic 
compounds 2-52 and 2-53 (Scheme 2.10) would be more likely to undergo oxidation under 
conditions mild enough to not decompose the substrate. Thus, one final revision to the 
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retrosynthesis was made, one which included halides to facilitate ring closure and a partially 
oxidized arene, to enable oxidation to the quinone. 
 
 
Scheme 2.11. Synthesis of diazaanthracene 2-53 and attempts to oxidize 2-53 to SCH 538415. 
 
2.3.3. Successful synthetic route to SCH 538415 
Of the potential precursors to diazaanthracenols 2-52 or 2-53 the most successful route 
was through 2-61 (Scheme 2.12). The specific disposition of halides in compound 2-61 was 
envisioned to arise through sequential directed ortho lithiation of 2,6-dichloroanisole. As 
diiodination under such conditions is difficult, intermediate disilane 2-62 was targeted. Chloride 
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is known to be a weak directing group for ortho-lithiation, but has been successfully utilized in a 
number of settings.34,35 However, lithium-chloride exchange appeared to be the dominant 
reaction in a variety of n- and s-butyllithium-mediated reactions, presumably due to the strong 
directing effects of the methoxy group. However, it was found that deprotonation with lithium 
diisopropyl amide (LDA) was both efficient and selective for the 3- and 5-positions (Scheme 
2.12).36 In addition, the two-step sequence could be carried out in one pot. Trimethylsilyl 
chloride was an effective in situ-quench reagent, with highest conversions when additions of 
reagent were sequential, beginning with LDA.36 Iododesilylation of 2-62 by the action of iodine 
monochloride was rapid and quantitative, producing 2-61. 
Miyaura borylation conditions23 then provided cross-coupling partner 2-64 in good yield 
but contaminated with variable amounts of bis(pinacolborane). The two-step yield after the 
subsequent cross-coupling was higher when 2-64 was used without purification, thus after 
workup 2-64 was typically taken directly into the cross-coupling. The double Suzuki cross-
coupling of 2-64 with iodoamide 2-17 proceeded as expected with an acceptable 55% yield of 2-
65. Finally, the Pd(OAc)2/X-Phos system effectively cyclized the electron-rich, ortho-substituted 
compound 2-65 in excellent yield. 
After a brief survey of oxidants, it was found that, though more electron rich than 
diazaanthracene 2-51, 2-53 was still challenging to oxidize. Attempts to deprotect the phenol, 
which should be more prone to oxidation than the anisole, met with failure. Attempts to follow 
this synthetic scheme beginning with other protecting groups (e.g, -OMOM, -OBn, -OPBM, -
OTHP, -OSEM) surprisingly all failed at various steps. We found that oxidation of 2-53 was 
possible under forcing conditions. Thus, brief heating of 2-53 in concentrated nitric acid 
produced SCH 538415 as a bright red-orange solid in 40% yield along with variable amounts (0-
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14%) of nitrated product 2-66, the structure of which was confirmed by single-crystal x-ray 
diffraction. By this route the first total synthesis of the natural product was completed in six steps 
and 9.7% overall yield from 2,6-dichloroanisole. Spectral data matched that of the natural 
product.17,18,37 
 
 
Scheme 2.12. Total synthesis of SCH 538415. 
 
2.4. Synthesis of DNQ 
The simplest approach to apply this route to the synthesis of DNQ would involve a 
selective mono-N-methylation of nor-methyl diazaanthracenol 2-67 (Scheme 2.13). Primary 
amide 2-70 was synthesized but found to be an unreactive partner in the Suzuki coupling with 2-
64 (Scheme 3). The N-para-methoxybenzyl amide 2-71 was then synthesized in 82% yield from 
2-butynoic acid by hydroiodination20,38 and treatment of the corresponding acid chloride with p-
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methoxybenzyl amine (Scheme 2.13). This route was employed because the reaction of ethyl 2-
butynoate with p-methoxybenzyl amine resulted primarily in 1,4-addition to the alkyne. The 
Suzuki cross-coupling of 2-64 with 2-71 produced 2-72 in 42% yield. The subsequent amidation 
proceeded in quantitative yield to generate the protected tricyclic compound 2-73. Removal of 
the PMB protecting groups from 2-73 in hot concentrated HBr was rapid and produced 2-67 in 
97% yield. We found that methylation of 2-67 was highly unselective, generating a mixture of 
mono- and di- N- and O- alkylated products. Although a trace amount of DNQ was isolated by 
subsequent hydrolysis of o-alkylated products, oxidation in nitric acid, and chromatographic 
purification, we deemed this route impractical.  
 
Scheme 2.13. Inefficient synthesis of DNQ by methylation of 2-67. 
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An alternate route to DNQ focused on the synthesis of nonsymmetric diamide 2-74. 
Although routes involving iterative Suzuki coupling38,39 initially appeared promising, a mixed 
cross-coupling between bisboronate 2-64 and iodoamides 2-17 and 2-71 was found to be the 
simplest method to form 2-74. Separation of 2-74 from the accompanying symmetric products 
was easily effected by chromatography. Aryl amidation under the previously employed 
conditions efficiently formed tricycle 2-75 along with variable amounts of unprotected amide 2-
76. Isolation at this step was unnecessary, as subjection of the crude amidation products to acidic 
hydrolysis produced 2-77 in 76% yield over two steps. Oxidation of phenol 2-77 was markedly 
more facile than oxidation of anisole 2-53. Oxidation of 2-77 catalyzed by salcomine under O2 
produced DNQ in 77% yield. Overall the synthesis consisted of 7 steps in the longest linear 
sequence, 12% overall yield. This compares to 11 steps and <0.84% yield for the previous 
synthesis of DNQ.2,7 By this method we have synthesized 400 mg of DNQ in a single sequence 
without encountering any difficulty related to scale. 
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Scheme 2.14. Robust and scalable synthesis of DNQ. 
 
2.5. Formal synthesis of deoxynybomycin 
Diazaanthracenol 2-77 was previously reported by Rinehart as a degradation product of 
deoxynybomyin (2-2).7 In this same report the authors demonstrate the conversion of 2-77 to 
deoxynybomycin (Figure 2.15). Thus en route to DNQ we completed a formal total synthesis of 
deoxynybomycin by synthesizing 2-77 from 2-63 in 6 steps and 16% overall yield.  
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Scheme 2.15. Rinehart’s conditions for the conversion of deoxynybomycin to 2-77 and 2-77 to 
deoxynybomycin.7 
 
 
48 
2.6. Synthesis of nor-methyl anthraquinone 2-78 
Having previously synthesized 2-73 we sought to make the previously-reported nor-
methyl DNQ derivative 2-78 for comparison with DNQ and SCH 538415.16 Unlike for 2-52, 
heating in HBr over 4 hours also removes the phenol-protecting methyl group from 2-73. 
Oxidation of diazaanthracenol 2-79 in HNO3 at 60 ºC generates a red solution from which a red-
orange solid precipitates upon cooling and dilution with water. Unfortunately, putative 
compound 2-78 is insoluble in all solvents except concentrated acids or bases, thus rendering 
purification difficult, as impurities are similarly insoluble. Although we are confident that we 
successfully synthesized 2-78 based on comparison of NMR chemical shifts with SCH 538415, 
the spectral data do not match those reported previously.16 
 
 
 
2.7. Summary 
 In conclusion, the total syntheses of SCH 538415, DNQ, and deoxynybomycin were 
accomplished using concise and modular routes that relied heavily on modern Pd-mediated 
cross-coupling reactions. Three synthetic hurdles were overcome: formation of the tricyclic 
skeleton, oxidation of the diazaanthracene to the anthraquinone, and synthesis of non-symmetric 
intermediates en route to DNQ. The tricycle was formed through a double intramolecular 
amidation of electron-rich and sterically hindered aryl chlorides which had to be carried through 
from the beginning of the sequence. Attempts to oxidize diazaanthracene 2-51 were 
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unsuccessful, but the more electon rich anisole 2-53 was successfully oxidized to SCH 538415 
under forcing conditions. It was found that a straight-forward mixed Suzuki cross-coupling was a 
viable method for producing the non-symmetric diamide 2-74 en route to DNQ. Finally, 
oxidation of phenol 2-77 was accomplished under mild, cobalt-catalyzed conditions to deliver 
the target compound, DNQ. 
 
 
2.8 Materials and Methods 
Reagents were purchased from Aldrich, Strem (metal catalysts and ligands), GFS 
(alkynes), Frontier Scientific (B2pin2) and used without further purification unless otherwise 
noted. Elesclomol39 and tirapazamine40 were synthesized according to the literature procedures. 
Solvents were dried by passage through columns packed with activated alumina (THF, CH2Cl2, 
diethyl ether) or activated molecular sieves (DMSO). Amines were freshly distilled over CaH2 
under a nitrogen atmosphere. Reactions involving n-BuLi or LDA were performed using 
standard Schlenk techniques under argon. 
 
1H-NMR and 13C-NMR spectra were recorded on Varian Unity spectrometers at 500 
MHz and 125 MHz, respectively. Spectra generated from a solution of CDCl3 were referenced to 
residual chloroform (1H: δ 7.26 ppm, 13C: δ 77.23 ppm). Spectra generated in mixtures of CDCl3 
and CD3OD were referenced to tetramethylsilane (1H: δ 0.00 ppm) or CD3OD (13C: δ 49.0 ppm). 
Spectra generated from d-TFA were referenced to residual H (1H: δ 11.50 ppm) or F3CCO2D 
(13C: δ 164.2 ppm). 
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Synthetic Protocols and Characterization 
 
 
 To a solution of ethyl 2-butynoate (2.18 g, 19.5 mmol) in methanol (5 mL), chilled in an 
ice-water bath was added 11.75 mL (23.5 mmol) of a 2M solution of methylamine in methanol. 
The reaction was stirred at 0 ºC for 6h, after which the cold bath was removed and the mixture 
was allowed to stir for another hour. Solvent and excess reagent were evaporated directly from 
the flask and the residue was recrystallized from ether/hexanes to yield 9 (1.40 g) as pale yellow 
prisms. The mother liquor was evaporated and the residue purified by filtration through a silica 
plug followed by recrystallization to yield additional 2-18 (0.243 g) as fine needles. Total 
product: 1.65 g, 17.0 mmol, 87%. 
1H-NMR (CDCl3, 500 MHz): δ 5.77 (bs, 1H, major rotomer NH), 5.58 (bs, 1H, minor rotomer 
NH), 3.01 (d, 3H, J = 5.0 Hz, minor rotomer NCH3), 2.84 (d, 3H, J = 5.0 Hz, major rotomer 
NCH3), 2.03 (s, 3H, minor rotomer allylic CH3), 1.93 (d, 3H, J = 1.0 Hz, major rotomer allylic 
CH3). 
13C-NMR (CDCl3, 125 MHz): δ 157.2 (minor), 154.4 (major), 90.4 (minor), 83.0 (major), 74.8 
(major), 72.4 (minor), 29.7 (minor), 26.4 (major), 3.9 (minor), 3.6 (major). 
HRMS (EI) calcd for C5H7NO (M)+: 97.05277, found: 97.05257. 
Melting point: 61.5-63.5 ºC. 
IR (cm-1, thin film in CDCl3): 3449 (w), 3293 (b, m), 3076 (b, w), 2944 (w), 2251 (m), 2226 (m), 
1640 (s), 1532 (s), 1412 (m), 1295 (m), 1162 (w). 
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 To a 40-mL I-Chem vial with a stir bar was added 2-18 (1.18 g, 12.1 mmol), NaI (3.66 g, 
24.4 mmol), and acetic acid (7.0 mL, 122 mmol). The vial was closed with a Teflon-lined plastic 
screw-on cap and plunged into a preheated oil bath at 115 ºC for 8h. Reaction completion was 
determined by removing aliquots for 1H-NMR analysis. The deep red reaction mixture was 
diluted with water (35 mL) and CH2Cl2 (20 mL), treated with NaHSO3 until colorless, and 
carefully neutralized with a saturated aqueous solution of NaHCO3 (100 mL). This mixture was 
poured into a separatory funnel with 100 mL CH2Cl2, shaken and separated. The aqueous 
fraction was extracted with CH2Cl2 (3 x 25 mL). The combined organic fractions were washed 
with brine, dried over MgSO4, and evaporated to yield 2.61 g (96%) of 2-17 as a pale yellow oil 
which solidifies slowly under vacuum. (Dehydrohalogenation is facile and 2-17 is often 
contaminated with ~1% 2-18. Further attempts to purify 2-17 generate additional 2-18.) 
1H-NMR (CDCl3, 500 MHz): δ 6.82 (bs, 1H, NH), 6.26 (d, 1H. J = 1.5 Hz, vinyl CH), 2.76 (d, 
3H, J = 5.0 Hz, NCH3), 2.56 (d, 3H, J = 1.5 Hz, allylic CH3). 
13C-NMR (CDCl3, 125 MHz): δ 165.7, 128.9, 106.1, 35.9, 26.4. 
HRMS (ESI-TOF) calcd for C5H8NOI (M+H)+: 225.9729, found: 225.9721. 
Melting point: 47-52 ºC. 
IR (cm-1, thin film in CDCl3): 3454 (w), 3305 (b, m), 3083 (w), 2966 (w), 1653 (s), 1628 (s), 
1427 (m), 1412 (m), 1376 (w), 1332 (w), 1233 (s), 1161 (w), 1091 (m). 
 
52 
 
From 2-20: 
 2-20 (0.204 g, 0.729 mmol) was dissolved in 1M NaOH (0.73 mL, 0.73 mmol). A 
solution of 3% H2O2 (0.86 mL, 0.88 mmol) was added over a few minutes then stirred for 2 
hours 45 minutes. The product precipitated and was removed by filtration and dried under 
vacuum. 2-15 (0.140 g, 0.523 mmol, 72 %) was pure by NMR. 
1H-NMR (d6-acetone, 500 MHz): δ 8.23 (bs, 2H), 7.06 (s, 2H). 
 
 
From 2-22: 
 2-22 (1.22 g, 3.93 mmol) was dissolved in 1M NaOH (40 mL) and stirred for 15 minutes. 
The solution was rendered acidic with a solution of 1M HCl at which a voluminous pink 
precipitate formed. The mixture was extracted with ethyl acetate (3 x 20 mL). The combined 
organic fractions were washed with dried over magnesium sulfate, filtered through a silica plug 
and concentrated. 2-15 (1.01 g, 3.77 mmol, 96%) was isolated as a white solid.  
1H-NMR (CDCl3, 400 MHz): δ 7.00 (s, 2H), 5.49 (bs, 1H), 4.68 (bs, 1H). 
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 4-acetoxyphenol (2-21, 0.161 g, 1.06 mmol) was dissolved in 15 mL CH2Cl2 and the 
solution was cooled to -37 ºC. NBS (0.346 g, 2.11 mmol) was then added and the mixture was 
allowed to warm to room temperature and stir for 3 days. The solution was loaded directly onto a 
silica gel column and eluted with 9:1 to 4:1 hexane:EtOAc. 15 (0.250 g, 0.807 mmol, 76%) was 
collected as a white solid.  
1H-NMR (CDCl3, 400 MHz): δ 7.25 (s, 2H), 5.87 (s, 1H), 2.27 (s, 3H).  
 
 
 Acetic anhydride (1.40 mL, 14.8 mM) was added to 2-15 (0.500 g, 1.87 mmol) under 
argon and was heated to 80 ºC for 24h. The solvent was evaporated under reduced pressure and 
the residue was dissolved in ether and washed with NaHCO3 and water. The organic layer was 
dried over magnesium sulfate and concentrated. 2-23 (0.624 g, 1.77 mmol, 95%) was collected 
as a white solid.  
1H-NMR (CDCl3, 500 MHz): δ 7.36 (s, 2H), 2.38 (s, 3H), 2.27 (s, 3H). 
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2,5-bis-benzyloxy-1,3-dibromobenzene (2-24) 
 2-15 (0.248 g, 0.926 mmol), K2CO3 (0.522 g, 3.77 mmol) and benzyl bromide (0.34 mL, 
2.86 mmol) were added to 10 mL acetone and the solution was heated to reflux for 1.5 hours. 
The solvent was evaporated under reduced pressure and the residue was partitioned between 
water and ether. The layers were separated and the organic layer was washed once with water, 
dried over magnesium sulfate and concentrated. The crude material was purified by silica gel 
chromatography by eluting with 4:1 hexanes:CH2Cl2. 2-24 (0.263 g, 0.588 mmol, 63%) was 
collected as white crystals.  
1H-NMR (CDCl3, 500 MHz): δ 7.60 (d, 2H, J = 7.0 Hz), 7.43-7.35 (m, 8H), 7.18 (s, 2H), 5.01 
(s, 2H), 4.98 (s, 2H).
 
 
 
2-15 (0.103 g, 0.385 mmol) and imidazole (0.141 g, 2.07 mmol) were dissolved in DMF 
(2 mL) in an oven-dried flask under Ar. In a separate flask, TBSCl (0.186 g, 1.24 mmol) was 
dissolved in DMF (3 mL). The TBSCl solution was added to the other reagents and the 
combined solution was stirred overnight. The DMF solution was extracted with hexanes (4 x 10 
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mL) and the combined hexane fractions were washed with water (1 x 10 mL), dried over 
magnesium sulfate, filtered through silica, and concentrated. 2-25 (0.187 g, 0.377 mmol, 98%) 
was collected as a clear/colorless oil that slowly solidified to a white solid.  
1H-NMR (CDCl3, 500 MHz): δ 6.98 (s, 2H), 1.04 (s, 9H), 0.96 (s, 9H), 0.33 (s, 6H), 0.18 (s, 
6H).  
 
 
K2CO3 (0.525 g, 3.80 mmol) and dimethylsulfate (0.36 mL, 3.8 mmol) were added to a 
solution of 2-15 (0.249 g, 0.931 mmol) in acetone (25 mL). This mixture was heated to reflux 
under air. After 3h the solvent was evaporated and the residue was dissolved in ether and water, 
shaken and the layers were separated. The organic layer was dried over magnesium sulfate and 
concentrated. The residue was purified by silica gel chromatography (4:1 hexanes:CH2Cl2). 2-26 
(0.202 g, 0.682 mmol, 73%) was collected as a colorless oil.  
1H-NMR (CDCl3, 400 MHz): δ 7.04 (s, 2H), 3.82 (s, 3H), 3.75 (s, 3H).  
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 2-16 (4.91 g, 12.2 mmol) was dissolved in 1M NaOH (120 mL) and stirred for 15 
minutes. The solution was rendered acidic with a solution of 14% HCl at which a voluminous 
pink precipitate formed. The mixture was extracted with ethyl acetate (3 x 50 mL), following 
which the combined organic fractions were washed with brine (1 x 40 mL), dried over 
magnesium sulfate and concentrated. The residue was recrystallized from toluene/hexane to yield 
2-16 as peach-colored needles (4.08 g, 11.3 mmol, 93%).  
1H-NMR (d6-acetone, 500 MHz): δ 8.00 (bs, 2H), 7.29 (s, 2H). 
 
 
 4-Acetoxyphenol (1.004 g, 6.60 mmol) and NaHCO3 (1.10 g, 13.1 mmol) were added to 
20 mL methanol at 0 ºC. A solution of ICl in methanol (1.75 M, 7.50 mL, 13.1 mmol) was 
dripped in over one minute. The reaction solution was stirred on ice for 26 hours. Toluene (25 
mL) was added and solution volume was reduced to about 10 mL by rotary evaporation at 
ambient temperature. This dark mixture was loaded directly onto a silica gel column and eluted 
with 1:1 hexane:CH2Cl2. 2-33 (1.89 g, 4.68 mmol, 71%) was collected as a yellow solid.  
1H-NMR (d6-acetone, 400 MHz): δ 7.58 (s, 2H), 2.23 (s, 3H). 
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 Acetic anhydride (2 mL, 20 mM) was added to 2-33 (58.3 mg, 0.144 mmol) under argon 
and was heated to 80 ºC for 48h. The solvent was evaporated under reduced pressure and the 
residue was dissolved in DMC and filtered through silica gel. 2-34 (61.9 mg, 0.139 mmol, 96%) 
was collected as a white solid. 
1H-NMR (CDCl3, 500 MHz): δ 7.57 (s, 2H), 2.40 (s, 3H), 2.27 (s, 3H).  
 
 
 2-35 (1.00g, 2.76 mmol) and K2CO3 (1.53 g, 11.1 mmol) were added to 50 mL acetone 
and purged with argon. Benzyl bromide (0.92 mL, 7.74 mmol) was added and the solution was 
heated to reflux under argon for 2.5 hours. The solvent was evaporated under reduced pressure 
and the residue was dissolved in 40 mL CH2Cl2 and 20 mL H2O. The layers were separated and 
the aqueous layer was extracted once with CH2Cl2 (20 mL). The combined organic fractions 
were washed with water (1 x 10 mL), dried over magnesium sulfate and concentrated. The crude 
material was purified by silica gel chromatography by eluting with 4:1 to 2:1 hexanes:CH2Cl2. 2-
35 (1.39 g, 2.57 mmol, 93%) was collected as white crystals.  
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1H-NMR (CDCl3, 400 MHz): δ 7.67 (d, 2H, J = 7.2 Hz), 7.44-7.37 (m, 10H), 5.00 (s, 2H), 4.96 
(s, 2H). 
 
 
 
2-16 (0.14 g, 0.39 mmol) and imidazole (0.187 g, 2.75 mmol) were dissolved in DMF (5 
mL) in an oven-dried flask under Ar. In a separate flask, TBSCl (0.193 g, 1.28 mmol) was 
dissolved in DMF (3 mL). The TBSCl solution was added to the other reagents and the 
combined solution was stirred for 72h. The DMF solution was extracted with hexanes (4 x 10 
mL) and the combined hexane fractions were washed with water (2 x 10 mL), dried over 
magnesium sulfate, filtered through celite, and concentrated. 2-36 (0.20 g, 0.34 mmol, 87%) was 
collected as a clear/colorless oil that slowly solidified to a white solid.  
1H-NMR (CDCl3, 500 MHz): δ 7.27 (s, 2H), 1.06 (s, 9H), 0.96 (s, 9H), 0.44 (s, 6H), 0.18 (s, 
6H).  
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 2-35 (0.770 g, 1.42 mmol), potassium acetate (1.6 g, 16 mmol), PdCl2(dppf) (0.223 g, 
0.273 mmol) and bispinacolborane (0.825 g, 3.25 mmol) were added to an oven-dried flask and 
purged by cycling between vacuum and argon 3 times. Dry DMSO (10 mL) was added by 
syringe and the mixture was heated to 80 ºC for 24 hours. After cooling, the mixture was diluted 
to 20 mL with DMSO and extracted with hexane (3 x 25 mL). The combined hexane fractions 
were washed with water (2 x 10 mL) and brine (1 x 10 mL) then dried over magnesium sulfate 
and concentrated to a colorless oil that solidified under vacuum. The crude material (2-38) (0.587 
g) was used in the next step without further purification.  
1H-NMR (CDCl3, 400 MHz): δ 7.71 (d, 2H, J = 5.6 Hz), 7.49-7.32 (m, 12H), 5.07 (s, 2H), 4.96 
(s, 2H), 1.32 (s, 24H). 
 
 
Crude 2-38 was added to a flask with PdCl2(dppf) (0.179 g, 0.219 mmol), potassium 
carbonate (1.20 g, 8.68 mmol) and 2-17 (1.01 g, 4.50 mmol) before being purged by cycling 
between vacuum and argon twice. Argon-purged DME (9 mL) and water (1 mL) were added by 
syringe and the solution was heated to 80 ºC for 5 hours. The mixture was partitioned between 
water (10 mL) and ethyl acetate (10 mL) and the layers were separated after mixing. The 
aqueous fraction was extracted further with ethyl acetate (2 x 10 mL). The combined organics 
were washed with brine (1 x 10 mL), dried over magnesium sulfate, and concentrated. The crude 
60 
material was purified by silica gel chromatography by eluting with 1:1 hexane:EtOAc then with 
EtOAc. 2-40 (0.173 g, 0.357 mmol, 25% over 2 steps) was collected as a brown oil.  
1H-NMR (CDCl3, 500 MHz): δ 7.41-7.29 (m, 10H), 6.65 (s, 2H), 6.00 (bs, 2H), 5.94 (d, 2H, J = 
1.5 Hz), 4.96 (s, 2H), 4.82 (s, 2H), 2.65 (d, 6H, J = 4.5 Hz), 1.99 (d, 6H, J = 1.5 Hz). 
 
 
 2-37 (0.771 g, 1.98 mmol), potassium acetate (1.20 g, 12.3 mmol), PdCl2(dppf) (0.339 g, 
0.415 mmol) and bispinacolborane (1.19 g, 4.67 mmol) were added to an oven-dried flask and 
purged with argon. Dry DMSO (7.5 mL) was added by syringe and the mixture was heated to 80 
ºC for 24 hours. After cooling, the mixture was diluted to 17.5 mL with DMSO and extracted 
with hexane (5 x 20 mL). The combined hexane fractions were washed with water (2 x 20 mL) 
then dried over magnesium sulfate and concentrated to a colorless oil that solidified under 
vacuum. The crude material (2-39, 0.591 g) was used in the next step without further 
purification.  
1H-NMR (d6-acetone, 400 MHz): δ 7.24 (s, 2H), 3.77 (s, 3H), 3.73 (s, 3H), 1.34 (s, 24H). 
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 Crude 2-39 (511 mg, 1.31 mmol) was added to a flask with potassium carbonate (1.085 g, 
7.85 mmol), PdCl2(dppf) (217 mg, 0.266 mmol) and 2-17 (864 mg, 3.84 mmol) before purging 
by cycling between vacuum and argon twice. Argon-purged DME (10 mL) and water (2 mL) 
were added by syringe and the solution was heated to 80 ºC for 26 hours. The mixture was 
partitioned between water (10 mL) and EtOAc (10 mL) and the layers were separated after 
shaking. The aqueous fraction was extracted once more with EtOAc (10 mL). The combined 
organics were washed with brine (1 x 10 mL), dried over magnesium sulfate, and concentrated. 
The crude material was purified by silica gel then reverse-phase chromagraphy. 2-41 (0.14 g, 
0.43 mmol, 25% from 2-37) was isolated as a yellow oil. 
1H-NMR (CDCl3, 400 MHz): δ 6.45 (s, 2H), 6.28 (d, 2H, J = 4.5 Hz), 5.88 (d, 2H, J = 1.5 Hz), 
3.66 (s, 3H), 3.58 (s, 3H), 2.60 (d, 6H,J = 5.0 Hz), 2.07 (d, 6H, J = 1.0 Hz).  
 
 
 2-16 (0.994 g, 2.75 mmol), K2CO3 (1.53 g, 11.1 mmol) and Me2SO4 (0.63 mL, 6.66 
mmol) were added to 50 mL acetone, purged with Ar, and heated to reflux for 2 hours. The 
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solvent was evaporated under reduced pressure and the residue was dissolved in CH2Cl2 and 
H2O. The layers were separated and the aqueous layer was extracted once with CH2Cl2 (20 mL). 
The combined organics were filtered through a silica plug (~75 mL silica) and the plug was 
washed to a total volume of 200 mL filtrate. The solvent was evaporated to a pale brown oil 
which solidified under vacuum. 2-37 (1.02 g, 2.62 mmol, 95%) was pure by NMR.  
1H-NMR (CDCl3, 400 MHz): δ 7.30 (s, 2H), 3.80 (s, 3H), 3.74 (s, 3H).  
 
 
 H5IO6 (1.00 g, 4.39 mmol) was dissolved in 10 mL conc. H2SO4. The solution was cooled 
on ice then KI (2.18 g, 13.1 mmol) was added portionwise to control the exotherm. After KI was 
added the solution was allowed to warm to RT before being chilled again on ice. 2-58 was added 
over 1 min. After stirring 10 minutes, the ice bath was removed and the mixture stirred another 
40 min. The mixture was then poor carefully onto ice and the precipitate was collected by 
filtration and was washed with methanol. The solid was dried under vacuum to yield 2-57 (2.97 
g, 7.45 mmol, 85% yield) was a white solid.  
1H-NMR (CDCl3, 400 MHz): δ 8.29 s, 1H), 7.52 (s, 1H).  
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 To a hot, oven-dried Schlenk flask with stir bar was added KOAc (1.50 g, 15.3 mmol) 
and vacuum was applied to dry the salt until the flask was cool. To this flask was added 
PdCl2(dppf) (0.300 g, 0.367 mmol, 15 mol%), B2pin2 (1.30 g, 5.12 mmol) and 2-59 (1.01 g, 2.52 
mmol). The flask was evacuated and backfilled with argon (2x). Dry DMSO (20 mL) was added 
by syringe and the mixture was plunged into an oil bath at 90 ºC. Color changed from yellow to 
red to black over five minutes. The mixture was allowed to stir with heating for 23 hours. After 
cooling, the mixture was poured into a separatory funnel with an additional 15 mL DMSO and 
then extracted with hexanes (10 x 25 mL). The combined hexane extracts were washed with 
water until the organic layer was clear. The organic fraction was then dried over MgSO4, filtered, 
and evaporated to an off-white solid. The crude solid (0.883 g) was a mixture of 2-59 and B2pin2 
(molar ratio ~7:1). The yield of 2-59 was calculated from this ratio to be 78% (780 mg, 2.0 
mmol). This material was used without purification in the subsequent Suzuki cross coupling. 
1H-NMR (CDCl3, 400 MHz): δ 7.95 (s, 1H), 7.37 (s, 1H), 1.36 (s, 24H). 
 
 
To a Schlenk flask with a stir bar was added crude 2-59 (753 mg total mass, estimated 
663 mg and 1.66 mmol 2-59), PdCl2(dppf) (302 mg, 0.37 mmol, 20 mol%), K2CO3 (1.56 g, 11.3 
mmol), and 2-17 (1.45 g, 5.63 mmol) and the flask was evacuated and backfilled with argon 
three times. Water (1 mL) and DME (9 mL) were added by syringe after degassing the solvents 
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by bubbling with argon for 45 minutes. The flask was plunged into an oil bath at 90 ºC for 16h. 
The mixture was poured into a separatory funnel and diluted with water (20 mL). The mixture 
was extracted five times with DCM. The combined organic extracts were washed with water (1 x 
10 mL), dried over MgSO4, filtered and evaporated to a deep red oil. The crude product was 
dissolved in CH2Cl2 and loaded onto a silica plug and eluted with EtOAc. The fractions 
containing 2-60 were evaporated to an orange solid. This solid was recrystallized from EtOAc 
with hot filtration to remove an insoluble solid. Compound 2-60 was isolated as pale pink 
crystals (251 mg, 0.736 mmol, 34% over two steps from 2-57).  
1H-NMR (CDCl3, 500 MHz): δ 7.47 (s, 1H), 6.93 (s, 1H), 5.95 (q, 2H, J = 1.5 Hz), 5.47 (bs, 2H, 
NH), 2.70 (d, 6H, J = 5.0 Hz, NCH3), 2.12 (d, 6H, allylic CH3, J = 1.5 Hz). 
 
 
 To a 40 mL I-Chem vial with a stir bar was added 2-60 (220 mg, 0.645 mmol), K2CO3 
(325 mg, 0.3.87 mmol), Pd(OAc)2 (15.2 mg, 0.068 mmol), and X-Phos (62.1 mg, 0.130 mmol). 
i-PrOH (9 mL) was added and the vial was capped while flushing with argon. The vial was 
plunged into an oil bath at 85 ºC. The reaction was allowed to stir with heating for 13.5 hours. 
The solvent was evaporated and the residue was slurried in CH2Cl2 and loaded onto a silica gel 
column and eluted with DCM with increasing amounts of methanol (0-5%). Crude product was 
further purified by recrystallization from chloroform (30 mL). The filtrate was evaporated and 
the residue was purified by column chromatography (0-5% MeOH in EtOAc) and combined with 
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the recrystallized material. 2-51 (178 mg, 0.663 mmol, quantitative within error of the balances) 
was isolated as an off-white solid.  
1H-NMR (2:1 CDCl3:CD3OD, 500 MHz): δ 8.11 (s, 1H), 7.32 (s, 1H, aryl CH), 6.60 (d, 2H, J = 
1.0 Hz, vinyl CH), 3.82 (s, 6H, N-CH3), 2.61 (d, 6H, J = 1.0 Hz, allylic CH3). 
 
 
 Preparation of LDA: To an oven-dried Schlenk flask was added dry THF (23.2 mL), 
diisopropylamine (14.0 mL, 99.9 mmol) and a stir bar. After cooling the flask in a dry 
ice/isopropanol bath, n-BuLi (1.6 M in hexanes, 62.8 mL, 100. mmol) was added dropwise over 
about 15 minutes. The flask was then transferred to an ice bath for temporary storage. 
 To an oven-dried 250 mL Schlenk flask and stir bar under argon was added dry THF (50 
mL) and 2,6-dichloroanisole (2-63, 5.00 mL, 36.5 mmol). The flask was chilled in a -75 ºC bath 
and freshly prepared LDA (1.0 M, 44 mL, 44 mmol) was added by syringe over 15 minutes. The 
reaction was stirred for 3.25h between -65 and -75 ºC and was kept in this temperature range for 
the duration of the reaction. TMSCl (5.60 mL, 43.8 mmol) was then added and the mixture was 
stirred for 1h. A second aliquot of LDA (47 mL, 47 mmol) was then added followed, after three 
more hours, by a second aliquot of TMSCl (6.50 mL, 50.9 mmol). The mixture was allowed to 
stir and warm overnight and had reached -20 ºC after 14 h. The cloudy yellow solution was 
quenched with 15 mL water, which dissolved the precipitate. The mixture was transferred to a 
separatory funnel, diluted with 1M HCl (15 mL) and ether (20 mL), and shaken and separated. 
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The aqueous phase was extracted once with ether (1 x 30 mL), and the combined organic 
extracts were washed with brine (1 x 20 mL), dried over MgSO4, filtered, and evaporated to a 
pale yellow oil which solidified under vacuum. Recrystallization from MeOH/H2O in two crops 
yielded 7.25 and 1.42 g of 2-62 as white flakes (8.67 g, 27.0 mmol, 74%). 
1H-NMR (CDCl3, 500 MHz): δ 7.25 (s, 1H, aryl CH), 3.89 (s, 3H, OCH3), 0.36 (s, 18H, 
Si(CH3)3. 
13C-NMR (CDCl3, 125 MHz, d1 delay set to 20 sec, dm = nny): δ 151.9, 138.7, 137.0, 136.7, 
60.5, -0.5. 
HRMS (EI) calcd for C13H22OSi2Cl2 (M)+: 320.0586, found: 320.0583. 
Melting point: 78.5-80.5 ºC. 
IR (cm-1, thin film in CDCl3): 2958 (w), 1397 (w), 1342 (m), 1251 (m). 
 
 
 Iodine monochloride (11.41 g, 70.28 mmol) was weighed into a 100 mL round-bottom 
flask with a stir bar and dissolved in 35 mL CH2Cl2. The flask was chilled on an ice-water bath 
and 2-62 (7.49 g, 23.3 mmol) was added portionwise at a slow enough rate to keep the solution 
temperature below 20 ºC. After the addition, a thick precipitate formed and more CH2Cl2 (35 
mL) was added to dissolve it. Stirring was continued for 0.5 h, after which water (10 mL) was 
added and NaHSO3 was added by spatula until the color of the solution ceased to fade. The 
aqueous layer was a clear yellow and the organic layer was colorless. The mixture was poured 
into a separatory funnel, diluted with water (20 mL) and CH2Cl2 (50 mL), and shaken and 
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separated. The aqueous phase was further extracted with CH2Cl2 (2 x 15 mL). The combined 
organic extracts were then washed with brine (1 x 20 mL), dried over MgSO4, filtered and 
evaporated to yield 2-61 as a white solid (9.965g, 23.24 mmol, 99.6%). Product may be 
recrystallized from hexanes to produce colorless needles. 
1H-NMR (CDCl3, 500 MHz): δ 8.14 (s, aryl CH), 3.88 (s, -OCH3). 
13C-NMR (CDCl3, 125 MHz): δ 152.6, 144.3, 135.0, 97.7, 60.8. 
HRMS (EI) calcd for C7H6OCl2 (M)+: 427.7729, found: 427.7731. 
Melting point: 138.5-140.5 ºC. 
IR (cm-1, thin film in CCl4): 1528 (w), 1394 (m), 1361 (s), 1005 (s). 
 
 
 To a hot, oven-dried Schlenk flask with stir bar was added KOAc (1.24 g, 12.6 mmol) 
and vacuum was applied to dry the salt until the flask was cool. To this flask was added 
PdCl2(dppf) (0.256 g, 15.0 mol%), B2pin2 (1.17 g, 4.59 mmol) and 2-61 (0.896 g, 2.09 mmol). 
The flask was evacuated and backfilled with argon (3x). Dry DMSO (12 mL) was added by 
syringe and the mixture was plunged into an oil bath at 80 ºC. Color changed from yellow to red 
to black over five minutes. The mixture was allowed to stir with heating for 19 hours. After 
cooling, the mixture was poured into a separatory funnel with an additional 5 mL DMSO and 
then extracted with hexanes (3 x 100 mL). The combined hexane extracts were washed with 
water (2 x 100 mL) until the organic layer was clear. The organic fraction was then dried over 
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MgSO4, filtered, and evaporated to an off-white solid. The crude solid (0.858 g) was a mixture of 
6 and B2pin2 (molar ratio ~3:1). The yield of 2-64 was calculated from this ratio to be 79% (712 
mg, 1.66 mmol). This material was generally used without purification in the subsequent Suzuki 
cross couplings. Recrystallization of the mixture from pentane yields pure 2-64 as colorless 
needles. 
1H-NMR (CDCl3, 500 MHz): δ 7.67 (s, 1H, aryl CH), 3.86 (s, 3H, OCH3), 1.37 (s, 24H, 
C(CH3)2). 
13C-NMR (CDCl3, 125 MHz): δ 152.3, 138.0, 137.1 (2C), 130 (broad, 2C), 84.5 (2C), 60.5, 25.0 
(8C). 
HRMS (ESI-TOF) calcd for C19H28B2O5Cl2 (M+H)+: 429.1587, found: 429.1591. 
Melting point: 185-187 ºC. 
IR (cm-1, thin film in CCl4): 2982 (m), 2935 (w), 1574 (m), 1446 (m), 1362 (s), 1333 (s), 1143 
(s), 1033 (m). 
 
 
 To a Schlenk flask with a stir bar was added crude 2-64 (404 mg total mass, estimated 
323 mg and 0.755 mmol 2-64), PdCl2(dppf) (123 mg, 20 mol%), K2CO3 (627 mg, 4.54 mmol), 
and 2-17 (510 mg, 2.27 mmol) and the flask was evacuated and backfilled with argon three 
times. Water (1 mL) and DME (9 mL) were added by syringe after degassing the solvents by 
bubbling with argon for 45 minutes. The flask was plunged into an oil bath at 80 ºC for 3h. The 
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mixture was poured into a separatory funnel and diluted with water (5 mL). The mixture was 
extracted with EtOAc (3 x 20 mL). The combined organic extracts were dried over MgSO4, 
filtered and evaporated to a deep red oil. The crude product was dissolved in CH2Cl2 and loaded 
onto a silica plug (diameter: 48 mm, height: 30 mm) and eluted with EtOAc. The fractions 
containing 2-65 were evaporated to a red solid. This solid was stirred in 3 mL EtOAc and 
filtered. The solid was washed twice with 2 mL portions of EtOAc then allowed to dry on the 
filter. Compound 2-65 was isolated as colorless crystals (152 mg, 0.409 mmol, 55% from 
estimated 2-64, 43% over two steps from 2-61). 
1H-NMR (CDCl3, 500 MHz): δ 6.73 (s, 1H, aryl CH), 5.94 (q, 2H, J = 1.5 Hz, vinylic CH), 5.59 
(bs, 2H, NH), 3.91 (s, 3H, OCH3), 2.69 (d, 6H, J = 4.5 Hz, NCH3), 2.12 (d, 6H, allylic CH3, J = 
1.0 Hz). 
13C-NMR (CDCl3, 125 MHz): δ 165.8, 145.4, 140.0, 125.5, 124.2, 124.2, 123.3, 61.0, 26.5, 
25.4. 
HRMS (ESI-TOF) calcd for C17H20N2O3Cl2 (M+H)+: 371.0929, found: 371.0915. 
Melting point: Darkened at 210 ºC, decomposed at 230 ºC. 
IR (cm-1, thin film in CDCl3): 3383 (w), 3326 (b, w), 2979 (w), 2939 (w), 1663 (m), 1641 (m), 
1608 (m), 1525 (m), 1368 (m). 
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 To a 1-dram vial with a stir bar was added 2-65 (16.3 mg, 0.0440 mmol), K2CO3 (36.70 
mg, 0.266 mmol), Pd/X-Phos (3.25 mg, 10.0 mol%), and X-Phos (2.20 mg, 10.5 mol%). The vial 
was cycled between vacuum and argon three times and i-PrOH (1.75 mL) was added while 
flushing the vial with argon. The vial was sealed with a Teflon-lined cap and immersed in an oil 
bath at 110 ºC. The reaction was allowed to stir with heating for 16 hours. Insoluble materials 
were removed by filtration through Celite and rinsed with CH2Cl2. The filtrate was evaporated 
and the residue was purified by column chromatography (0-5% MeOH in EtOAc). Compound 2-
53 (12.6 mg, 0.0422 mmol, 96%) was isolated as white solid. 
1H-NMR (CDCl3, 500 MHz): δ 7.68 (s, 1H, aryl CH), 6.57 (d, 2H, J = 1.5 Hz, vinyl CH), 3.86 
(s, 6H, N-CH3), 3.50 (s, 3H, OCH3), 2.50 (d, 6H, J = 1.0 Hz, allylic CH3). 
13C-NMR (CDCl3, 125 MHz): δ 164.1, 146.1, 137.2, 136.3, 120.8, 119.8, 116.9, 62.4, 35.9, 
19.2. 
HRMS (ESI-TOF) calcd for C17H18N2O3 (M+H)+: 299.1396, found: 299.1385. 
Melting point: >250 ºC. 
IR (cm-1, thin film in CDCl3): 2962 (w), 1648 (s), 1619 (m), 1583 (s), 1445 (m), 1394 (m), 
1354 (m), 1325 (m), 1035 (m). 
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 In a 7-mL vial with a stir bar, 2-53 (29.8 mg, 0.100 mmol) was dissolved in conc. HNO3 
(3 mL) and the vial was plunged into an oil bath at 80 ºC. After 15 minutes the flask was 
removed from heat and the solution was diluted with water (4 mL), transferred to a separatory 
funnel and extracted with CH2Cl2 (3 x 10 mL). The aqueous phase was carefully neutralized with 
10 M NaOH (a dark color persists when the acid is consumed) and extracted once more with 
CH2Cl2 (10 mL). The organic extracts were loaded directly onto a silica gel column and eluted 
with a gradient of 0 to 5% MeOH in EtOAc. Product was isolated as a deep red fraction which 
was evaporated to a bright red-orange solid. This was dissolved in 5 mL CH2Cl2 and filtered to 
remove a sparingly soluble yellow material. The filtrate was evaporated to yield SCH 538415 as 
a bright red-orange solid (11.9 mg, 0.0399 mmol, 40%). Spectral data match the reported natural 
product.17,18 SCH 538415 can be further purified by sublimation (180 ºC, 300 mtorr). 
1H-NMR for 2-10 (CDCl3, 500 MHz): δ 6.65 (d, 2H, J = 1.0 Hz, vinyl CH), 3.73 (s, 6H, NCH3), 
2.56 (d, 6H, J = 1.0 Hz, allylic CH3). 
13C-NMR for 2-10 (CDCl3, 125 MHz): δ 181.5, 178.9, 161.5, 149.1, 143.0, 126.6, 117.0, 34.2, 
22.8. 
HRMS for 2-10 (ESI-TOF) calcd for C16H14N2O4 (M+H)+: 299.1032, found: 299.1020. 
Melting point for 2-10: >250 ºC. 
IR for 2-10 (cm-1, thin film in CDCl3): 1662 (b, w), 1362 (w). 
1H-NMR for 2-66 (CDCl3, 500 MHz): δ 6.70 (d, 1H, J = 1.0 Hz, vinyl CH), 3.83 (s, 3H, NCH3), 
3.74 (s, 3H, NCH3), 2.56 (s: accidental overlap – two separate signals are seen in other spectra, 
6H, allylic CH3). 
13C-NMR for 2-66 (CDCl3, 125 MHz): δ 180.4, 177.8, 161.2, 154.3, 148.9, 142.9, 142.5, 140.8, 
127.2, 117.8, 115.4, 35.3, 34.2, 22.7, 16.9. 
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 To a 7 mL vial with stirbar was added ethyl 2-butynoate (506 mg, 4.51 mmol) and 
concentrated NH4OH (~30%, 1.5 mL, 18 mmol) and the biphasic solution was stirred vigorously 
for 17 h during which time a thick white precipitate formed. This solid was collected by filtration 
and dried under vacuum to yield 2-69 as a white solid (198 mg, 2.38 mmol, 53%). 
1H-NMR (d6-DMSO, 500 MHz): δ 7.813 (bs, 1H, NH), 7.362 (bs, 1H, NH), 1.91 (s, 3H, CH3). 
13C-NMR (d6-DMSO, 125 MHz): δ 154.4, 82.4, 75.9, 3.0. 
HRMS (EI) calcd for C4H5NO (M)+: 83.0371, found: 83.0370. 
Melting point: 151-152.5 ºC. 
IR (cm-1, thin film in CDCl3): 1665 (w), 1583 (w), 1369 (w). 
 
 
To a 1-dram vial with a stir bar was added 2-69 (118 mg, 1.41 mmol), NaI (337 mg, 2.25 
mmol), and acetic acid (0.52 mL, 9.1 mmol). The vial was closed with a screw-on cap and 
plunged into a preheated oil bath at 100 ºC for 16h. The deep red reaction mixture was diluted 
with water (20 mL) and EtOAc (20 mL), treated with NaHSO3 until the color stopped fading 
(pale yellow), then neutralized with 8 mL 1M NaOH. This mixture was poured into a separatory 
funnel and the aqueous layer was extracted with EtOAc (1 x 10 mL). The combined organic 
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layers were washed with sat. NaHCO3 (1 x 10 mL) and brine (1 x 10 mL), dried over MgSO4, 
and evaporated to yield 162 mg (0.765 mmol, 54%) of 2-70 as a white flakey solid. 
1H-NMR (CDCl3, 500 MHz): δ 6.28 (d, 1H, J = 1.0 Hz, vinyl CH), 5.80 (bs, 2H, NH2), 2.69 (d, 
3H, J = 1.0 Hz, allylic CH3) 
13C-NMR (CDCl3, 100 MHz): δ 165.4, 128.7, 105.7, 35.3. 
HRMS (ESI-TOF) calcd for C4H6NOI (M+H)+: 211.9572, found: 211.9582. 
Melting point: 87-92 ºC. 
IR (cm-1, thin film): 3332 (s), 3167 (s), 1665 (s), 1622 (s), 1425 (m), 1403 (s), 1260 (m). 
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 To a flask containing 2-butynoic acid (0.503 g, 5.98 mmol), NaI (1.434 g, 9.57 mmol) 
and a stir bar was added glacial acetic acid (2.2 mL, 38 mmol) and the flask was immersed in an 
oil bath at 115 ºC for 3h. The reaction mixture was poured into a separatory flask and diluted 
with water (10 mL) and ether (10 mL). NaHSO3 was added until the color of the solution faded 
to a pale yellow, then the mixture was shaken and separated. The aqueous fraction was extracted 
with ether (3 x 10 mL) then the combined organic fractions were dried over MgSO4 and 
evaporated to yield 2-73 as a white solid (1.19 g, 5.59 mmol, 94%). Acid 2-73 can be 
recrystallized with good recovery from CHCl3/heptane to yield large prismatic crystals. 
1H-NMR (CDCl3, 500 MHz): δ 12.19 (bs, 1H, COOH), 6.36 (d, 1H. J = 1.5 Hz, vinyl CH), 2.77 
(d, 3H, J = 1.0 Hz, allylic CH3). 
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13C-NMR (CDCl3, 125 MHz): δ 169.8, 125.4, 117.1, 37.3. 
HRMS (ESI-TOF) calcd for C4H5O2I (M+Na)+: 234.9232, found: 234.9234. 
Melting point: 113-115 ºC. 
IR (cm-1, thin film in CDCl3): 2978 (b, m), 2702 (m), 2589 (m), 2506 (m), 1699 (s), 1619 (s), 
1434 (m), 1406 (m), 1303 (m), 1222 (s). 
 
 
 To an oven-dried 40 mL I-Chem vial with a stirbar was added 2-73 (1.03 g, 4.85 mmol) 
and the flask was evacuated and backfilled with argon. Dry CH2Cl2 (12 mL) was added and the 
solution was chilled on an ice-water bath. Oxalyl chloride (1.25 mL, 14.3 mmol) was added by 
syringe and the cold bath was removed. After 5h at room temperature the volatile components 
were evaporated directly from the vial. Dry CH2Cl2 (10 mL) was added to the residual oil and the 
vial was chilled on a dry ice/isopropanol bath. Freshly distilled p-methoxybenzyl amine (740 mg, 
5.39 mmol) was added dropwise by syringe followed by NEt3 (0.675 mL, 4.85 mmol). The 
mixture was allowed to warm to -40 ºC after 2h, then 1 M HCl (20 mL) was added and the 
solution was poured into a separatory funnel with CH2Cl2 (10 mL). Shaken and separated. The 
aqueous fraction was extracted with CH2Cl2 (4 x 10 mL) then dried over MgSO4 and evaporated 
to a white solid. The solid was slurried in 50 mL ether and hot filtered through Celite. The filtrate 
was diluted with 50 mL hexanes and heated to reflux until crystallization began. After cooling, 
pale tan crystals of 2-71 were collected by filtration (1.23 g). The mother liquor was purified by 
75 
column chromatography (hexanes/EtOAc = 2/1) then recrystallized from ether/hexanes to yield 
additional product as white needles (169 mg). Total 2-71: 1.40 g, 4.24 mmol, 87%. 
1H-NMR (CDCl3, 500 MHz): δ 7.20 (d, 2H, J = 8.0 Hz, aryl CH), 6.82 (d, 2H. J = 8.0 Hz, aryl 
CH), 6.35 (bs, 1H, NH), 6.23 (q, 1H, J = 1.5 Hz, vinylic CH), 4.37 (d, 2H, J = 3.5 Hz, NCH2), 
3.75 (s, 3H, OCH3), 2.61 (d, 3H, J = 1.5 Hz, allylic CH3). 
13C-NMR (CDCl3, 125 MHz): δ 164.7, 159.1, 130.0, 129.5, 128.9, 114.1, 106.5, 55.4, 43.1, 35.9. 
HRMS (ESI-TOF) calcd for C12H13NO2I (M+H)+: 332.0148, found: 332.0154. 
Melting point: 95-98 ºC. 
IR (cm-1, thin film in CDCl3): 3436 (w), 3311 (bw), 2959 (w), 2838 (w), 1656 (m), 1513 (s), 
1465 (w), 1302 (w), 1250 (m), 1176 (m), 1088 (w), 1035 (m). 
 
 
To a 7-mL vial with a stir bar was added crude 2-64 (97 mg total mass, estimated 81 mg 
and 0.19 mmol 2-64), PdCl2(dppf) (30.6 mg, 0.038 mmol, 20 mol%), K2CO3 (156 mg, 1.13 
mmol), and 2-71 (155 mg, 0.468 mmol) and the vial was evacuated and backfilled with argon 
three times. Water (1 mL) and DME (9 mL) were added by syringe after degassing the solvents 
by bubbling with argon for 45 minutes. The flask was plunged into an oil bath at 87 ºC for 2h. 
The mixture was poured into a separatory funnel and diluted with water (5 mL). The mixture was 
extracted with EtOAc (2 x 5 mL). The combined organic extracts were dried over MgSO4, 
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filtered and evaporated to a deep red oil. The crude product was dissolved in CH2Cl2 and purified 
by silica gel chromatography. The product was further purified by recrystallization from 
chloroform/heptanes. Compound 2-72 was isolated a microcrystalline solid (57.4 mg, 0.098 
mmol, 42% over two steps from 2-61). 
1H-NMR (CDCl3, 500 MHz): δ 6.99 (bs, 4H), 6.76-6.74 (m, 5H), 5.97 (d, 2H, J = 1.5 Hz, 
vinylic CH), 6.0-5.3 (bd, 2H), 4.3-4.1 (bd, 4H), 3.75 (s, 6H, OCH3), 3.72 (s, 3H, OCH3), 2.09 
(bs, 6H, allylic CH3). 
13C-NMR (CDCl3, 125 MHz): δ 165.1, 159 (bs), 145.3, 140 (bs), 131 (bs), 129.0, 125.6, 124.3, 
123.5 (bs), 114.0, 60.8, 55.5, 42.9, 25.5. 
 
 
 To a 1-dram vial with a stir bar was added 2-72 (29.4 mg, 0.0504 mmol), K2CO3 (42.2 
mg, 0.305 mmol), and Pd/X-Phos (6.1 mg, 0.005 mmol, 10.0 mol%). The vial was cycled 
between vacuum and argon and i-PrOH (1.5 mL) was added while flushing the vial with argon. 
The vial was sealed with a Teflon-lined cap and immersed in an oil bath at 85 ºC. The reaction 
was allowed to stir with heating for 14.5 hours. The solvent was evaporated and the residue was 
purified by column chromatography (0-100% EtOAc in hexanes). Compound 2-73 (23 mg, 
quant.) was isolated an oily solid. 
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1H-NMR (CDCl3, 500 MHz): δ 7.62 (s, 1H, aryl CH), 7.01 (bd, 4H, J = 7.5 Hz), 6.74 (d, 4H, J = 
8.0 Hz) 6.58 (s, 2H, vinyl CH), 5.9-5.4 (bs, 2H), 5.2-5.4 (bd, 4H), 3.72 (s, 6H, OCH3), 2.9 (bs, 
3H), 2.48 (s, 6H, allylic CH3). 
 
 
 2-73 (200 mg, 0.390 mmol) was slurried in 48% HBr (8 mL) and heated in an oil bath at 
115 ºC for 7 minutes. The reaction was diluted to 50 mL with water and the product was 
collected by filtration and washing with water and EtOAc. 2-67 was collected as a light yellow 
solid (102 mg, 0.378 mmol, 97%).   
1H-NMR (2:1 CDCl3:CD3OD, 500 MHz): δ 7.82 (s, 1H, aryl CH), 6.51 (d, 2H, J = 1.5 Hz, vinyl 
CH), 3.94 (s, 3H), 2.59 (d, 6H, J = 1.5 Hz, allylic CH3).  
 
OMe
Cl Cl
Bpin
2-64
pinB
NH HNO O
PMB ClCl
OMe
2-74
20% PdCl2(dppf)
6 equiv. K2CO3
1.5 equiv. 2-17
1.3 equiv. 2-71
DME/H2O = 9/1
85 ºC, 2h
27% from 2-61
 
 To a 40 mL I-Chem vial was added crude 2-64 (750 mg, 1.45 mmol), PdCl2(dppf) (239.1 
mg, 20 mol%), K2CO3 (1.20 g, 8.69 mmol), 2-17 (490.3 mg, 2.18 mmol), and 2-71 (625.4 mg, 
1.89 mmol) and the vial was capped with a screw-on lid with a septum and evacuated and 
backfilled with argon. Water (1 mL) and DME (10 mL) were added by syringe after degassing 
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the solvents by bubbling with argon for 30 minutes. The flask was immersed in an oil bath at 90 
ºC for 2.5 hours. The mixture was allowed to cool and then was poured into a separatory funnel, 
diluted with water (25 mL) and extracted with EtOAc (3 x 20 mL). The combined organic 
extracts were washed with brine (1 x 15 mL), dried over MgSO4, filtered and evaporated. The 
residue was purified by column chromatography (4:1 EtOAc:hexanes) to yield 2-74 as a pale 
yellow foam (231 mg, 0.484 mmol, 34% yield from estimated 2-64, 27% over two steps from 2-
61). 
1H-NMR (CDCl3, 500 MHz): δ 7.03 (bs, 2H, PMB CH), 6.74 (d, 3H, J = 8.0 Hz, PMB CH and 
aryl CH), 6.55 (bs, 1H, NH), 5.99 (bs, 1H, NH), 5.96 (s, 1H, vinyl CH), 5.92 (s, 1H, vinyl CH), 
4.20 (bd, 2H, J = 29 Hz, benzyl CH2), 3.79 (s, 3H), 3.73 (s, 3H), 2.57 (d, 3H, J = 3.5 Hz, NCH3), 
2.09 (s, 3H, allyl CH3), 2.07 (bs, 3H, allyl CH3). 
1H-NMR (CDCl3, 60 ºC, 500 MHz): δ 7.02 (bd, 2H, J = 6.5 Hz, PMB CH), 6.75 (d, 2H, J = 8.0 
Hz, PMB CH), 6.74 (s, 1H, aryl CH), 6.3 (bs, 1H, NH), 5.97 (s, 1H, vinyl CH), 5.93 (s, 1H, vinyl 
CH), 5.87 (bs, 1H, NH), 4.21 (bs, 2H, benzyl CH2), 3.80 (s, 3H), 3.73 (s, 3H), 2.58 (d, 3H, J = 
4.5 Hz, NCH3), 2.09 (s, 6H, allyl CH3), 2.06 (s, 3H, allyl CH3). 
13C-NMR (CDCl3, 60 ºC, 125 MHz): δ 165.9, 165.1, 159.1, 153.5, 145.4, 144.6, 140.2, 140.1, 
131.1, 128.9, 125.6, 125.5, 124.5, 124.3, 123.5, 114.2, 60.7, 55.4, 42.9, 26.3, 25.2 (2C). 
HRMS (ESI-TOF) calcd for C24H26Cl2N2O4 (M+H)+: 477.1348, found: 477.1331. 
Melting point: 157-162 ºC. 
IR (cm-1, thin film in CDCl3): 3404 (w), 2940 (w), 1663 (w), 1613 (w), 1514 (m), 1369 (w), 
1249 (w), 1029 (w). 
 
79 
 
 To a 1-dram vial with a stir bar was added 2-74 (39.9 mg, 0.0835 mmol), K2CO3 (69.9 
mg, 0.506 mmol), Pd/X-Phos (6.15 mg, 10.0 mol%), and X-Phos (4.03 mg, 10.1 mol%). The vial 
was cycled between vacuum and argon three times and i-PrOH (3.4 mL) was added while 
flushing the vial with argon. The vial was sealed with a Teflon-lined cap and immersed in an oil 
bath at 110 ºC. The reaction was allowed to stir with heating for 15 hours. After cooling, 
insoluble materials were removed by filtration through Celite and rinsing with CH2Cl2. [At this 
point 2-75 can be isolated in >95% yield by chromatographic purification with 0 to 2.5% MeOH 
in EtOAc. 1H-NMR (CDCl3, 500 MHz): δ 7.64 (s, 1H, anisole CH), 7.09 (d, 2H, J = 8.5 Hz, 
PMB CH), 6.73 (d, 2H, J = 8.5 Hz, PMB CH), 6.65 (d, 1H, J = 1.0 Hz, vinyl CH), 6.52 (d, 1H, J 
= 1.0 Hz, vinyl CH), 5.30 (bd, 2H, benzyl CH2), 3.72 (s, 3H), 3.65 (s, 3H), 3.25 (bs, 3H), 2.52 (d, 
3H, J = 1.0 Hz, allylic CH3), 2.46 (d, 3H, J = 1.5 Hz, allylic CH3).] The filtrate was evaporated 
and a stir bar and 2 mL 48% HBr were added. The flask was immersed in an oil bath at 110 ºC. 
[After 5 minutes of heating, 2-76 can be isolated in >95% yield by dilution of the acid in water 
and collection of the resulting precipitate. 1H-NMR (2:1 CDCl3:CD3OD, 500 MHz): δ 7.84 (s, 
1H, aryl CH), 6.58 (d, 1H, J = 1.5 Hz, vinyl CH), 6.55 (d, 1H, J = 1.5 Hz, vinyl CH), 3.98 (s, 
3H), 3.82 (s, 3H), 2.61 (d, 3H, J = 1.0 Hz, allylic CH3), 2.57 (d, 3H, J = 1.5 Hz, allylic CH3). 
13C-NMR (CDCl3, 125 MHz): δ 164.7, 164.0, 149.9, 148.0, 134.7, 134.2, 133.9, 120.5, 120.1, 
119.7, 117.8, 117.6, 62.8, 34.2, 19.5, 19.1. HRMS (ESI-TOF) calcd for C16H16N2O3 (M+H)+: 
285.1239, found: 285.1226.] After 17 hours the reaction was removed from heat. The mixture 
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was carefully rendered basic over an ice bath by adding 10 M NaOH until the precipitate 
dissolved into a yellow solution. The residual solid was removed by filtration through hardened 
filter paper and discarded. The filtrate was rendered acidic with 1 M HCl, whereupon a colloidal 
precipitate formed. The mixture was then centrifuged (3220 x g for 5 minutes). The resulting 
semi-compact gelatinous solid was collected by filtration through hardened filter paper and dried 
to a constant mass under vacuum to yield 17.2 mg of 2-77 as light brown solid (17.2 mg, 0.0636 
mmol, 76% over 3 steps). 
1H-NMR (d-TFA, 500 MHz): δ 8.37 (s, 1H, aryl CH), 7.20 (s, 1H, vinyl CH), 7.03 (s, 1H, vinyl 
CH), 4.38 (s, 3H, NCH3), 2.78 (s, 3H, allylic CH3), 2.75 (s, 3H, allylic CH3). 
13C-NMR (d-TFA, 125 MHz): δ  167.2, 166.6, 160.4, 159.3, 135.7, 134.9, 133.6, 125.2, 123.6, 
120.4, 119.9, 116.1, 39.6, 20.9, 20.2. 
HRMS (ESI-TOF) calcd for C15H14N2O3 (M+H)+: 271.1083, found: 271.1076. 
Melting point: >250 ºC. 
IR (cm-1, thin film in CDCl3): 3156 (b, m), 1674 (s), 1651 (s), 1589 (m), 1562 (m), 1432 (w), 
1378 (m), 1351 (m), 1332 (m), 1052 (w). 
 
 
 To a 7-mL vial containing 2-77 (17.2 mg, 0.0636 mmol), salcomine (2.08 mg, 0.0064 
mmol), and a stir bar was added MeOH (4 mL) and CH2Cl2 (2 mL). A balloon containing O2 was 
fitted over the mouth of the vial and the slurry was stirred at room temperature. The solid 
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dissolved after about 30 minutes. After 2.75h stirring, the solvent was evaporated and the residue 
was purified by silica gel chromatography (6% MeOH in CH2Cl2). DNQ was collected as a 
bright pink-red solid (13.9 mg, 0.0489 mmol, 77%). Product can be further purified by 
sublimation (200 ºC, 300 mtorr). 
1H-NMR (d5-pyridine, 500 MHz): δ 6.81 (s, 1H, vinyl CH), 6.76 (s, 1H, vinyl CH), 4.97 (bs, 
NH), 3.99 (s, 3H, NCH3), 2.57 (d, 3H, allylic CH3), 2.53 (d, 3H, allylic CH3). 
HRMS (ESI-TOF) calcd for C15H12N2O4 (M+H)+: 285.0875, found: 285.0864. 
Melting point: >250 ºC. 
IR (cm-1, thin film in CDCl3): 1656 (b, w), 1585 (w), 1469 (w), 1397 (w), 1379 (w), 1344 (w), 
1290 (w), 1098 (w). 
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Chapter 3. Determination of the Mode of Action of DNQ 
 
Portions of this Chapter are reprinted with permission from Bair, J. S.; Palchaudhuri, R.; and 
Hergenrother, P. J. J. Am. Chem. Soc. 2010, 132, 5469-5478. Copyright 2010 American 
Chemical Society. Contributions from R. P. are noted in the Figures.  
 
3.1. DNQ kills cells through ROS generation 
 
3.1.1 Activity versus cancer cells in culture. 
The abilities of DNQ and SCH 538415 to induce death of cancer cell lines in culture were 
determined using the sulforhodamine B assay.1 For these experiments, four cancer cell lines were 
used: SK-MEL-5 (human melanoma), MCF-7 (human breast cancer), HL-60 (human leukemia) 
and HL-60/ADR (doxorubicin-resistant HL-60). In addition to DNQ and SCH 538415, 
doxorubicin (DOX), elesclomol, fenretinide, β-lapachone, and arsenic trioxide were evaluated to 
obtain a side-by-side comparison with compounds that have ROS generation as part of their 
mechanism of anti-cancer activity (Chart 3.1). As shown in Table 3.1, DNQ potently induces 
death in these cancer cell lines, with nanomolar toxicity similar to the most potent compounds, 
DOX and elesclomol. DNQ is on average an order of magnitude more potent than SCH 538415 
against all cell lines. Importantly, while the HL-60/ADR cells are extremely resistant to DOX 
(~80-fold), they are only minimally resistant (~3-fold) to DNQ. 
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Chart 3.1. Cytotoxic compounds that have ROS production as part of their anticancer 
mechanism. 
 
Table 3.1. Toxicity of compounds to cancer cell lines in culture. Cell lines were incubated with 
compound for 72 hours, biomass was quantified using the SRB assay, and IC50 values were 
calculated from logistical dose-response curves. All IC50 values are in µM. Error is standard 
deviation of the mean, n ≥ 3. 
 SK-MEL-5 MCF-7 HL-60a HL-60/ADR 
DNQ 0.024 ± 0.002 0.016 ± 0.006 0.21 ± 0.13 0.67 ± 0.26 
SCH 538415 0.76 ± 0.25 0.87 ± 0.16 1.30 ± 0.04 2.5 ± 0.8 
DOX 0.16 ± 0.02 0.33 ± 0.04 0.064 ± 0.004 5.1 ± 2.1 
elesclomol 0.11 ± 0.04 0.024 ± 0.010 0.009 ± 0.004  
fenretinide >10000 12.5 ± 0.7 3.2 ± 1.9  
β-lapachone 1.0 ± 0.4 1.5 ± 0.1 0.72 ± 0.26  
As2O3 2.8 ± 1.0 5.9 ± 1.6 3.7 ± 1.6  
a
 Cell viability assessed by the MTS assay. 
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3.1.2 Hypoxia and antioxidants.  
As described in section 2.1.3 a previous study of multiple quinones suggested that ROS 
are generated in cells treated with DNQ.2 Thus, DNQ could generate ROS through redox cycling 
in the presence of O2 (as shown in Figure 3.1), ROS could be generated through another 
mechanism, or ROS could be a product of the cell death process. To explore the connection 
between ROS and cell death, cytotoxicity evaluations were made in the presence of antioxidants 
and under different partial pressures of O2. Antioxidants can quench ROS, and thus antioxidant 
treatment may decrease the cytotoxicity of an anticancer compound for which ROS is critical to 
cell death. In a similar fashion, if a compound generates cytotoxic ROS through redox cycling 
with O2 (Figure 3.1), cells grown in hypoxia should be less sensitive to the effect of the 
compound. Thus, the effect of DNQ and other anti-cancer agents were evaluated against HeLa 
cells in normoxia (~20% O2), in the presence of the antioxidant N-acetyl cysteine (NAC, 5 mM), 
under hypoxia (1% O2), or combined with NAC under hypoxia. Tirapazamine, a compound 
whose cytotoxicity is more pronounced under hypoxia,3-6 was utilized as a control.  
 
 
 
 Figure 3.1. Possibilities for DNQ ROS 
Quinones can be bioreduced to semiquinones
oxygen the quinone can be regenerated, forming superoxide. Alternatively, a two
bioreduction of quinones leads to the hydroquinone
oxidized by oxygen back to the parent quinon
 
The most striking results were found for 
NAC provided significant protection from both 
20-fold, respectively).8 Incubation under hypoxia also strongly protected the cells from these two 
compounds, but whereas complete cell death was still observed at the highest concentration of 
DNQ (10 µM), elesclomol-treated hypoxic cells were greater than 50% alive even at the highest 
concentrations (Figure 3.2). When co
was essentially nontoxic whereas 
conditions, still caused ~60% cell death at 10 
induces cell death through a ROS
radical anion from O2. SCH 538415
protection being observed by co-
production through a bioreduction/oxidation process. 
 via a one-electron process. In the presence of 
 which, although frequently stable, may by 
e.7  
DNQ and elesclomol (Table 3.2 and Figure 
DNQ- and elesclomol-induced toxicity (4
-treated with NAC under hypoxic conditions, elesclomol 
DNQ, although 25-fold less toxic than under normoxic 
µM (Figure 3.2). These results suggest that 
-based mechanism that relies on the production of superoxide 
 responded less strongly than DNQ in these assays, with no 
treatment with NAC (Table 3.2).  
87 
 
-electron 
3.2). 
- and 
DNQ 
88 
 
 The behavior of the other compounds was generally consistent with literature reports 
(Table 3.2): tirapazamine became significantly more toxic under 1% O2, whereas the toxicity of 
mitomycin C (known to require more severe hypoxia to increase in potency)9 remained 
unchanged. As expected, both menadione and arsenic trioxide were less toxic in the presence of 
NAC.10-13 The remaining compounds are known to display variable and cell line-dependent 
effects under these conditions.14-21 
 
 
 
 
 
 
 
 
 
89 
 
 
 
Figure 3.2. The effect of DNQ and elesclomol on HeLa cells in hypoxia and normoxia, and in 
the presence of NAC. Cells were treated with compound for 48 hours, and death was determined 
via the SRB assay. Error is standard deviation of the mean, n ≥ 3. 
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Table 3.2. IC50 values for compounds versus HeLa cells under normoxic (20% O2) and hypoxic 
(1% O2) conditions in the presence or absence of NAC.a  
 Normoxia Normoxia 
+ 5 mM NAC 
Hypoxia Hypoxia 
+ 5 mM NAC 
DNQ 0.20 ± 0.02 0.75 ± 0.06 
fc = 3.8a 
1.80 ± 0.44 
fc = 8.4 
5.1 ± 1.3 
fc = 26 
SCH 538415 
 
1.40 ± 0.250 1.4 ± 0.2 
fc = 1.0 
5.2 ± 2.4 
fc = 3.6 
7.9 ± 3.9 
fc = 5.4 
DOX 
 
0.10 ± 0.02 0.12 ± 0.02 
fc = 1.2 
0.05 ± .01 
fc = -2.2 
0.07 ± 0.03 
fc = -1.4 
etoposide 
 
1.3 ± 0.7 1.2 ± 0.2 
fc = 1.1 
0.520 ± 0.170 
fc = -2.1 
0.64 ± 0.27 
fc = -1.6 
mitomycin C 
 
0.10 ± 0.03 0.14 ± 0.04 
fc = 1.40 
0.06 ± 0.02 
fc = -1.5 
0.12 ± 0.04 
fc = 1.3 
menadione 
 
5.9 ± 1.2 19.0 ± 2.4 
fc = 3.5 
7.0 ± 0.7 
fc = 1.3 
22.0 ± 5.4 
fc = 4.0 
As2O3 
 
1.30 ± 0.25 3.7 ± 1.2 
fc = 2.9 
2.3 ± 1.1 
fc = 1.8 
6.0 ± 1.8 
fc = 4.5 
β-lapachone 
 
1.2 ± 0.2 1.6 ± 0.5 
fc = 1.3 
3.8 ± 1.0 
fc = 3.2 
6.1 ± 3.2 
fc = 5.4 
fenretinide 
 
4.4 ± 1.2 4.0 ± 0.5 
fc = -1.1 
4.40 ± 0.95 
fc = 1.0 
3.90 ± 0.87 
fc = -1.1 
elesclomol 
 
0.012 ± 0.004 0.26 ± .21 
fc = 20 
Xb X 
tirapazamine 
 
38 ± 6 42 ± 9 
fc = 1.1 
1.9 ± 0.3 
fc = -20 
2.10 ± 0.06 
fc = -18 
a
 Fold change (fc) is with respect to normoxia. Cells were treated with compounds for 48 hours, biomass 
was quantified using the SRB assay, and IC50 values were calculated from logistical dose-response 
curves. All IC50 values are in µM. Error is standard deviation of the mean, n ≥ 3. b X indicated that cells 
were >50% viable at every concentration. 
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3.1.3 Transcript profiling.  
To further investigate the mechanism by which DNQ induces death in cancer cells, cells 
treated with DNQ were analyzed by global transcript profiling, and the pattern of transcriptional 
response was compared to that of compounds with known modes of action. For this experiment, 
U-937 cells were treated with DNQ or vehicle control at 350 nM for 6 hours, at which point the 
mRNA was harvested and whole genome transcript profiling was performed using the Illumina 
HumanHT-12 array. This DNQ concentration and time point were chosen such that the data 
could be readily compared with the transcript profile data from cells treated with other 
compounds, as outlined in the Connectivity Map.22 The Connectivity Map consists of transcript 
profile data for >1300 compounds, many of which have known cellular targets. Previous studies 
have shown that, in many cases, compounds with similar modes of action will induce similar 
patterns of transcriptional response in cells.22,23 Comparing the transcript profile of DNQ with 
those compounds in the Connectivity Map database22 showed that none of the >1300 compounds 
strongly correlate with DNQ (See Supporting Figure 3.1). Importantly, the Connectivity Map 
database contains hundreds of cytotoxins and multiple quinones including doxorubicin, 
daunorubicin, and mitoxantrone. 
 The top 20 up-regulated and repressed genes in response to DNQ treatment are listed in 
Table 3.3. The largest individual transcript elevation upon treatment of U-937 lymphoma cells 
with DNQ occurred for the HMOX1 gene, encoding the antioxidant heme oxygenase 1 (HO-1) 
(8.8 fold change, Table 3.3). HO-1, a 32 kDa heat-shock protein, regulates cellular heme and 
iron concentrations.24,25 Elevated levels of this protein prevent cell death by converting heme to 
biliverdin, a potent antioxidant.26 This conversion also results in the production of carbon 
monoxide (a potential neurotransmitter), and free iron, which serves as an oxidative stress 
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signal.24 Biliverdin produced by heme oxygenase is rapidly degraded into bilirubin, another 
potent small molecule antioxidant.26 Other transcripts elevated in DNQ-treated cells include 
those for various ferritins, which are under the transcriptional control of NRF2, a transcription 
factor that may be activated under oxidative stress.27 Ferritins are responsible for the storage of 
free iron in a non-toxic and soluble form.27 Other oxidative stress-related transcripts that are also 
elevated include oxidative stress induced growth inhibitor 1 (OKL38) and sulfiredoxin 1 
homolog (SRXN1).28,29 The NRF2-oxidative stress pathway was also the most strongly 
implicated pathway by Ingenuity Pathway Analysis software (see Supporting Figure 3.2). In 
summary, global transcriptional profiling provides strong evidence that DNQ induces the 
oxidative stress response, consistent with a ROS-based mechanism of cell death. 
  
Table 3.3. HeLa cells were treated with DNQ (350 nM) or 1% DMSO for 6 hours, at which time 
the mRNA was isolated and the global transcriptional profile was determined. The top 20 
elevated and repressed transcripts from this experiment are listed. (Experiment performed by 
R.P.) 
Symbol Protein Function p value Fold 
Change 
HMOX1 heme oxygenase 1 antioxidant 0 8.8 
ADM adrenomedullin hypotensive and vasodilatator 
agent 
0.0000002 4.0 
IL8a interleukin 8 inflammation 0 3.7 
IL8a interleukin 8 inflammation 0 3.5 
DDIT4 DNA damage inducible transcript 4 cell growth inhibition 0.0000017 3.4 
FTH1 ferritin, heavy polypeptide-like 1 intracellular iron storage 0.0000002 2.3 
CDKN1A cyclin-dependent kinase inhibitor 
1A 
p53-dependent G1 phase arrest  0 2.3 
FTHL12 ferritin, heavy polypeptide-like 12 intracellular iron storage 0.0000012 2.3 
FTHL8 ferritin, heavy polypeptide-like 8 intracellular iron storage 0.0000187 2.2 
SLC2A3 facilitative glucose transporter glucose transport 0.0000018 2.2 
TNF tumor necrosis factor death ligand 0 2.2 
OKL38 oxidative stress induced growth 
inhibitor 1 
oxidative stress 0.0000005 2.2 
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Table 3.3 (cont.) 
FTHL11 ferritin, heavy polypeptide-like 11 intracellular iron storage 0.0000399 2.1 
FTHL2 ferritin, heavy polypeptide-like 2 intracellular iron storage 0.0002126 2.1 
CCL3L3 G0/G1 switch regulatory protein 
19-2 
cytokine 0 2.1 
SRXN1 sulfiredoxin 1 homolog oxidative stress 0 2.1 
MAFB V-maf musculoaponeurotic 
fibrosarcoma oncogene homolog B 
represses ETS1-mediated 
transcription 
0.0000005 2.1 
CCL3 G0/G1 switch regulatory protein 
19-1 
HIV-suppressive factor 0.0000003 2.1 
SLC2A14 glucose transporter type 14 glucose transport 0.0000044 2.0 
NDRG1 N-myc downstream regulated 1 p53-mediated caspase 
activation/apoptosis 
0.0000098 2.0 
VCX variably charged protein X-B1  0.0000004 -2.0 
VCX-C variably charged protein X-C  0.0000005 -1.9 
VCX3A variably charged protein X-A  0.0000001 -1.9 
GJB2 gap junction protein beta 2 cell-to-cell channel for 
ion/small molecules transfer 
0.0000094 -1.8 
MS4A7 CD20 antigen monocyte maturation 0.0000163 -1.7 
RBBP9 retinoblastoma-binding protein 9 resistance to TGF-beta1 growth 
inhibition  
0.0002341 -1.7 
ZFYVE26 zinc finger, FYVE domain 
containing 26 
 0.0000159 -1.7 
DHRS9 3-alpha hydroxysteroid 
dehydrogenase 
retinoic acid biosynthesis 0.0000457 -1.7 
RBM17 RNA binding motif protein 17 sickle cell anemia 0.0000303 -1.6 
FARP1 chondrocyte-derived ezrin-like 
protein 
 0.0000568 -1.6 
CCDC26 coiled-coil domain containing 2  0.0003167 -1.6 
CD47 CD47 molecule membrane transport/signal 
transduction 
0.0016747 -1.6 
MEF2D myocyte enhancer factor 2D transcription factor 0.0001738 -1.5 
CCDC136 coiled-coil domain containing 136  0.0005653 -1.5 
CXCL10 interferon-inducible cytokine IP-10 immune cell migration 0.0045669 -1.5 
CENPE centromere protein E G2-phase motor protein 0.001486 -1.5 
MS4A7 CD20 antigen monocyte maturation 0.0002341 -1.5 
KIF20A mitotic kinesin-like protein 2  0.0005729 -1.5 
TXNIP thioredoxin-binding protein 2 oxidative stress mediator 0.0252104 -1.5 
C5orf29 GRB2-binding adaptor protein transmembrane protein 0.0003523 -1.5 
aThese are different probes for the same transcript. 
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 To confirm that the treatment of cells with DNQ elevates heme oxygenase at the protein 
level, a Western blot for HO-1 was performed from cells treated with 0.5 or 1.0 µM DNQ for 6 
hours. As shown in Figure 3.3A, DNQ treatment elevated HO-1 protein levels in U-937 cells, an 
effect that could be substantially prevented by co-treatment with the antioxidant NAC. The 
induction of antioxidant genes encoding HO-1 and the ferritins is likely in response to cellular 
ROS generated upon treatment of cells with DNQ. 
 It has been noted that oxidative stress can activate the heat shock response (HSR) 
expression pathway and upregulate HSP-70.8,12,30 Thus, HSP-70 protein levels in cells treated 
with DNQ were analyzed by Western blot. Both DNQ and elesclomol caused an increase in 
HSP-70 levels in U-937 cells (Figure 3.3B), consistent with oxidative stress mediated 
upregulation of HSP-70. 
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A)  
 
B) 
 
 
Figure 3.3. DNQ treatment enhances the levels of proteins involved in the oxidative stress 
response. U-937 cells were treated with DNQ and control compounds, and the lysates were then 
probed by Western blot. A) Western blot for HO-1. B) Western blot for HSP-70. (Experiment 
performed by R.P.) 
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 Common biological properties of anthracycline-type compounds similar in structure to 
DNQ include DNA binding, topoisomerase inhibition, and cell cycle arrest in the S or G2/M 
phases.31-34 Thus, various in vitro and cell-based assays were performed to determine the 
importance of these mechanisms in cell death mediated by DNQ.  
 
3.1.4. Cell cycle arrest.  
Modes of cell death may be broadly categorized by their effects on the progression of 
actively dividing cells through the cell cycle. For example, DNA damaging agents and 
microtubule disrupters or stabilizers frequently arrest cells in mitosis (M-phase) whereas 
compounds that inhibit DNA synthesis or replication arrest in the synthesis (S) phase. Gene 
expression analysis of DNQ revealed the elevation of several transcripts related to p53 dependent 
pathways and G0/G1 cell cycle regulation (CDKN1A, CCL3L3, CCL3, NDRG1, OKL38). The 
down regulation of G2/M associated motor kinesin transcripts was also observed (CENPE and 
KIF20A, Table 3). The effect of DNQ on cell cycle progression was observed by treating HL-60 
cells with DNQ for 6 hours (Figure 3.4A). Consistent with the transcript profiling results DNQ 
caused significant cell cycle arrest in the G1 phase. In contrast, DOX-treated cells exhibited 
weak G2/M-phase arrest at low concentrations and a pronounced S-phase arrest at higher 
concentrations (Figure 3.4B).  
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A) 
 
B) 
 
Figure 3.4. A) DNQ treatment leads to arrest of cells in the G1-phase of the cell cycle, while B) 
doxorubicin treatment leads to S-phase arrest. HL-60 cells were treated with the indicated 
concentrations of compound (or DMSO control) for 6 hours, at which point DNA levels were 
analyzed by propidium iodide staining. Error bars represent standard deviation of the mean, n = 
3. (Experiment performed by R.P.) 
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3.1.5. DNA interaction.  
The capacity of DNQ to interact with DNA was assessed using an ethidium bromide 
displacement assay;35,36 DOX and 9-aminoacridine (9-AA) were also evaluated for comparison. 
Double-stranded DNA was preincubated with ethidium bromide in buffer before compound 
addition (final DMSO concentration: 5%). After 30 minutes the competition reached equilibrium 
and the fluorescence was measured. As shown in Figure 3.5A, DOX has a very strong effect in 
this assay, while DNQ has a much weaker effect. Considering the nearly equipotent cellular 
toxicity of DOX and DNQ, these data are consistent with the notion that DNA binding is not of 
primary importance in the anti-cancer action of DNQ.  
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A) 
 
B) 
  
Figure 3.5. A) Ethidium bromide displacement assay reveals large differences between DNQ 
and doxorubicin. Ethidium bromide was preincubated with herring sperm DNA prior to 
compound addition. Fluorescence was measured 30 min after compound addition. Error bars 
represent the standard deviation of the mean, n = 3. B) DNQ does not inhibit topoisomerase II in 
vitro. Topoisomerase II was added to a solution of catenated DNA, ATP and compound in assay 
buffer, and the reactions were allowed to proceed for 30 minutes at 37 ºC. Products were 
analyzed by agarose gel electrophoresis.  
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3.1.6. Topoisomerase II inhibition.  
The ability of DNQ to inhibit topoisomerase II in vitro was evaluated using a 
decatenation assay,37,38 and compared to the known topoisomerase II inhibitors DOX and 
etoposide. For this assay catenated DNA was incubated at 37 ºC for 30 minutes in a buffer 
containing purified topoisomerase II, ATP, and various concentrations of compound in DMSO. 
As shown in Figure 3.5B, DOX completely inhibited the topoisomerase II reaction at 10 µM, 
while DNQ showed virtually no inhibition at this concentration; the limited aqueous solubility of 
DNQ precluded its evaluations at higher concentrations. This data, together with the 
transcriptional profiling, cell cycle arrest, and DNA interaction assay results, supports the notion 
that DNQ-mediated death does not involve mechanisms common to anthracycline-type 
compounds. 
 
3.1.7. Discussion  
 The facile synthesis of DNQ described herein has allowed for the comprehensive 
biological evaluation of this interesting antineoplastic agent. As shown by cytotoxicity assays 
(Tables 3.1 & 3.2, Figure 3.2), DNQ induces death of cancer cells in culture with potencies on 
par with the front-line anticancer drug doxorubicin and the experimental therapeutic elesclomol. 
Among compounds evaluated that are believed to induce death predominantly through a ROS-
based mechanism of action, DNQ and elesclomol are by far the most potent and respond the 
most strongly to NAC and hypoxia. These latter results suggest that DNQ and elesclomol most 
directly cause death by ROS production and not by other mechanisms. However, despite these 
commonalities, the mechanisms by which these compounds produce superoxide appear to be 
very different. Elesclomol, a clinically-promising anticancer agent,39 is believed to produce ROS 
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through the chelation of copper and facilitation of copper redox, resulting in superoxide 
formation.40,41 In contrast, DNQ appears to induce death in cancer cells through rapid redox 
cycling of the quinone, a process that directly generates superoxide. To the best of our 
knowledge, DNQ is the most potent antineoplastic agent that operates predominantly through 
this direct ROS generation, bioreduction mechanism.  
 Additional evidence for the role of ROS in DNQ-mediated cell death was uncovered by 
global transcript profiling. As shown by the transcript profiles of a number of agents, oxidative 
stress results in the upregulation of genes related to three pathways: the antioxidant response 
(NRF2),42 the heat shock response,30 and metallothioneins.43,44 Small molecules that induce 
oxidative stress (arsenic trioxide,12,45,46 menadione,47 hydrogen peroxide,47,48 t-butyl peroxide,47 
elesclomol,8 motexafin gadolinium49,50) generally activate one or more of these pathways. The 
transcript profiling data presented suggests that DNQ strongly activates the NRF2 pathway, 
resulting in upregulation of genes such as HMOX1 and many ferritins which are downstream of 
antioxidant response elements. Western blot analysis demonstrates that DNQ also activates the 
HSR pathway resulting in upregulation of HSP70. Finally, experimental evidence indicates that 
common targets of planar polycyclic compounds (such as the anthracyclines, acridines, and 
ethidium bromide) are of minimal importance in DNQ-mediated toxicity, as DNQ-treated cells 
show a lack of S or G2/M phase arrest, no topoisomerase II inhibition, and minimal DNA 
intercalation.  
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3.2. DNQ generates ROS through a 2-electron bioreduction/oxidation mechanism catalyzed 
by NQO1. 
 As described in Chapter 1, quinones can generate ROS through either a 1- or 2-election 
bioreduction/oxidation process. While 1-electron reduction can be mediated by a number of 
reductases that are ubiquitously expressed in the body, 2-electron reduction is mediated almost 
exclusively by the enzyme NQO1, which is frequently overexpressed in tumors. 
Herein we show that DNQ undergoes an NQO1-dependent futile cycle, where oxygen is 
consumed, ROS is formed and extensive DNA damage triggers PARP1 hyperactivation, with 
dramatic decreases in essential NAD+/ATP nucleotide pools, indicative of programmed necrosis. 
Importantly, DNQ is 20- to 100-fold more potent than β-lap, with a significantly enhanced 
therapeutic window in NQO1+ versus NQO1- NSCLC cells. NQO1-dependent cytotoxicity of 
DNQ is also shown in breast, prostate, and pancreatic cancer models in vitro. Furthermore, we 
show that in vitro NQO1 processes DNQ much more efficiently than β-lap, suggesting that 
increased utilization accounts for its increased potency. Thus, DNQ offers significant promise as 
a selective therapeutic agent for the treatment of solid tumors with elevated NQO1 levels.  
 
3.2.1. DNQ kills cancer cells in an NQO1-dependent manner.  
 The lethality of DNQ was examined in the presence or absence of dicoumarol (DIC), a 
fairly specific NQO1 inhibitor, using two cancer cell lines, MCF-7 (breast) and A549 (NSCLC), 
that endogenously express elevated NQO1 levels (Figure 3.6). DNQ-induced lethality was also 
compared to lethality induced by β-lap or menadione (Chart 3.1). DIC potentiated menadione 
lethality in MCF-7 cells but did not affect menadione lethality in A549 cells (Figure 3.6C) for 
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unknown reasons.51,52 DIC spared DNQ lethality in both cell lines, similar to β-lap (Figure 
3.6A). However, DNQ was ~20-fold more potent than β-lap in both cell lines (compare Figs. 
3.6A to 3.6B). As with β-lap (5 µM), a minimum 2 hr exposure of A549 cells to DNQ (0.25 µM) 
was required for complete lethality (Supporting Figure 3.3), and this dose was used in all 
subsequent studies. 
 
Figure 3.6 (cont. on next page) 
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Figure 3.6. DNQ-induced lethality is NQO1-dependent. A) Endogenous, NQO1 over-expressing 
A549 or MCF-7 cells were treated with or without DNQ at various doses (µM, 2 h), in the 
presence or absence of DIC (DIC, 40 µM, 2 h). Lethality was monitored by relative survival 
assays as described in ‘Materials and Methods’. Data are means, ±SE for three independent 
experiments performed six times. B) Cells described in A were treated with or without β-lap at 
indicated doses (µM, 2 h) in the presence or absence of DIC. C) Cells were treated with or 
without menadione (µM, 2 h) in the presence or absence of DIC as in A. DIC potentiated 
menadione-mediated toxicity in MCF-7, but not in A549, cells. Control cells in ‘A-C’ were 
treated with identical concentrations of DMSO (<0.01%). ***, p < 0.001 (Experiment performed 
by Ying Dong, UTSW) 
 
 
 When assessed as a substrate for NQO1 in vitro, DNQ was processed at a significantly 
increased rate relative to β-lap, and relative to four other quinones (streptonigrin, menadione, 
RH1, mitomycin C). At 1 µM, DNQ was reduced by NQO1 ~13-fold more efficiently than other 
quinones (Table 3.4). Importantly, at IC100 levels (0.25 µM for DNQ, 5 µM for β-lap) in A549 
cells, the in vitro NQO1 NADH recycling activities using DNQ or β-lap were essentially 
identical, suggesting that the catalytic efficiency of NQO1 for DNQ was at least 20-fold greater 
than for β-lap. Menadione was a significantly (>20-fold) less efficient substrate in vitro for 
NQO1 at its IC90, as reported.52 These data appear to explain the differential cytotoxicity of 
DNQ, β-lap and menadione in NQO1 overexpressing cells. 
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Table 3.4. Rate of NADH oxidation with different quinone substrates 
(µmol NADH oxidized/min/nmol protein) (Experiment performed by Betsy Parkinson) 
Compound 10 µM 5 µM 1 µM 0.25 µM 
DNQ 4000 ± 200 - 1400 ± 80 530 ± 60 
β-Lap 1600 ± 200 680 ± 110 110 ± 20 - 
Streptonigrin 1430 ± 50 - 193 ± 5 - 
SCH 538415 260 ± 40 - <100 - 
Menadione <100 - <100 - 
RH1 <100 - <100 - 
Mitomycin C <100 - <100 - 
Doxorubicin <100 - <100 - 
 
 
3.2.2. DNQ efficiently kills a wide spectrum of cancer cells in an NQO1-dependent manner. 
 DNQ efficiently killed human MIA-PaCa2 pancreatic (Figure 3.7A) and HT1080 
sarcoma cancer cells (Figure 3.7B) with IC50 values of 48 and 178 nM, respectively. DIC 
protected both cell types from DNQ-induced lethality. We then treated genetically matched 
NQO1+ vs NQO1- human H596 NSCLC or MDA-MB-231 breast cancer cells with DNQ; *2 
NQO1- polymorphic H596 and MDA-MB-231 cells were separately corrected for NQO1 
expression as clones or pooled populations at levels mimicking endogenous enzyme levels.52,53 
DNQ killed all NQO1+ clones and pooled populations, but not genetically matched NQO1- cells 
(Figure 3.7C-D). Similarly, human PC-3 cells stably knocked down for NQO1 expression 
(shNQ) were spared vs NQO1+ PC-3 cells expressing non-silencing shRNA (Figure 3.7E). 
Furthermore, DNQ-induced cytotoxicity of non-silenced NQO1+ PC-3 cells was prevented by 
DIC (Figure 3.7E), as in parental PC-3 cells; note that PC-3 cells treated with DIC were similarly 
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spared from DNQ lethality as stably NQO1-knocked down shNQ PC-3 cells (Figure 3.7E). 
Colony forming assays confirmed the NQO1-dependency of DNQ lethality in human PC-3 cells 
(Figure 3.7F). IC50 values for DNQ vs β-lap cytotoxicities in various cancers are listed in Table 
3.5, highlighting the high NQO1-dependent potency of DNQ. 
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Figure 3.7. DNQ-induced lethality in various cancer cells is NQO1-dependent. DNQ killed 
human Mia-PaCa2 pancreatic A) and HT1080 sarcoma B) cells with IC50 values of 0.048 and 
108 
 
0.18 µM, respectively, where DIC completely rescued its cytotoxicity. In C,D), NQO1- *2 H596 
NSCLC cells C) or MDA-MB-231 breast cancer D) were resistant to DNQ. Exogenous over-
expression of CMV-directed NQO1 in these cells resulted in significantly enhanced DNQ 
lethality. E) Human PC-3 prostate cancer cells knocked down for NQO1 expression using 
transient shRNA-NQO1 (shNQ) were resistant to DNQ (µM, 2h). In contrast, PC-3 cells 
containing non-nonsilencing shRNA (no addition) were sensitive to DNQ, where DIC 
suppressed its lethality similar to shNQ PC-3 cells. F) Clonogenic survival assays confirmed 
DNQ lethality in NQO1+ shRNA-nonsilenced Ns PC-3 cells, whereas resistance was noted in 
shNQ PC-3 cells, or in Ns PC-3 cells treated with DIC. All treatments were as described in E). 
No addition, DMSO alone as described in Figure 3.6. In the inset, Western immunoblotting 
shows NQO1 knockdown with NQO1 levels of 26 ± 10 units (Table 3.5). ***, p < 0.001. 
(Experiment perfomed by Ying Dong, UTSW) 
 
Table 3.5. The cytotoxicity of DNQ to a panel of cell lines correlates with the amount of 
NQO1 activity in each cell line. (Experiment performed by Ying Dong, UTSW) 
 
 
 
Cell lines NQO1 activity IC50 of DNQ
(µM)
IC50 of β-lap
(µM)
A549 3000 ± 300 0.125 2.5
MIA-PaCa2 410 ± 17 0.05 4.5
MCF-7 2641 ± 555 0.125 2.2
H596 NQ+ 260 ± 5 0.1 3.8
H596 NQ- ND > 1 > 20
231 NQ+ 1800 ± 50 0.06 6.6
231 NQ- ND > 1 14.2
PC-3 200 ± 5 0.07 3.2
PC-3 shNQ 26 ± 10 > 1 > 20
• IC50 of 2 h exposure
• ND, not detected. < 0.01 units of NQO1 were detected in these cells. 
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3.2.3. Potential NQO1-dependent therapeutic window of DNQ.  
 Differential NQO1 expression in various solid tumors vs normal tissue can be effectively 
exploited using β-lap, resulting in a wide therapeutic window in cell culture53 that correlated with 
its dramatic antitumor efficacy in vivo.54,55 A549 cells were, therefore, exposed to various DNQ 
doses in the presence or absence of DIC (40 µM) for various times (30 min to 72 h) and long-
term survival was assessed similar to prior β-lap studies.53 In A549 cells, DNQ exhibited a much 
broader therapeutic window than β-lap.53 A549 cells exposed to a lethal dose of DNQ (0.25 µM) 
were completely rescued by DIC (Figure 3.11A-H), consistent with NQO1-dependent lethality. 
DIC continued to exert a significant protective effect, even with prolonged exposure to DNQ. 
Coincubation of cells with DNQ and DIC for 24, 48, and 72 hours provided 10-, 8-, and 5-fold 
protection, respectively (Figure 3.11 I-K). Similar data were obtained using NQO1+ vs NQO1- 
human H596 NSCLC cells (not shown). Thus, a broad (significantly broader than β-lap53) 
NQO1-dependent therapeutic window was noted in NQO1+ vs NQO1- cells for DNQ. 
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Figure 3.8 (cont. on next page) 
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Figure 3.8. DNQ shows a broad NQO1-dependent therapeutic window. Long-term relative 
survival assessments were performed with A549 cells treated with various concentrations of 
DNQ (µM) in the presence or absence of DIC (40 µM) for 30 min (A), 1 hr (B), 2 hr (C), 4 hr 
(D), 6 hr (E), 8 hr (F), 12 hr (G), 24 hr (H), 48 hr (I) and 72 hr (J). Graphed are means, ±SE of 
duplicate experiments performed in six replicates. 
 
3.2.4. Discussion 
 The potency of DNQ, its potential NQO1-dependent therapeutic window (Figure 3.8) and 
its apparent lack of metabolism by one-electron oxidoreductases, make this drug (or derivatives) 
very promising. To date, the only detailed study of DNQ suggested that ROS formation was a 
key and unique feature of this compound’s lethality.56 Here, we elucidated its mechanism of 
action in NSCLC cells, showing that DNQ lethality is NQO1- and PARP1-dependent and 
induces programmed necrotic cell death identical to β-lap, but with ~20-fold increased potency. 
NQO1+ cells were selectively hypersensitive to DNQ, whereas genetically matched NQO1- cells 
were resistant. Furthermore, NQO1+ cells were rescued from DNQ-induced cytotoxicity by 
NQO1 shRNA-mediated knockdown or by DIC, a fairly specific NQO1 inhibitor. As with β-lap, 
a minimum 2 hr exposure of DNQ was sufficient to elicit programmed necrosis, but at doses in 
the nanomolar range, ~20- to ~100-fold (in other cancer cells) lower than β-lap. Exposure of 
NQO1+ cancer cells to DNQ elicited elevated levels of superoxide, with concomitant and 
significant O2 consumption. Downstream, DNQ stimulated PARP1 hyperactivation in a 
mechanism essentially identical to β-lap. DNQ stimulated PARP1 hyperactivation that correlated 
well with loss of NAD+ and ATP, and NADH recycling assays confirmed DNQ futile cycling by 
NQO1.  
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 DNQ has an apparently broad NQO1-dependent therapeutic window (Figure 3.8), if one 
assumes that NQO1- or DIC-exposed cancer cells respond in a similar resistant manner as most 
normal tissue. This apparent therapeutic window, using A549 NSCLC cells, was a far more 
potent and efficacious than noted with β-lap.53 We hypothesize that DNQ may not be as good a 
substrate as β-lap for one-electron oxidoreductases, p450R and b5R, since β-lap-treated cells 
consumed O2 even in the presence of DIC, whereas O2 consumption was blocked in DNQ-
treated cells (data not shown).  
 To understand its increased potency, we compared DNQ to various quinones as NQO1 
substrates in vitro using NADH reutilization assays.52 At 1 µM, NQO1 processed DNQ ~13-fold 
more efficiently than β-lap (1400 ± 80 vs 110 ± 20 µmol/min/nmol protein, Table 3.4). 
Importantly, at equitoxic (IC100) levels similar NQO1 enzymatic activities (680 ± 110 vs 530 ± 
60 µmol/min/nmol protein for 5 µM β-lap vs 0.25 µM DNQ, respectively (Table 3.4), were 
noted. Although assessments in vitro, these data appear to explain the cellular responses noted 
with each drug. Because DNQ is much more potent than β-lap, and because it appears to have a 
broader therapeutic index and greater specificity for NQO1 over 1e- reducing enzymes, it has 
great potential to be more efficacious and safer to use in vivo.  
 
3.3. DNQ slows tumor growth in vivo 
 
3.3.1. Formulation of DNQ for in vivo administration 
The aqueous solubility of DNQ at pH 7.4 in phosphate buffered saline (PBS) was 
measured by LC-MS. DNQ was sonicated for 30 minutes in PBS then undissolved solid was 
removed by filtration through a 0.45 µm syringe filter and the filtrate was analyzed by LC-MS (λ 
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= 275 nm, ESI-TOF in negative mode). The optimal sonication time was determined by 
sonicating DNQ for 1, 5, 10, and 30 minutes. While the concentration of DNQ in solution 
increased substantially between 1, 5, and 10 minutes, there was only a minor difference between 
10 and 30 minutes. During the 30 minute sonication the water bath warmed to 45 ºC (samples 
were cooled to room temperature before filtration). A calibration curve was generated from 1-
100 µM by dissolving DNQ in methanol to a concentration of 500 µM and making dilutions of 
this stock in 80:20 water:methanol. The calibration curve (measure by UV absorbance) was 
linear over this range; 1 µM was approximately the limit of detection. The solubility of DNQ in 
PBS was measured to be 115 µM. The solution was very pale yellow.  
 Because of the poor aqueous solubility of DNQ we investigated the use of 2-
hydroxypropyl-beta-cyclodextrin (HPβCD), a common excipient, to improve the solubility of 
DNQ. In the absence of HPβCD, the solubility of DNQ increases significantly in strongly basic 
solutions and DNQ precipitates when the pH is returned to neutral. However, in the presence of a 
sufficient amount of HPβCD, DNQ does not precipitate when the pH is returned to neutral. This 
same neutral solution of DNQ in HPβCD cannot be made directly (i.e. without pH adjustment). 
This appears to indicate that DNQ is deprotonated in base and this deprotonated molecule forms 
a tight complex with HPβCD which is stable enough to prevent protonation as the pH decreases. 
The only proton on DNQ that might reasonably be deprotonated in aqueous base is the N-H. 
Although the acidity of the N-H bond of DNQ has not been measured, it has been measured for a 
derivative of DNQ (see section 4.6) and found to have a pKa of 8.0.  
The protocol for formulating DNQ in HPβCD is as follows: DNQ is slurried in a 20% 
solution of HPβCD in pH 7.4 PBS and the pH is then increased by the addition of 10 M NaOH to 
induce dissolution of DNQ. The pH is returned to pH 7.5-8.0 by the careful addition of 1 M HCl. 
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A 3.3 mM solution of DNQ can be made by this method which is stable at least 24 hours. This 
represents a 30-fold increase in solubility over PBS alone.  
We chose a 20% HPβCD solution based on the advice of Adsorption Systems Inc. who 
indicated that 20% was the highest concentration that could be administered to humans. 
However, we have found that β-lap was formulated as a 40% solution of HPβCD for human 
clinical trials.57 Our experience with DNQ indicates that the concentration of DNQ increases 
linearly with that of HPβCD; thus a 40% HPβCD solution would permit the creation of a 6.6 
mM solution of DNQ. 
 
3.3.2. Antitumor effect in A549 lung cancer xenograft in nude mice and potentiation of 
radiation. 
The formulation of DNQ in HPβCD was sufficiently concentrated to dose at reasonable 
levels in mice (~10 mg/kg from a 200 µL injection). Both our group and the Boothman group are 
actively experimenting with DNQ in mouse models of cancer. The Boothman lab has completed 
a pilot study of DNQ in an A549 subcutaneous xenograft model in nude mice.58 Because β-lap 
has been shown to potentiate the effect of ionizing radiation, and because DNQ and β-lap have 
highly similar mechanisms of cytotoxicity, they treated mice with or without ionizing radiation 
to determine if DNQ also potentiates the effect of radiation (Figure 3.9).54 
Athymic nude mice were inoculated with A549 NSCLC cells and established tumors 
were allowed to grow to ~200 mm3. Mice were assigned to one of six treatment groups – four 
mice per group. Three groups received DNQ (0, 2.5, or 5 mg/kg) by tail vein injection on days 1, 
3, 5, 7, and 9. The doses of DNQ were chosen based on the observation that 10 mg/kg DNQ 
elicited adverse reactions in mice. The other three groups received the same DNQ regimen and 
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also received 2 grays of ionizing radiation on each treatment day. Tumor volumes were 
measured over the subsequent weeks (Figure 3.9). 
Because each treatment group comprised only four animals, the statistical significance of 
the results is low. However, an examination of the average trends in Figure 3.9 indicates that 
both groups that received 5 mg/kg DNQ experienced a slower the rate of tumor growth relative 
to control. On the other hand, the difference between mice that did or did not receive radiation 
appears to be small and further experiments will be required to demonstrate whether or not DNQ 
potentiates the effect of radiotherapy. With these exciting preliminary results in hand, both we 
and the Boothman group are beginning mouse models of cancer with full-size treatment groups. 
 
 
Figure 3.9. Nude mice were inoculated with A549 cells and tumors were allowed to establish 
and grow to 200 mm3. Mice were divided into 6 cohorts (4 mice per cohort) and treated on days 
1, 3, 5, 7, and 9. Tumor volumes were measured by caliper. 
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The Boothman group noted that the maximum tolerated dose (MTD) of DNQ in mice 
contained a similar concentration of HPβCD to the MTD of β-lap. Although HPβCD is tolerated 
at very high doses by IP injection (> 5 g/kg),59 the MTD of HPβCD by IV injection for mice has 
not been reported. The MTD of HPβCD by IV injection in rats has been reported to be 
approximately 2.25 g/kg.60 If the MTD in mice is much lower than that, it is possible that the 
vehicle is causing the dose-limiting toxicity. The Boothman group has yet to directly determine 
the MTD of HPβCD in mice when delivered IV. 
Because of the difficulty of repeated tail vein injections in mice, our group is using IP 
administration of compound. The MTD of HPβCD appears to be greater than can be delivered 
even by a 1 mL injection of a saturated aqueous solution of HPβCD. Thus, when injected IP, the 
dose of HPβCD should be irrelevant.  
We have found the MTD of DNQ to be about 5 mg/kg by IP injection. At this dose mice 
become lethargic and unresponsive to touch. The effects subside after 1-2 hours and the mice 
return to a healthy state. Daily injections of this dose were not tolerated, but dosing every other 
day was tolerated. 
Although the mouse model experiment provided encouraging results, two liabilities for 
future use of DNQ were noted: 1) DNQ is poorly tolerated by mice at the doses required to see 
an anticancer effect, and 2) the poor aqueous solubility of DNQ necessitates the use of large 
amounts of HPβCD, the use of which is undesirable from both cost and potential toxicity 
standpoints. In Chapter 4 we present our efforts to solve these problems through the synthesis 
and evaluation of derivatives of DNQ. 
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3.4 Materials and Methods 
Cell culture toxicity. 
 
MCF-7 cells: 
In vitro cell-line toxicity was determined using the sulforhodamine B assay in 96-well 
plates.1 Compounds were tested at 10 concentrations spanning 5 orders of magnitude and the 
value for each concentration was determined as the average of 5 replicate wells. DMSO stocks of 
each compound for each concentration were prepared at 100x the final desired concentration. 
Arsenic trioxide was dissolved in pH 12 aqueous NaOH solution and was made fresh before each 
use. The DMSO solution of elesclomol must also be made fresh before each use. A 2 µL solution 
of the compound stocks were added per well followed by 198 µL cell-containing media that 
resulted in approximately 5000 cells/well. Cell-free death control and vehicle controls were each 
included in quintuplicate. Cells were incubated at 37 ºC, 100% humidity, and 5% CO2 for 72 h. 
Cells were fixed by the addition of 100 µL 10% w/w aqueous trichloroacetic acid and stored at 4 
ºC overnight. Biomass was assessed by staining with sulforhodamine B, dissolving the bound 
dye with 10 mM tris base solution and quantifying absorbance by UV-Vis spectroscopy at 510 
nM. IC50 values are the concentration of compound which results in 50% of the biomass (live 
cells) of the vehicle control wells vs cell-free wells. 
SK-MEL-5 cells: 
The above protocol was followed with one exception: As growth of SK-MEL-5 cells is 
significantly slowed by 1% DMSO, all DMSO stocks were diluted tenfold with Milli-Q water for 
analysis of this cell line only 
HL-60/ADR cells: 
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The MCF-7 protocol was followed with two exceptions: (1) The initial cell concentration was 
20,000 per well; (2) Cells were fixed with 50 mL 50% trichloroacetic acid. 
HL-60 cells: 
As fixing HL-60 cells proved unreliable, the MTS assay was used in place of the SRB assay for 
this cell line only. Thus, after incubation of cells (20,000 per well) with compound for 72h, 20 
µL of MTS solution (95% MTS, 5% PMS) was added per well and the plates were restored to 
the incubator until sufficient difference between live and dead control wells was seen (~1hr). 
Absorbance was measured at 490 nm. 
 
Cell culture toxicity in the presence of NAC or under hypoxia. 
98 µL of cell-containing media (50,000 cells/mL) was added to each well of a 96-well plate 
except for the cell-free death control wells. Plates were incubated for 4hr under either hypoxia or 
normoxia. Plates were then removed and 100 µL media with or without NAC was added. Plates 
were incubated in their respective incubators for 2 more hours. Plates were then briefly removed 
and treated with compounds (2 µL) before being restored to their respective incubators. After 48 
hours cell viability was measured using the sulforhodamine B assay as described above. A set of 
4 plates for each compound was set up and analyzed simultaneously (one plate under normoxia, 
one under normoxia + NAC, one under hypoxia, and one under hypoxia + NAC). 
 
Ethidium bromide displacement assay. 
The ability of DNQ and other compounds to displace ethidium bromide from double-stranded 
DNA was measured by the following assay. Herring sperm DNA was premixed with the buffer 
containing ethidium bromide (buffer composition: 50 mM tris, 100 mM NaCl, 1 mM EDTA, 5 
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µM ethidium bromide). 95 µL of this solution was added to a black 96-well plate containing 5 
µL of DMSO solutions of compounds. In addition to vehicle controls, wells lacking either DNA 
or ethidium bromide ensured that the compounds interacted with neither of these in a manner 
that influenced fluorescence. Doxorubicin and 9-aminoacridine were used as positive controls for 
ethidium bromide displacement while etoposide was used as a negative control (data not shown, 
etoposide did not displace ethidium bromide). The reactions reached equilibrium after incubating 
for 30 minutes. Fluorescence was read at 590 nm (excited at 390 nm). 
 
Topoisomerase II inhibition. 
The relative abilities of DNQ, etoposide, and doxorubicin to inhibit the action of topoisomerase 
II in vitro were evaluated using a decatenation assay. Catenated DNA was incubated at 37 ºC for 
30 minutes in an assay buffer containing purified topoisomerase II, ATP and various 
concentrations of compound in DMSO. DNA in different catenation states were separated by 
electrophoresis in a 1% agarose gel at 95 V for 45 min and analyzed by staining with ethidium 
bromide and measuring fluorescence. The poor aqueous solubility of DNQ precludes its testing 
at higher concentrations than 10 µM. 
 
Cell Cycle Arrest 
Human leukemia HL-60 cells (106 in 1 mL RPMI 1640 with 10% FBS) were treated with 0, 500, 
1000, and 2000 nM of DNQ (0.5% final DMSO v/v) in triplicate and incubated for 6 hr (37 oC 
5% CO2 incubator) in a 24-well plate. The cells were isolated by centrifugation (400 x g for 5 
min), washed with PBS and fixed with 70% ice-cold ethanol for 1 hr at -20 oC. The cells were 
pelleted (1200 x g 5 min), washed with PBS, RNase treated (50 µL of 1 mg/mL RNase A in 
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PBS) for 1 h, after which propidium iodide was added (450 µL of 50 µg/mL in PBS). DNA 
content was assessed by flow cytometry on a Benton Dickinson LSR II flow cytometer. 
Distribution of cells in the different phases was determined using FCS Express software. 
Doxorubicin’s effect on HL-60 cell cycle (8 hr treatment) was investigated using the same 
procedure. 
 
Western Blot Analysis 
Human lymphoma U-937 cells (8 mL of 0.5x106 cells/mL) were treated with compound for 6 hr 
(1% final DMSO v/v). After centrifugation and washing, the cells were lysed with RIPA lysis 
buffer containing protease inhibitor and cell debris was removed by centrifugation (16000 x g for 
5 min). Protein concentration was determined by Bradford assay and whole cell lysate (40-60 µg) 
was resolved by 12% SDS-PAGE gel electrophoresis at 120 V for 90 min after which proteins 
were transferred onto nitrocellulose membranes (50 V for 2 h) and blocked in 5% BSA TBST for 
2h at room temperature. The membranes were blotted for molecules of interest with anti-HMOX-
1 (1:5000 in 5% BSA TBST), anti-HSP70 (1:1000 in 0.5% BSA TBST), anti-actin (1:1000 in 
5% BSA TBST) overnight at 4 ºC. The bound primary antibodies were detected using 
appropriate secondary HRP conjugated antibodies (1:20000 in 0.5% BSA TBST) for 1 hr at 
room temperature and visualized by ECL autoradiography. The membranes were stripped in 
acidic methanol and re-probed as necessary. 
 
Gene Expression Analysis 
U-937 cells (3,000,000 in 6 mL RPMI 1640 with 10% FBS) were incubated in the presence of 
350 nM DNQ or DMSO vehicle (0.2% final DMSO v/v) for 6 hours in a 12-well plate. Aliquots 
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(500 µL) were taken at 6 and 24 hours to assess viability (by annexin V/PI staining and flow 
cytometry) in order to ensure that minimal toxicity occurred at 6 hours but significant toxicity 
was observed at 24 hours. After 6 hours of incubation, 5 mL of cells were pelleted (500 x g 5 
min) and RNA isolated with on-column DNase digestion. RNA integrity was assessed using an 
Agilent Bioanalyzer. Whole genome transcript profiling was performed on the Illumina 
HumanHT-12 BeadChip array for seven compounds and DMSO control from three independent 
experiments. The raw bead-level files were processed with Illumina® BeadStudio 3.1, Gene 
Expression Module v3.2.6,61 without background correction or normalization, to get one value 
per bead type for each array. These 48,803 bead type values were then input into R62 using the 
bead array package63 from the Bioconductor Project.64 The vsn algorithm65 was used for 
background correction, normalization and transformation of the beadtype values to the glog2 
scale. Differential expression was assessed using a mixed linear model using the Limma 
package,66 which uses an empirical Bayes correction67 that helps to improve power by borrowing 
information across bead types. All the desired pair-wise comparisons between the 8 treatment 
groups (control + DNQ + 6 unrelated compounds) were pulled as contrasts from the model and 
the p-values were corrected for multiple hypothesis testing using the False Discovery Rate 
method68 separately for each contrast. In order to facilitate comparisons of our results with those 
of Connectivity Map database we used Illumina’s probe mapping file that matched probes from 
Illumina’s HumanWG-6v3 array (same probes as the HumanHT-12 array) to Affymetrix’s 
U133Plus2.0 array.69 The top 50 up- and down-regulated probe set IDs ordered according to fold 
change were used to create the seed for the connectivity map (CMAP) database matching. 
Analysis of the canonical pathways was performed using Ingenuity Pathway Analysis (IPA, 
Ingenuity Systems) software using a p-value cutoff of 0.05 to define the network eligible genes. 
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Chemicals, Reagents and Antibodies. DNQ and ß-lap were synthesized as described.52,56 
Streptonigrin, mitomycin C, menadione, Hoechst 33258, hydrogen peroxide (H2O2), cytochrome 
c, propidium iodide (PI) and DIC were purchased from Sigma-Aldrich (St. Louis, MO). All 
quinones and BAPTA-AM (Calbiochem (La Jolla, CA) were dissolved in DMSO. 
Dihydroethidium (DHE, 5 mM in DMSO) was purchased from Invitrogen Life Technologies 
(Eugene, OR). RH1 and α-human NQO1 antibody were provided by Dr. David Ross (University 
of Colorado Health Science Center, Denver, CO) and used at a 1:5000 dilution overnight, 4 ºC. 
α-PAR (BD Pharmingen, San Jose, CA), which detects poly (ADP-ribosyl)ated (PAR) proteins 
(typically ADP-ribosylated PARP1), and α-PARP1 (sc-8007, Santa Cruz Biotechnology) 
antibodies were used at 1:4000 and 1:2000 dilutions, respectively. α-Tubulin was monitored for 
loading.70 
 
NQO1 enzyme Assays. DNQ, β-lap, or other quinones (Supplemental Figure , 1) were 
monitored as NQO1 substrates using an NADH (400 µM) recycling assay and recombinant 
NQO1 (Sigma).52 Assays were monitored by NADH oxidation to NAD+ by change in 
absorbance (A340 nm) and data recorded at 2 s intervals for 5 mins. NADH oxidation rates were 
compared to reactions lacking β-lap or DNQ, or containing DIC (10 µM). Initial velocities were 
calculated and data expressed as DIC-inhibited relative units (µmol NADH oxidized/min/gm 
protein).52 
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O2 Consumption Rates. Assays were performed using the Seahorse 24-well cell culture plate in 
conjunction with an XF24 sensor cartridge and a XF24 Extracellular Flux Analyzer (Seahorse 
Biosciences, Billerica, MA). Briefly, 30,000 cells/well were seeded using a two-step process, and 
cells grown as above with unseeded background correction wells. O2 consumption rates (OCR) 
and proton production rates (PPR) were measured using the XF24 Analyzer and Assay Wizard 
software. Data represent means, %treated/control (T/C, %) ±SE from quadruplet assessments.  
 
Nucleotide Analyses. Changes in intracellular NAD+ pools were measured using Fluorescent 
NAD/NADH Detection Kits (Cell Technology, Inc., Mountain View, CA). NAD+/NADH levels 
were expressed as %treated/control levels (T/C, %) as means, ±SE from three independent 
experiments. ATP levels were analyzed from whole-cell extracts using CellTiter-Glo 
Luminescent Cell Viability Assays (Promega, Madison, WI). Data were graphed as means, ±SE 
from at least three independent experiments performed in sextuplets each.  
 
Immunoblotting, ROS Formation. Westerns were performed as described.54 ROS (superoxide) 
formation was monitored by DHE staining and microscopy. Quantitative data were analyzed 
using NIH Image J software, where data are means, ±SE of 100 cells and duplicate experiments 
performed in triplicate.  
 
Quantitative analysis of PAR formation. Chemiluminescent ELISA assays to quantify PAR 
formation were performed by HT PARP in vivo Pharmacodynamic II Assays (Trevigen, Inc., 
Gaithersburg, MD). Briefly, overnight attached cells (5 x 106) were treated and harvested at 
indicated times. Cells were then incubated with α−PAR antibody, then goat α−Rabbit IgG-HRP. 
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Chemiluminescent readings were obtained using PeroxyGlowTM reagents. Data were expressed 
as means, ±SE from three independent experiments. 
 
TUNEL Assays. Terminal deoxynucleotidyl transferase dUTP nick end-labeling (TUNEL) 
assays were performed as described.52 Samples were analyzed by FC-500 flow cytometry 
(Beckman Coulter Electronics, Brea, CA) and Elite acquisition software. Data were expressed as 
means, ±SE from three independent experiments, performed in triplicate. 
 
Cell Lines and Culture. Endogenous NQO1 over-expressing human A549 NSCLC, MCF-7 
breast, Mia-PaCa pancreatic, PC-3 prostate, and HT1080 sarcoma cells were obtained as 
described.53-55 NQO1- *2 polymorphic human H596 NSCLC or MDA-MB-231 triple-negative 
breast, and genetically matched NQO1+, cancer cells were generated by us 53,71. NQO1+ human 
PC-3, and its genetically matched stable lentiviral shRNA-NQO1 knockdown, prostate cancer 
cells were established by us (Boothman lab).55 Cancer cells were grown in Dulbecco’s minimal 
essential medium (DMEM) with 5% fetal bovine serum (FBS). MDA-MB-231 cells were grown 
in RPMI 1640 medium. Cells were cultured at 37 °C in a 5% CO2-95% air humidified 
atmosphere and were free of mycoplasma. 
 
PARP1 siRNA knock down. siRNA specific to the open reading frame (orf) of PARP1, 5’-
CCAAAGGAATTCCGAGAAA-3’ was prepared (Thermo Fisher Scientific, Lafayette, CO) and 
transiently transfected in A549 or other cancer cells. PARP1 knockdown was confirmed using 
Western assays. Results were confirmed using the ON-TARGETplus PARP1 SMARTpool.  
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Relative Survival Assays. Relative survival assays were assessed as described54 and correlated 
well with colony forming assays.70 Results were reported as means, ±SE from sextuplate repeats. 
Experiments were repeated at least three independent times.  
 
Statistical Analyses. Student’s t-tests were used to determine statistical significance from 
experiments repeated at least three independent times. p values were reported by appropriate 
asterisks.  
 
Supporting Figure 3.1. Top 20 DNQ-correlating compounds in the CMAP database. 
rank cmap name mean n enrichment p specificity 
percent non-
null 
1 menadione 0.639 2 0.981 0.00064 0.0133 100 
2 spiperone 0.561 2 0.98 0.00074 0.0101 100 
3 terfenadine 0.542 3 0.955 0.0001 0.0246 100 
4 phenoxybenzamine 0.532 4 0.985 0 0.0545 100 
5 1,4-chrysenequinone 0.531 2 0.97 0.00163 0.0109 100 
6 STOCK1N-35215 0.515 3 0.949 0.00012 0 100 
7 securinine 0.504 4 0.917 0.00004 0.0065 100 
8 MG-262 0.503 3 0.967 0.00004 0.0595 100 
9 
15-delta 
prostaglandin J2 0.492 15 0.822 0 0 86 
10 helveticoside 0.489 6 0.943 0 0.0085 100 
11 astemizole 0.478 5 0.96 0 0.0047 100 
12 ciclopirox 0.475 4 0.681 0.02216 0.1594 75 
13 piperlongumine 0.47 2 0.959 0.00292 0.0325 100 
14 primaquine 0.463 4 0.86 0.00052 0 100 
15 5182598 0.46 2 0.95 0.00455 0.0719 100 
16 lanatoside C 0.459 6 0.936 0 0.0092 100 
17 digitoxigenin 0.446 4 0.857 0.00056 0.0333 100 
18 5224221 0.445 2 0.957 0.00324 0.1453 100 
19 lomustine 0.445 4 0.919 0.00004 0.0235 100 
20 disulfiram 0.435 5 0.905 0.00004 0.0058 100 
 
 
 Supporting Figure 3.2. Top 10 pathways correlating with DNQ regulation of transcripts.
 
Ingenuity Canonical 
Pathways 
 NRF2-mediated Oxidative 
Stress Response 
 p38 MAPK Signaling 
 IL-10 Signaling 
 Glucocorticoid Receptor 
Signaling 
 TREM1 Signaling 
 Aryl Hydrocarbon Receptor 
Signaling 
 ATM Signaling 
 IL-17 Signaling 
 VDR/RXR Activation 
 PPAR Signaling 
 
Supporting Figure 3.3 (cont. on
 -Log(P-
value) 
Ratio Molecules 
7.57 6.49E-02 GSR, HMOX1, FOS, SOD2, JUN, 
NQO1, ATF4, HERPUD1, DNAJB6, 
GCLM, TXNRD1, FTH1
4.76 7.37E-02 TGFBR2, MEF2D, ATF4, IL1B, 
IRAK3, TNF, IRAK2 
4.72 8.45E-02 CCR1, HMOX1, FOS, JUN, IL1B, 
TNF 
4.50 3.56E-02 TGFBR2, IL8, FOS, JUN, CCL2, 
CDKN1A, GTF2H1, IL1B, CCL3, 
TNF 
3.94 7.25E-02 IL8, CCL2, IL1B, CCL3, TNF
3.80 4.46E-02 FOS, JUN, NQO1, CDKN1A, IL1B, 
TNF, CHEK1 
3.74 9.62E-02 JUN, GADD45A, CDKN1A, ATF4, 
CHEK1 
3.36 6.85E-02 CXCL10, IL8, JUN, CCL2, PTGS2
3.28 6.25E-02 CXCL10, SPP1, GADD45A, PPARD, 
CDKN1A 
3.12 4.90E-02 FOS, JUN, PPARD, IL1B, TNF
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Supporting Figure 3.3. Assessment of minimal time to death in A549 NSCLC cells after 
various doses of DNQ. Long-term survival assays were performed to evaluate the minimum time 
needed for DNQ lethality with dose of drug, in an identical manner as previously described with 
β-lap.53 Data are means, ± SE for representative experiments performed six times each. 
(Experiment performed by Ying Dong, UTSW) 
 
3.5 References 
 (1) Vichai, V.; Kirtikara, K. "Sulforhodamine B colorimetric assay for cytotoxicity 
screening." Nat. Protocols 2006, 1, 1112. 
 (2) Tudor, G.; Gutierrez, P.; Aguilera-Gutierrez, A.; Sausville, E. A. "Cytotoxicity and 
apoptosis of benzoquinones: redox cycling, cytochrome c release, and BAD protein expression." 
Biochem. Pharmacol. 2003, 65, 1061. 
 (3) McKeown, S. R.; Cowen, R. L.; Williams, K. J. "Bioreductive drugs: from concept to 
clinic." Clin Oncol-UK 2007, 19, 427. 
 (4) Zeman, E. M.; Brown, J. M.; Lemmon, M. J.; Hirst, V. K.; Lee, W. W. "SR-4233: a new 
bioreductive agent with high selective toxicity for hypoxic mammalian cells." Int. J. Radiat. Oncol. Biol. 
Phys. 1986, 12, 1239. 
 (5) Koch, C. J. "Unusual oxygen concentration dependence of toxicity of SR-4233, a 
hypoxic cell toxin." Cancer Res 1993, 53, 3992. 
 (6) Brown, J. M.; Wilson, W. R. "Exploiting tumour hypoxia in cancer treatment." Nat Rev 
Cancer 2004, 4, 437. 
 (7) Gutierrez, P. L. "The metabolism of quinone-containing alkylating agents: free radical 
production and measurement " Frontiers in Bioscience 2000, 5, 629. 
 (8) Kirshner, J. R.; He, S.; Balasubramanyam, V.; Kepros, J.; Yang, C.-Y.; Zhang, M.; Du, 
Z.; Barsoum, J.; Bertin, J. "Elesclomol induces cancer cell apoptosis through oxidative stress." Mol. 
Cancer Ther. 2008, 7, 2319. 
 (9) Marshall, R. S.; Rauth, A. M. "Modification of the cytotoxic activity of mitomycin C by 
oxygen and ascorbic acid in Chinese hamster ovary cells and a repair-deficient mutant." Cancer Res 1986, 
46, 2709. 
 (10) Maeda, H.; Hori, S.; Nishitoh, H.; Ichijo, H.; Ogawa, O.; Kakehi, Y.; Kakizuka, A. 
"Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-
independent prostate cancer." Cancer Res 2001, 61, 5432. 
 (11) Karlsson, J.; Edsjo, A.; Pahlman, S.; Pettersson, H. M. "Multidrug-resistant 
neuroblastoma cells are responsive to arsenic trioxide at both normoxia and hypoxia." Mol. Cancer Ther. 
2005, 4, 1128. 
 (12) Kim, Y. H.; Park, E. J.; Han, S. T.; Park, J. W.; Kwon, T. K. "Arsenic trioxide induces 
Hsp70 expression via reactive oxygen species and JNK pathway in MDA231 cells." Life Sci. 2005, 77, 
2783. 
 (13) Qu, G.-p.; Xiu, Q.-Y.; Li, B.; Liu, Y.-a.; Zhang, L.-Z. "Arsenic trioxide inhibits the 
growth of human lung cancer cell lines via cell cycle arrest and induction of apoptosis at both normoxia 
and hypoxia." Toxicol Ind Health 2009, 25, 505. 
 (14) Batra, S.; Reynolds, C. P.; Maurer, B. J. "Fenretinide cytotoxicity for Ewing's sarcoma 
and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by 
ceramide modulators." Cancer Res 2004, 64, 5415. 
128 
 
 (15) Keyes, S. R.; Rockwell, S.; Sartorelli, A. C. "Modification of the metabolism and 
cytotoxicity of bioreductive alkylating agents by dicoumarol in aerobic and hypoxic murine tumor cells." 
Cancer Res 1989, 49, 3310. 
 (16) Vallis, K. A.; Wolf, C. R. "Relationship between the adaptive response to oxidants and 
stable menadione-resistance in Chinese hamster ovary cell lines." Carcinogenesis 1996, 17, 649. 
 (17) Chen, Q.; Cederbaum, A. I. "Menadione cytotoxicity to Hep G2 cells and protection by 
activation of nuclear factor-kappaB." Mol Pharmacol 1997, 52, 648. 
 (18) Beck, R.; Verrax, J.; Dejeans, N.; Taper, H.; Calderon, P. B. "Menadione reduction by 
pharmacological doses of ascorbate induces an oxidative stress that kills breast cancer cells." Int. J 
Toxicol. 2009, 28, 33. 
 (19) Gupta, V.; Costanzi, J. J. "Role of hypoxia in anticancer drug-induced cytotoxicity for 
Ehrlich ascites cells." Cancer Res 1987, 47, 2407. 
 (20) Salustiano, E. J.; Netto, C. D.; Fernandes, R. F.; da Silva, A. J.; Bacelar, T. S.; Castro, C. 
P.; Buarque, C. D.; Maia, R. C.; Rumjanek, V. M.; Costa, P. R. "Comparison of the cytotoxic effect of 
lapachol, alpha-lapachone and pentacyclic 1,4-naphthoquinones on human leukemic cells." Invest New 
Drugs 2009. 
 (21) Reinicke, K. E.; Bey, E. A.; Bentle, M. S.; Pink, J. J.; Ingalls, S. T.; Hoppel, C. L.; 
Misico, R. I.; Arzac, G. M.; Burton, G.; Bornmann, W. G.; Sutton, D.; Gao, J.; Boothman, D. A. 
"Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated 
NAD(P)H:quinone oxidoreductase 1 levels." Clin Cancer Res 2005, 11, 3055. 
 (22) Lamb, J.; Crawford, E. D.; Peck, D.; Modell, J. W.; Blat, I. C.; Wrobel, M. J.; Lerner, J.; 
Brunet, J. P.; Subramanian, A.; Ross, K. N.; Reich, M.; Hieronymus, H.; Wei, G.; Armstrong, S. A.; 
Haggarty, S. J.; Clemons, P. A.; Wei, R.; Carr, S. A.; Lander, E. S.; Golub, T. R. "The Connectivity Map: 
using gene-expression signatures to connect small molecules, genes, and disease." Science 2006, 313, 
1929. 
 (23) Gheeya, J.; Johansson, P.; Chen, Q. R.; Dexheimer, T.; Metaferia, B.; Song, Y. K.; Wei, 
J. S.; He, J.; Pommier, Y.; Khan, J. "Expression profiling identifies epoxy anthraquinone derivative as a 
DNA topoisomerase inhibitor." Cancer Lett 2010, 293, 124. 
 (24) Gozzelino, R.; Jeney, V.; Soares, M. P. "Mechanisms of cell protection by heme 
oxygenase-1." Annual review of pharmacology and toxicology, 50, 323. 
 (25) Shibahara, S. "The heme oxygenase dilemma in cellular homeostasis: new insights for 
the feedback regulation of heme catabolism." Tohoku J. Exp. Med. 2003, 200, 167. 
 (26) Stocker, R.; Yamamoto, Y.; McDonagh, A. F.; Glazer, A. N.; Ames, B. N. "Bilirubin is 
an antioxidant of possible physiological importance." Science 1987, 235, 1043. 
 (27) Pietsch, E. C.; Chan, J. Y.; Torti, F. M.; Torti, S. V. "Nrf2 mediates the induction of 
ferritin H in response to xenobiotics and cancer chemopreventive dithiolethiones." J. Biol. Chem. 2003, 
278, 2361. 
 (28) Li, R.; Chen, W.; Yanes, R.; Lee, S.; Berliner, J. A. "OKL38 is an oxidative stress 
response gene stimulated by oxidized phospholipids." J. Lipid Res. 2007, 48, 709. 
 (29) Soriano, F. X.; Baxter, P.; Murray, L. M.; Sporn, M. B.; Gillingwater, T. H.; 
Hardingham, G. E. "Transcriptional regulation of the AP-1 and Nrf2 target gene sulfiredoxin." Mol. Cells 
2009, 27, 279. 
 (30) Burdon, R. H.; Gill, V. M.; Rice-Evans, C. "Oxidative stress and heat shock protein 
induction in human cells." Free Radic. Res. Commun. 1987, 3, 129. 
 (31) Wang, H.; Mao, Y.; Zhou, N.; Hu, T.; Hsieh, T.-S.; Liu, L. F. "ATP-bound 
Topoisomerase II as a Target for Antitumor Drugs." J. Biol. Chem. 2001, 276, 15990. 
 (32) Gewirtz, D. A. "A critical evaluation of the mechanisms of action proposed for the 
antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin." Biochem. Pharmacol. 
1999, 57, 727. 
129 
 
 (33) Hazlehurst, L. A.; Krapcho, A. P.; Hacker, M. P. "Correlation of DNA reactivity and 
cytotoxicity of a new class of anticancer agents: Aza-anthracenediones." Cancer Lett 1995, 91, 115. 
 (34) Potter, A. J.; Rabinovitch, P. S. "The cell cycle phases of DNA damage and repair 
initiated by topoisomerase II-targeting chemotherapeutic drugs." Mutat. Res. 2005, 572, 27. 
 (35) Snyder, R. D. "A review and investigation into the mechanistic basis of the genotoxicity 
of antihistamines." Mutat. Res. 1998, 411, 235. 
 (36) Baguley, B. C.; Falkenhaug, E. M. "The interaction of ethidium with synthetic double-
stranded polynucleotides at low ionic strength." Nucleic Acids Res 1978, 5, 161. 
 (37) Palchaudhuri, R.; Hergenrother, P. J. "DNA as a target for anticancer compounds: 
methods to determine the mode of binding and the mechanism of action." Curr. Opin. Biotechnol. 2007, 
18, 497. 
 (38) Haldane, A.; Sullivan, D. M. In DNA Topoisomerase Protocols Part 2: Enzymology and 
Drugs; Osheroff, N., Bjornsti, M.-A., Eds.; Humana Press: Totowa, 2001, p 13. 
 (39) O'Day, S.; Gonzalez, R.; Lawson, D.; Weber, R.; Hutchins, L.; Anderson, C.; Haddad, J.; 
Kong, S.; Williams, A.; Jacobson, E. "Phase II, randomized, controlled, double-blinded trial of weekly 
elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma." J Clin Oncol 2009, 
27, 5452. 
 (40) Nagai, M.; Vho, N.; Kostik, E.; He, S.; Kepros, J.; Ogawa, L. S.; Inoue, T.; Blackman, R. 
K.; Wada, Y.; Barsoum, J. In AACR-NCI-EORTC International Conference: Molecular Targets and 
Cancer Therapeutics; Molecular Cancer Therapeutics: Boston, MA, 2009; Vol. 8. 
 (41) Chow, S.; Nagai, M.; He, S.; Blackman, R. K.; Barsoum, J.; Vukovic, V.; Hedley, D. In 
American Society of Hematology Annual Meeting and Exposition New Orleans, LA, 2009; Vol. 51. 
 (42) Nguyen, T.; Sherratt, P. J.; Pickett, C. B. "Regulatory mechanisms controlling gene 
expression mediated by the antioxidant response element." Annu. Rev. Pharmacol. Toxicol. 2003, 43, 233. 
 (43) Kumari, M. V.; Hiramatsu, M.; Ebadi, M. "Free radical scavenging actions of 
metallothionein isoforms I and II." Free Radic. Res. 1998, 29, 93. 
 (44) Andrews, G. K. "Regulation of metallothionein gene expression by oxidative stress and 
metal ions." Biochem. Pharmacol. 2000, 59, 95. 
 (45) Burnichon, V.; Jean, S.; Bellon, L.; Maraninchi, M.; Bideau, C.; Orsière, T.; Margotat, 
A.; Gérolami, V.; Botta, A.; Bergé-Lefranc, J.-L. "Patterns of gene expressions induced by arsenic 
trioxide in cultured human fibroblasts." Toxicol. Lett. 2003, 143, 155. 
 (46) Morales, A. A.; Gutman, D.; Cejas, P. J.; Lee, K. P.; Boise, L. H. "Reactive Oxygen 
Species Are Not Required for an Arsenic Trioxide-induced Antioxidant Response or Apoptosis." Journal 
of Biological Chemistry 2009, 284, 12886. 
 (47) Chuang, Y.-Y. E.; Chen, Y.; Gadisetti; Chandramouli, V. R.; Cook, J. A.; Coffin, D.; 
Tsai, M.-H.; DeGraff, W.; Yan, H.; Zhao, S.; Russo, A.; Liu, E. T.; Mitchell, J. B. "Gene Expression after 
Treatment with Hydrogen Peroxide, Menadione, or t-Butyl Hydroperoxide in Breast Cancer Cells." 
Cancer Res 2002, 62, 6246. 
 (48) Desaint, S. p.; Luriau, S. p.; Aude, J.-C.; Rousselet, G.; Toledano, M. B. "Mammalian 
Antioxidant Defenses Are Not Inducible by H2O2." Journal of Biological Chemistry 2004, 279, 31157. 
 (49) Magda, D.; Lecane, P.; Miller, R. A.; Lepp, C.; Miles, D.; Mesfin, M.; Biaglow, J. E.; 
Ho, V. V.; Chawannakul, D.; Nagpal, S.; Karaman, M. W.; Hacia, J. G. "Motexafin gadolinium disrupts 
zinc metabolism in human cancer cell lines." Cancer Res 2005, 65, 3837. 
 (50) Lecane, P. S.; Karaman, M. W.; Sirisawad, M.; Naumovski, L.; Miller, R. A.; Hacia, J. 
G.; Magda, D. "Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell 
lymphoma lines." Cancer Res 2005, 65, 11676. 
 (51) Criddle, D. N.; Gillies, S.; Baumgartner-Wilson, H. K.; Jaffar, M.; Chinje, E. C.; 
Passmore, S.; Chvanov, M.; Barrow, S.; Gerasimenko, O. V.; Tepikin, A. V.; Sutton, R.; Petersen, O. H. 
"Menadione-induced reactive oxygen species generation via redox cycling promotes apoptosis of murine 
pancreatic acinar cells." J Biol Chem 2006, 281, 40485. 
130 
 
 (52) Pink, J. J.; Planchon, S. M.; Tagliarino, C.; Varnes, M. E.; Siegel, D.; Boothman, D. A. 
"NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity." 
J. Biol. Chem. 2000, 275, 5416. 
 (53) Bey, E. A.; Bentle, M. S.; Reinicke, K. E.; Dong, Y.; Yang, C. R.; Girard, L.; Minna, J. 
D.; Bornmann, W. G.; Gao, J.; Boothman, D. A. "An NQO1- and PARP-1-mediated cell death pathway 
induced in non-small-cell lung cancer cells by beta-lapachone." Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 
11832. 
 (54) Dong, Y.; Bey, E. A.; Li, L. S.; Kabbani, W.; Yan, J.; Xie, X. J.; Hsieh, J. T.; Gao, J.; 
Boothman, D. A. "Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 
hyperactivation." Cancer Res 2010, 70, 8088. 
 (55) Li, L. S.; Bey, E. A.; Dong, Y.; Meng, J.; Patra, B.; Yan, J.; Xie, X. J.; Brekken, R. A.; 
Barnett, C. C.; Bornmann, W. G.; Gao, J.; Boothman, D. A. "Modulating endogenous NQO1 levels 
identifies key regulatory mechanisms of action of beta-lapachone for pancreatic cancer therapy." Clin 
Cancer Res 2011, 17, 275. 
 (56) Bair, J. S.; Palchaudhuri, R.; Hergenrother, P. J. "Chemistry and biology of 
deoxynyboquinone, a potent inducer of cancer cell death." J Am Chem Soc 2010, 132, 5469. 
 (57) Savage, R. E.; Tyler, A. N.; Miao, X. S.; Chan, T. C. "Identification of a novel 
glucosylsulfate conjugate as a metabolite of 3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione 
(ARQ 501, beta-lapachone) in mammals." Drug Metab. Dispos. 2008, 36, 753. 
 (58) Blanco, E.; Bey, E. A.; Khemtong, C.; Yang, S. G.; Setti-Guthi, J.; Chen, H.; Kessinger, 
C. W.; Carnevale, K. A.; Bornmann, W. G.; Boothman, D. A.; Gao, J. "Beta-lapachone micellar 
nanotherapeutics for non-small cell lung cancer therapy." Cancer Res 2010, 70, 3896. 
 (59) Nasongkla, N.; Wiedmann, A. F.; Bruening, A.; Beman, M.; Ray, D.; Bornmann, W. G.; 
Boothman, D. A.; Gao, J. "Enhancement of solubility and bioavailability of beta-lapachone using 
cyclodextrin inclusion complexes." Pharm Res 2003, 20, 1626. 
 (60) Gould, S.; Scott, R. C. "2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology 
review." Food Chem. Toxicol. 2005, 43, 1451. 
 (61) Illumina  2003-2007. 
 (62) R: A language and environment for statistical computing.; R Foundation for Statistical 
Computing, Vienna, Austria., R Development Core Team 2008. 
 (63) Dunning, M. J.; Smith, M. L.; Ritchie, M. E.; Tavare, S. "beadarray: R classes and 
methods for Illumina bead-based data." Bioinformatics (Oxford, England) 2007, 23, 2183. 
 (64) Gentleman, R. C.; Carey, V. J.; Bates, D. M.; Bolstad, B.; Dettling, M.; Dudoit, S.; Ellis, 
B.; Gautier, L.; Ge, Y.; Gentry, J.; Hornik, K.; Hothorn, T.; Huber, W.; Iacus, S.; Irizarry, R.; Leisch, F.; 
Li, C.; Maechler, M.; Rossini, A. J.; Sawitzki, G.; Smith, C.; Smyth, G.; Tierney, L.; Yang, J. Y.; Zhang, 
J. "Bioconductor: open software development for computational biology and bioinformatics." Genome 
biology 2004, 5, R80. 
 (65) Huber, W.; von Heydebreck, A.; Sultmann, H.; Poustka, A.; Vingron, M. "Variance 
stabilization applied to microarray data calibration and to the quantification of differential expression." 
Bioinformatics (Oxford, England) 2002, 18 Suppl 1, S96. 
 (66) Smyth, G. K. In Bioinformatics and Computational Biology Solutions using R and 
Bioconductor; Gentleman, R., Carey, V., Dudoit, S., Irizarry, R., Huber, W., Eds.; Springer: New York, 
2005, p 397. 
 (67) Smyth, G. K. "Linear models and empirical bayes methods for assessing differential 
expression in microarray experiments." Statistical applications in genetics and molecular biology 2004, 3, 
Article 3. 
 (68) Benjamini, Y.; Hochberg, Y. "Controlling the false discovery rate: a practical and 
powerful approach to multiple testing." Journal of the Royal Statistical Society Series B 1995, 57, 289. 
 (69) Illumina. 
131 
 
 (70) Wuerzberger, S. M.; Pink, J. J.; Planchon, S. M.; Byers, K. L.; Bornmann, W. G.; 
Boothman, D. A. "Induction of apoptosis in MCF-7:WS8 breast cancer cells by beta-lapachone." Cancer 
Res 1998, 58, 1876. 
 (71) Bentle, M. S.; Reinicke, K. E.; Bey, E. A.; Spitz, D. R.; Boothman, D. A. "Calcium-
dependent modulation of poly(ADP-ribose) polymerase-1 alters cellular metabolism and DNA repair." J. 
Biol. Chem. 2006, 281, 33684. 
 
 
132 
 
Chapter 4. Synthesis and Evaluation of Derivatives of DNQ 
 
4.1. Limitations of DNQ for in vivo administration 
Although DNQ displayed promising antitumor efficacy in the preliminary murine cancer 
model, we foresaw two potential hurdles for the future administration of DNQ in vivo: low 
aqueous solubility, and a narrow therapeutic window (Section 3.3.2). We were confident that an 
analysis of the structure-activity relationship (SAR) of DNQ, enabled by the synthesis of a 
library of derivatives, would reveal compounds that are both more soluble than and equipotent to 
DNQ. We planned to determine the MTD of all such derivatives in mice. Assuming that 
equivalent cytotoxicity in cell culture would translate into equivalent antitumor doses in mice, 
the compound with the highest MTD would provide the widest therapeutic window. Thus, we set 
out to discover a new lead compound by 1) synthesizing a library of DNQ derivatives, 2) 
establishing the SAR of DNQ, 3) establishing the structure-solubility relationship of DNQ, and 
4) determining the MTD of the best new derivatives in healthy mice. By this process, a new lead 
compound would be identified and its efficacy in multiple mouse models of cancer would be 
explored. 
 
4.1.1. Poor aqueous solubility 
Despite possessing multiple sites for hydrogen bonding interactions with water, DNQ is 
poorly soluble (100 µM in pH 7.4 PBS buffer, see section 3.3.1). Two potential reasons for the 
insolubility of DNQ are its ability to pi-stack in the solid state and double intermolecular 
hydrogen bonding. Both of these effects are clearly shown in a crystal structure of DNQ (Figure 
4.1) recently reported by Li and coworkers who isolated DNQ from a strain of Pseudonocardia 
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isolated from the South China Sea.1 Because SCH 538415 is much less potent than DNQ, it 
seemed that breaking up the intermolecular hydrogen bonding by substitution at the N-H would 
produce inactive derivatives. Therefore focus was placed on disruption of the pi-stacking with the 
thought that breaking up this pi-stacking by the addition of freely-rotating short alkyl chains 
would improve aqueous solubility despite increasing the lipophilicity. The synthetic route to 
DNQ was expected to be amenable to substitution at the three positions indicated by colored 
spheres in Figure 4.2. Although it was expected that the aqueous solubility of DNQ derivatives 
bearing short alkyl chains would be greater than that of DNQ, the lipophilicity of sufficiently 
long appendages would overcome the advantage of disrupting the pi-stacking and result in less 
soluble derivatives. The optimal alkyl length for maximal aqueous solubility would be 
determined by synthesizing a series of n-alkyl derivatives and assessing their properties. The 
addition of polar functional groups (e.g., -OH, -NH2, -COOH, etc.) to DNQ would be expected to 
have a strong positive effect on aqueous solubility. Unfortunately, such derivatives proved 
challenging to synthesize and work continues in that area. 
 
 
Figure 4.1. X-ray crystal structure of DNQ showing pi-stacking in the solid state. C – grey, H – 
white, N – blue, O – red. 
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Figure 4.2. Proposed site of derivatization on DNQ. 
 
4.1.2. Improving solubility in HPβCD solutions 
 Like DNQ, β-lap suffers from poor aqueous solubility (~160 µM in pH 7.4 PBS).2 It was 
found that dissolution of β-lap in a solution of HPβCD resulted in ~150-fold increase in 
solubility (20% HPβCD in H2O).3 When DNQ was dissolved in HPβCD solution (Section 3.3.1) 
solubility increased only 30-fold. The difference in fold solubility increase between DNQ and β-
lap is ascribed to the following: whereas β-lap is insoluble because of its high lipophilicity 
(which is offset by complexation with HPβCD) DNQ is insoluble because of stable solid packing 
– on which HPβCD has no effect. We proposed that the same DNQ derivatives described in the 
previous section might benefit more by dissolution with HPβCD than DNQ itself – by virtue of 
their increased lipophilicity. Furthermore, certain appendages might display very high affinity 
for HPβCD which would result in significant solubility gains. Thus, the solubility of all 
derivatives, whether more or less soluble in water than DNQ, would be tested in the presence of 
HPβCD. 
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4.1.3. Improving solubility in organic solvents 
 Another way that β-lap has been administered in vivo is encapsulated in micelles.2,4 
Whereas liposomal formulations are useful for water-soluble drugs – trapping them in the 
aqueous interior of the liposome – micelles trap lipophilic drugs in their hydrophobic interior. 
Thus, proposed lipophilic derivative of DNQ might be good candidates for micellar 
formulations. It was expected that the solubility of DNQ derivatives in organic solvents – such as 
DCM and THF – would be orders of magnitude greater than the solubility of DNQ itself because 
of the combined effects of destabilizing pi-stacking and increasing lipophilicity. 
 
4.2. Predicted SAR 
A large number of compounds with diverse structures have been identified as substrates 
of NQO1.5 This promiscuity suggests that derivatization of DNQ should yield compounds that 
are also substrates for the enzyme.  Molecular modeling performed by Elizabeth Parkinson based 
on crystal structures of NQO1 support this notion. Figure 4.3 (left) shows NQO1 with the 
inhibitor dicoumarol bound in the active site.6 As drawn, the western coumarin of DIC pi-stacks 
with the FAD cofactor, while the eastern half extends down a cavity that opens into the active 
site. Side chains of DNQ should be able to access this cavity as well. Northeast of the active site 
is another cavity through which the FAD passes that could potentially allow for substrate access 
as well. The western half of the active site is closed off - any side chains forced to lie in that area 
would reduce the binding affinity of the compound. Molecular modeling of DNQ in the NQO1 
active site suggests that DNQ will pi-stack with the FAD isoalloxazine moiety (Figure 4.3, right), 
but that the orientation of DNQ in the binding pocket may not be important. The affinity of side 
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chains of DNQ derivatives for the active site may make for stronger substrate-enzyme binding. 
Compounds that bind too weakly to NQO1 would be poor substrates, but compounds that bind 
too tightly would be inhibitors. Thus compounds with optimal binding properties should be the 
most potent cytotoxins in cell culture. 
The preliminary set of nine derivatives was to be synthesized to probe the effect of 
substituents on DNQ at the three positions noted (Chart 4.1). These compounds would be 
assessed for their potency in cell culture and their dependence on NQO1 for cytotoxicity by 
cotreating with dicoumarol. Based on the NQO1-dependent cytotoxicity of this initial set of 
derivatives, a second, larger set would be synthesized to further explore the SAR. Compounds 
that are equipotent to DNQ would then be assessed for their solubility properties in water, in 
HPβCD, and in organic solvents. 
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Figure 4.3. X-ray cystal structure of human NQO1 with inhibitor dicoumarol (left) or with DNQ 
modeled in using MOE software (right). The FAD cofactor is represented in stick form with the 
adenine moiety at the top of the image and the tricyclin flavin in the active site. Drawings of the 
substrates are included to aid in visualizing the orientation of the molecules in the NQO1 active 
site. (Modeling performed by Elizabeth Parkinson) 
 
4.3. Synthesis and NQO1-dependent cytotoxicity of an initial set of 9 DNQ derivatives 
We synthesized a set of nine derivatives bearing ethyl, propyl, or undecyl chains at each 
of three positions that are easily modified by the existing synthetic route to DNQ (Chart 4.1). 
The required alkyne esters (of the type 4-1 for derivatives 4-8 and 4-9), alkyne acids (of the type 
4-3 for derivatives 4-11 and 4-12), and primary amines (of the type 4-2 for derivatives 4-14 
through 4-16) were commercially available and were used to make the indicated compounds 
138 
 
through routes analogous to that for DNQ. The alkynes required to synthesize derivatives 4-10 
and 4-13 were synthesized from alkyne 4-17 as shown in Scheme 4.1. 
 
Chart 4.1. Initial set of nine DNQ derivatives. 
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Scheme 4.1. Synthesis of alkynes 4-19 and 4-21 required to synthesize derivatives 4-10 and 4-
13. 
 
The NQO1-dependent cytotoxicity of the first set of derivatives was determined in MCF-
7 cells which express high levels of NQO1. Cells were exposed to DNQ for 2 hours in the 
presence or absence of 25 µM DIC. The media was then removed and cells were washed once 
with media then fresh media was added and the cells were incubated for 72 hours. Cell death was 
assessed using the sulforhodamine B assay previously described. IC50 values for these 
compounds are listed in Table 4.1. While ethyl derivative 4-8 was equipotent with DNQ, propyl 
derivative 4-9 was significantly less toxic. Dodecyl derivative 4-10 was insoluble in DMSO 
(<0.1 mM) and could not be assessed in this assay. We found that substitution opposite the NH 
(4-11 and 4-12) was poorly tolerated, with even a single methylene addition causing a significant 
loss of toxicity. As was the case with 4-10, compound 4-13 was insoluble in DMSO. Substitution 
off the nitrogen appeared well tolerated (4-14 and 4-15). Dodecyl derivative 4-16 was inactive 
and the protective effect of DIC could not be assessed because of its poor solubility. 
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As further evidence that the activity of these DNQ derivatives is dependent on their 
ability to be reduced by NQO1, Betsy Parkinson performed full enzymatic measurements in 
vitro. The results are shown in Table 4.1. We found a strong correlation between catalytic 
efficiency of substrates in vitro and their cell culture toxicity. The most active derivatives in cell 
culture displayed catalytic efficiencies above 3 x 107 M-1s-1. This provides strong evidence that 
the cytotoxicity of DNQ and its derivatives are dependent primarily upon the activity of NQO1 
within the cell. 
 Table 4.1. Cytotoxicity and NQO1 dependence of nine initial DNQ derivatives. 
 
 
 
 
 
 
4.4. Synthesis and NQO1-dependent cytotoxicity of a second set of DNQ derivatives 
Having concluded that substitution off the nitrogen was likely to produce active 
derivatives, efforts were made to synthesize a second set of derivatives (Chart 4.2) to determine 
the optimal length of an n-alkyl chain (4-22 through 4-25) as well as the effect of multiple 
substitutions (4-26 through 4-29), branched alkyl substituents (4-30 through 4-39), and polar 
 IC50 vs. MCF-7 cells (µM  ± s.e.)   
Compound  + 25 µM DIC Fold protection by DIC 
kcat/KM 
(M-1s-1 x 107) 
DNQ 0.13 ± 0.02 1.7 ± 0.3 14 6.7 
4-8 0.28 ± 0.06 1.3 ± 0.4 4.5 3.3 
4-9 0.90 ± 0.25 2.6 ± 0.6 2.8 1.4 
4-10 -a -a -a -a 
4-11 0.55 ± 0.06 4.9 ± 0.8 8.9 2.3 
4-12 3.4 ± 0.6 5.3 ± 1.2 1.6 0.59 
4-13 -a -a -a -a 
4-14 0.20 ± 0.01 3.4 ± 0.2 17 3.1 
4-15 0.13 ± 0.01 1.3 ± 0.4 10 4.6 
4-16 8.0 ± 1.6 -a -a 0.89 
a.
 Insufficiently soluble to determine. 
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functionalities (4-40 through 4-42). Deviations from the standard synthetic route are outlined in 
Section 4.4.1, and full synthetic protocols are included in the Supporting Information. 
 
Chart 4.2. Second set of DNQ derivatives. 
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4.4.1. Synthesis of a second set of DNQ derivatives 
 Whereas most of the derivatives were synthesized by following the same protocol used to 
synthesize DNQ, a few derivatives required minor modifications of the route. The most sterically 
hindered amines were slow to react with ethyl-2-butynoate to generate the corresponding alkynyl 
amides, resulting in poor yields. It was found that the desired amides could be more efficiently 
synthesized using the route designed for the synthesis of the PMB-protected amide 2-71 (Figure 
4.4). Other derivatives were found to be sensitive to the harsh acidic conditions used to deprotect 
the phenol in the penultimate step. Where this was the case, we used the following two-step 
Protocol (Figure 4.5). Removal of the PMB protecting group was achieved in refluxing TFA and 
the product was isolated by chromatography. Treatment with BBr3 in DCM at room temperature 
revealed the phenol which was used without purification. Oxidation under standard conditions 
with salcomine provided the desired DNQ derivative. Derivatives 4-36 and 4-38 were not 
recovered after precursors 4-59 and 4-61 were subjected to the oxidation; the reasons for this are 
unknown. 
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OEt
amine
MeOH
I
OH
O (COCl)2;amine
CH2Cl2, -78 ºC
O
NHR
I
NHR
O
Amine Product Yield
H2N
H2N
H2N
H2N
4-43 12%
4-44 -
4-45 7%
4-46 11%
Amine Product Yield
4-47 74%
4-48 39%
4-49 78%
4-50 90%
H2N
H2N
H2N
H2N
Figure 4.4. Improved synthesis of amides bearing bulky substituents on nitrogen. 
 
 
Figure 4.5. Synthesis of DNQ derivatives bearing substituents sensitive to HBr-mediated 
deprotection. 
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 In addition to 4-36 and 4-38, derivatives 4-33, 4-40, and 4-42 were not successfully 
synthesized. Unsurprisingly, the intramolecular amidation en route to t-butyl derivative 4-33 
failed to provide the extremely congested tricyclic product even under elevated temperature and 
prolonged heating. Under conditions for the global deprotection of 4-63 or 4-64 en route to 
derivative 4-42 the pendant alcohol was converted to the alkyl bromide and attempts to convert 
the bromide back to the alcohol were unsuccessful (Scheme 4.2). The reason that the conversion 
to the bromide during deprotection occurred during synthesis of derivative 4-42 but not 4-41 is 
unknown.   
 
Scheme 4.2. Unexpected bromination of protected alcohols 4-63 and 4-64 during global 
deprotection. 
 
4.4.2. NQO1-dependent cytotoxicity of a second set of DNQ derivatives 
 All the DNQ derivatives synthesized were assayed for their toxicity to MCF-7 cells with 
or without DIC. The data from these experiments is organized in Table 4.2. Most of these 
compounds were found to be equipotent with DNQ and showed a strong dependence on 
uninhibited NQO1. Linear alkyl chains up to six carbons in length were tolerated (4-24), while 
the n-heptyl derivative 4-25 was somewhat less active. The only branched alkyl derivative that 
was significantly less toxic than DNQ was cyclooctyl compound 4-39. This tolerance of 
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sterically-demanding substituents corresponds with a flexible and promiscuous NQO1 active 
site. The poor activity of hydroxyl derivative 4-41 may be a result of either poor binding with the 
largely hydrophobic NQO1 active site or with an excessively strong substrate-enzyme interaction 
because of hydrogen bonding. Alternatively, because the catalytic efficiency of 4-41 is 
equivalent to many of the more potent derivatives, 4-41 might be limited by other factors such as 
cell permeability.    
 
Table 4.2. Cytotoxicity and NQO1 dependence of second set of DNQ derivatives. 
 IC50 vs. MCF-7 cells (µM ± s.e.)   
Compound  + 25 µM DIC 
Fold protection 
by DIC 
kcat/KM 
(M-1s-1 x 107) 
DNQ 0.13 ± 0.02 1.8 ± 0.3 14 6.7 
4-22 0.27 ± 0.04 1.5 ± 0.4 5.5 7.9 
4-23 0.20 ± 0.01 2.0 ± 0.9 10 5.0 
4-24 0.29 ± 0.04 3.0 ± 0.6 10 5.8 
4-25 0.42 ± 0.11 4.5 ± 0.4 11 - 
4-26 0.77 ± 0.19 2.2 ± 0.6 2.8 3.6 
4-27 6.3 ± 1.1 6.8 ± 1.6 1.1 0.63 
4-28 36 ± 11 31 ± 10 0.9 0.22 
4-29 3.8 ± 1.2 4.8 ± 1.1 1.3 0.46 
4-30 0.24 ± 0.02 2.1 ± 0.8 8.6 2.0 
4-31 0.23 ± 0.02 1.1 ± 0.1 4.8 6.1 
4-32 0.18 ± 0.03 1.8 ± 0.5 10 7.3 
4-34 0.23 ± 0.01 2.1 ± 0.7 8.9 4.9 
4-35 0.22 ± 0.04 1.6 ± 0.6 7.1 6.7 
4-37 0.22 ± 0.01 1.4 ± 0.2 6.1 2.8 
4-39 0.83 ± 0.07 4.1 ± 0.8 3.8 1.7 
4-41 0.68 ± 0.15 3.4 ± 0.6  5.0 3.9 
 
    
 
4.5. Solubility of DNQ derivatives 
 To establish the relationship between structure and solubility of DNQ derivatives we 
assessed the solubility of every derivative in PBS buffer (pH 7.4), DCM, THF, DMSO, and a 
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mixture of 33% methanol in DCM. The results are organized in Table 4.3 and shown graphically 
in the following sections. The compounds are color-coded in the graphs; red indicates an 
“active” compound (IC50 < 500 nM) and blue indicates an “inactive” compound (IC50 > 500 
nM). 
Table 4.3. Solubility of DNQ derivatives in PBS, HPβCD, and several organic solvents.  
Compound PBS (µM) HPβCD (mM) DMSO (mM) CH2Cl2 (mM) 2:1 CH2Cl2:MeOH (mM) 
DNQ 115 3.3 3.1 0.7 8.5 
4.8 439 4.4 31 5.5 37 
4.9 59 - 10 6.1 18 
4.10 < 5 - < 0.1 1.8 6.4 
4.11 105 - 16 11 35 
4.12 35 - 4.2 2.0 10 
4.13 < 5 - < 0.1 1.5 5.9 
4.14 319 5.7 24 9.5 19 
4.15 39 6.3 8.9 3.9 32 
4.16 < 5 - 1.2 34 34 
4-22 17 4.0 10 7.6 30 
4-23 < 5 5.0 17 22 95 
4-24 < 5 6.0 18 32 140 
4-25 < 5 3.0 13 30 - 
4-26 < 5 - 14 24 75 
4-27 < 5 - 10 17 49 
4-28 < 5 - 7.1 35 64 
4-29 84 - 21 10 46 
4-30 41 3.7 21 5.6 79 
4-31 115 13 110 180 140 
4-32 6 4.7 8.6 9.7 58 
4-34 24 9.4 16 23 100 
4-35 7 19 15 31 120 
4-37 114 4.3 25 13 51 
4-39 24 - 71 120 46 
4-41 485 - 24 0.3 11 
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4.5.1. Aqueous solubility 
The aqueous solubility of the compounds was determined by the LC-MS assay described 
in Section 3.3.1. We applied the calibration curve generated for DNQ to the derivatives under the 
assumption that the UV profile of the derivatives of DNQ would be similar to that of DNQ. 
After sonication and filtration most of the aqueous solutions were colorless. The solutions 
of DNQ, 4-31, and 4-37 were faintly yellow while 4-8, 4-14 and 4-41 were substantially more 
colored. The solution of 4-8, 4-14 and 4-41 were diluted 10-fold with PBS prior to LC-MS 
analysis to ensure that the concentrations fell within the range of the calibration curve. The 
results are given in Table 4.3 and Figure 4.6. 
As predicted, compounds 4-8 and 4-14 were more soluble than DNQ despite their 
increased lipophilicity. As the lipophilicity of derivatives increased further, however, solubility 
deceased. A few derivatives, such as 4-31 and 4-37, were substantially more soluble than 
derivatives of similar lipophilicity such as 4-22 and 4-23 indicating some advantage of moderate 
steric bulk near the nitrogen. It is unsurprising that compound 4-41 was the most soluble DNQ 
derivative. This highlights the necessity of making a series of alcohol-bearing derivatives in an 
attempt to find more active derivatives.   
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Figure 4.6. Solubility of DNQ derivatives in pH 7.4 PBS. Red indicates an “active” compound 
(IC50 < 500 nM) and blue indicates an “inactive” compound (IC50 > 500 nM). 
 
4.5.2. Solubility of DNQ derivatives in HPβCD. 
 Although we were pleased to find active derivatives of DNQ that were up to 4-fold more 
soluble in water – perhaps sufficiently soluble for continuous IV infusion for human 
administration – this level of solubility was insufficient for animal studies by bolus injection. We 
therefore determined the solubility of all the most active derivatives (IC50 below 500 nM) in 20% 
HPβCD solution. We used the same pH modulation protocol outlined for DNQ (Section 3.3.1.). 
The results are organized in Table 4.3 and Figure 4.7. While all compounds were more soluble in 
HPβCD than in buffer alone, the fold increase in solubility varied widely. We observed that, in 
general, the more lipophilic the compound the greater the enhancement of solubility by HPβCD. 
This result was expected based on the increased binding affinity of HPβCD for the lipophilic 
appendages. Of particular note is 4-35 which, although very poorly soluble in water, is the most 
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soluble derivative in HPβCD, with a fold enhancement of ~3000. This fold enhancement in 
solubility is among the highest ever reported for HPβCD formulations.7 In addition to being the 
most soluble derivative, 4-35 also appears to be the least sensitive to acidic pH. As the pH of the 
solution is lowered beyond the pKa of the N-H proton, the derivatives become substantially less 
soluble and precipitate rapidly. This is especially true for 4-8. However, once dissolved with 
HPβCD in basic solution, 4-35 remains in solution even when the pH is rendered acidic. The 
may results from a binding orientation between 4-35 and HPβCD which favors both a tight 
binding of the t-butyl in the cyclodextrin pocket as well as a strong hydrogen-bond between the 
deprotonated lactam and the hydroxyls at the rim of the cavity. This hydrogen bonding must be 
sufficiently strong to “hide” the deprotonated lactam from protons in the surrounding bulk water. 
This phenomenon of stability to acidic pH is displayed to varying lesser extents with the other 
derivatives. It is likely that compound 4-8 is oriented with the ethyl group in the cavity of the 
cyclodextrin which results in the deprotonated lactam being exposed to the bulk solvent. This 
would explain the strong dependence of the solubility of this compound on the pH of the 
solution.  
 
 Figure 4.7. Solubility of active DNQ derivatives in 20% HP
were not assessed. The order of the compounds is retained from Figure 4.5.
 
4.5.3. Solubility in organic solvents
 The solubility of DNQ derivatives in organic solvents was
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solubility of cyclooctyl compound 4-39 stems from its complete disruption of pi-stacking as well 
as its high lipophilicity, we cannot explain the impressive solubility of 4-31. Other compounds, 
such as active n-hexyl derivative 4-24 displayed good solubility and appear to be reasonable 
candidates for micellar formulations. 
 
Figure 4.8. Solubility of DNQ derivatives in DMSO. Red indicates an “active” compound (IC50 
< 500 nM) and blue indicates an “inactive” compound (IC50 > 500 nM). The order of the 
compounds is retained from Figure 4.5. 
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Figure 4.9. Solubility of DNQ derivatives in dichloromethane. Red indicates an “active” 
compound (IC50 < 500 nM) and blue indicates an “inactive” compound (IC50 > 500 nM). The 
order of the compounds is retained from Figure 4.5. 
 
 
Figure 4.10. Solubility of DNQ derivatives in 33% methanol in dichloromethane. Red indicates 
an “active” compound (IC50 < 500 nM) and blue indicates an “inactive” compound (IC50 > 500 
nM). The order of the compounds is retained from Figure 4.5. 
 
0
20
40
60
80
100
120
140
160
180
200
4
-1
0
4
-1
3
4
-2
8
4
-1
6
4
-2
7
4
-2
6
4
-2
5
4
-2
4
4
-2
3
4
-3
2
4
-3
5
4
-2
2
4
-3
4
4
-3
9
4
-1
2
4
-1
5
4
-3
0
4
-9
4
-2
9
4
-1
1
4
-3
7
D
N
Q
4
-3
1
4
-1
4
4
-8
4
-4
1
S
o
lu
b
il
it
y
 (
m
M
)
Compound
0
20
40
60
80
100
120
140
160
4
-1
0
4
-1
3
4
-2
8
4
-1
6
4
-2
7
4
-2
6
4
-2
5
4
-2
4
4
-2
3
4
-3
2
4
-3
5
4
-2
2
4
-3
4
4
-3
9
4
-1
2
4
-1
5
4
-3
0
4
-9
4
-2
9
4
-1
1
4
-3
7
D
N
Q
4
-3
1
4
-1
4
4
-8
4
-4
1
S
o
lu
b
il
it
y
 (
m
M
)
Compound
153 
 
4.6. Properties of 4-31 measured by Absorption Systems 
 A sample of compound 4-31 was delivered to Absorption Systems, a company that 
specializes in preclinical formulation and stability studies. They examined a large number of 
formulation and excipients but did not find conditions which better solubilized 4-31 than the 
HPβCD formulation described above. They measured a few physical properties of 4-31, 
including pKa, logP and logD. Through potentiometric titrations they measured the pKa of 4-31 
to be 8.0. The logP (octanol/0.15 M KCl partition coefficient of unionized compound) to be 1.8. 
The logD (octanol/0.15 M KCl partition coefficient of ionized compound) values at various pHs 
are shown in Table 4.4. 
 Absorption Systems measured the stability of 4-31 during incubation in rat, dog, and 
human plasma, whole blood, and liver microsomes. They report that 4-31 shows no sign of 
degradation after 2 hours in plasma or whole blood or after 1 hour in liver microsomes from any 
of the three species. This is in strong contrast to β-lap, which has been reported to be completely 
degraded within about 30 min in whole blood. 
Table 4.4. logD of compound 4-31 between pH 3.0 and pH 9.0. 
pH 3.0 4.0 6.8 7.0 8.0 9.0 
logD 1.78 1.78 1.76 1.75 1.49 0.76 
 
4.7. Maximum tolerated dose in mice 
 Thirteen of the 30 derivatives synthesized were found to be approximately equipotent to 
DNQ in cell culture and were at least as soluble as DNQ in HPβCD. All of these derivatives are 
currently being assessed for their maximum tolerated dose (MTD) in healthy mice. Compounds 
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are formulated in HPβCD and delivered by IP injection to two mice once daily for five days. 
Initial results for DNQ and nine of the derivatives are shown in Table 4.5. MTD is displayed 
both in mg/kg and in µmol/kg to facilitate direct comparison with DNQ without the larger 
molecular weights of the derivatives obfuscating the results. All the derivatives cause the same 
phenotype in mice: at the MTD, mice are lethargic and unresponsive to touch for up to one hour, 
after which time they recover fully. Thus far, 4-35 is the best tolerated; it is tolerated at 3.5 folder 
higher concentration than DNQ. Because of insufficient data, correlations between MTD and 
physical properties of these compounds cannot yet be reliably made.  
 
Table 4.5. Maximum tolerated dose of DNQ and nine derivatives in mice.  
 mg/kg µmol/kg 
DNQ 5 18 
4-8 ≤10 ≤35 
4-14 10 35 
4-15 ≥14 ≥44 
4-23 ≥15 ≥44 
4-24 ≥16 ≥44 
4-31 14 44 
4-32 15 44 
4-34 ≥15 ≥44 
4-35 22 62 
 
4.8. Conclusion  
Herein we have reported our efforts to develop deoxynyboquinone as a new candidate for 
the personalized treatment of cancer. We identified DNQ through a high-throughput screen for 
cytotoxicity and subsequently designed a flexible and modular synthetic route to DNQ. We 
demonstrated that DNQ kills cells through rapid ROS generation and that ROS generation 
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occurred through a 2-electron bioreduction/oxidation process mediated exclusively by NQO1. 
We showed that DNQ was able to slow tumor growth in a mouse model of cancer but that the 
most efficacious doses were poorly tolerated by mice. We then synthesized a library of 
derivatives of DNQ and assessed them for cytotoxicity, solubility, and tolerance in mice. 
Through this process we identified a number of compounds that are more soluble than, 
equipotent to, and better tolerated by mice than DNQ. The most promising of these derivatives 
will be assessed in mouse models of cancer to identify a candidate molecule for further 
evaluation in preclinical and human clinical trials. 
 
4.9 Materials and Methods 
 Reagents were purchased from Aldrich, Strem (metal catalysts and ligands), GFS 
(alkynes), Frontier Scientific (B2pin2) and used without further purification unless otherwise 
noted. Solvents were dried by passage through columns packed with activated alumina (THF, 
CH2Cl2, diethyl ether) or activated molecular sieves (DMSO). Amines were freshly distilled over 
CaH2 under a nitrogen atmosphere. Reactions involving n-BuLi were performed using standard 
Schlenk techniques under argon. 
 
1H-NMR and 13C-NMR spectra were recorded on Varian Unity spectrometers at 500 
MHz and 125 MHz, respectively. Spectra generated from a solution of CDCl3 were referenced to 
residual chloroform (1H: δ 7.26 ppm, 13C: δ 77.23 ppm). Spectra generated in mixtures of CDCl3 
and CD3OD were referenced to tetramethylsilane (1H: δ 0.00 ppm) or CD3OD (13C: δ 49.0 ppm). 
Spectra generated from d-TFA were referenced to residual H (1H: δ 11.50 ppm) or F3CCO2D 
(13C: δ 164.2 ppm). 
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General protocol A: Amidation of ester 
To a solution of alkynyl ester (1 equiv.) in methanol (2 mM), chilled in an ice-water bath 
was added alkyl amine (1.2 equiv.). The reaction was stirred at 0 ºC for 14h. The solvent was 
evaporated directly from the flask and the residue was separated by silica gel chromatography to 
yield the desired alkynyl amide. 
 
 
General protocol B: Amidation of acid chloride 
 To an oven-dried Schlenk flask with a stirbar was added iodoacid 2-73 and the flask was 
evacuated and backfilled with argon. Dry CH2Cl2 was added and the solution was chilled on an 
ice-water bath. Oxalyl chloride (3 equiv.) was added by syringe and the cold bath was removed. 
After 5h at room temperature the volatile components were evaporated directly from the flask. 
Dry CH2Cl2 (10 mL) was added to the residual oil and the vial was chilled on a dry 
ice/isopropanol bath. Freshly distilled p-methoxybenzyl amine (1.1 equiv.) was added dropwise 
by syringe followed by NEt3 (1.2 equiv.). The mixture was stirred for 10 minutes then was 
allowed to warm to RT. 1 M HCl (20 mL) was added and the solution was poured into a 
separatory funnel with CH2Cl2 (10 mL), shaken and separated. The aqueous fraction was 
(COCl)2;
NEt3
H2N-R2
CH2Cl2, -78 ºC
R1 NHR2
O
R1 OH
O
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extracted with CH2Cl2 (4 x 10 mL) then dried over MgSO4 and evaporated. The residue was 
purified by silica gel chromatography. 
 
 
General protocol C: Hydroiodination 
Alkynyl amide (1 equiv.), NaI (2 equiv.), and acetic acid (10 equiv.) were combined and 
heated to 115 ºC for 8h. Reaction completion was determined by removing aliquots for 1H-NMR 
analysis. The deep red reaction mixture was diluted with water and CH2Cl2, treated with 
NaHSO3 until colorless, and carefully neutralized with a saturated aqueous solution of NaHCO3. 
This mixture was poured into a separatory funnel with CH2Cl2, shaken and separated. The 
aqueous fraction was extracted with CH2Cl2. The combined organic fractions were washed with 
brine, dried over MgSO4, and evaporated to yield the desired iodoamide. 
 
 
General protocol D: Suzuki cross-coupling 
To a Schlenk flask with a stir bar was added pure (recrystallized) bispinacolboronate 4-6 
(1 equiv.), PdCl2(dppf) (20 mol%), K2CO3 (6 equiv.), and both desired iodoamides (1.3 equiv. of 
amide bearing PMB, 1.5 equiv. of N-alkyl amide) and the flask was evacuated and backfilled 
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with argon three times. Water (1 mL) and DME (9 mL) were added by syringe after degassing 
the solvents by bubbling with argon for 45 minutes. The flask was plunged into an oil bath at 80 
ºC for 3h. The mixture was poured into a separatory funnel and diluted with water (5 mL). The 
mixture was extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over 
MgSO4, filtered and evaporated to a deep red oil. The crude product was dissolved in CH2Cl2 
and separated by silica gel chromatography. The purity of the diamide product was highly 
variable and the product was subjected to intramolecular amidation without further purification. 
 
 
General protocol E: Intramolecular aryl amidation 
In a Schlenk flask or a vial with a Teflon-lined cap were combined the diamide starting 
material, K2CO3 (6 equiv.), Pd/X-Phos (10 mol%), and X-Phos (10 mol%). The flask was cycled 
between vacuum and argon three times and argon-sparged i-PrOH was added by syringe. The 
mixture was heated to 80 ºC with stirring for 14h. Insoluble materials were removed by filtration 
through Celite and rinsed with CH2Cl2. The filtrate was evaporated and the residue was used 
directly in the next step. 
 
 
NN OO
R3R1
PMBOMeR2
Pd/X-Phos
X-Phos
K2CO3
i-PrOH
80 ºC, 14h
NH HNO O
R1 R3
R2
ClCl
OMe
PMB
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General protocol F: HBr deprotection 
The crude diazaanthracene was dissolved in 48% HBr and heated to 110 ºC. After 19 
hours the reaction was removed from heat. The mixture was cooled on an ice bath and was 
carefully rendered basic by adding 10 M NaOH. The residual solid was removed by filtration 
through hardened filter paper and discarded. The filtrate was rendered acidic with 1 M HCl, 
whereupon a colloidal precipitate formed. The mixture was then centrifuged (3220 x g for 5 
minutes). The resulting semi-compact gelatinous solid was collected by filtration through 
hardened filter paper and dried to a constant mass under vacuum to yield the desired 
diazaanthracenol in frequently high purity as assessed by NMR. 
 
 
General protocol G: BBr3 deprotection and oxidation without isolation 
For substrates that proved sensitive to global deprotection by HBr, the following protocol was 
employed. 
 The product of intramolecular amidation (General Protocol E) was dissolved in TFA and 
heated to reflux for 1h. The solvent was then evaporated and the residue was purified by silica 
gel chromatography. 
In a Schlenk flask containing the PMB-deprotected material under Ar was added DCM 
and the solution was cooled in a dry ice/isopropanol bath. BBr3 (6 equiv.) was added by syringe 
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and the solution was stirred until starting material was consumed as shown by TLC. Residual 
BBr3 was quenched by the addition of conc. NaHCO3 solution until pH neutral. The solvents 
were evaporated. The residue was oxidized and the resulting DNQ derivative was purified using 
General Protocol H. 
 
 
General protocol H: Oxidation 
To a flask containing the diazaanthracenol starting material was added salcomine (10 
mol%) and DMF. A balloon containing O2 was fitted over the mouth of the flask and the slurry 
was stirred at room temperature. The solid dissolved after about 30 minutes. After 3h stirring, the 
mixture was diluted with one volume each of DCM and hexanes and loaded directly onto a 
chromatography column consisting of a layer of basic alumina (5 cm) under a layer of silica gel 
(5 cm) prepared in DCM. The column was flushed with increasing amounts of methanol (0-2%) 
in DCM until the red product band entered the alumina layer which retained the product, 
allowing coeluting impurities to be removed. The product was then released from the basic 
alumina by adding 1% HOAc to the mobile phase. The red fractions were evaporated and 
purified by chromatography through silica gel (0-5% MeOH in DCM) to yield the desired DNQ 
derivative as an orange, red, or red-pink solid. 
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Synthesized by General Protocol A. 78% yield. 
1H-NMR (CDCl3, 500 MHz): δ 6.1 (bs, 1H), 2.99 (d, 3H, J = 5.0 Hz, minor rotomer), 2.81 (d, 3H, J = 5.0 
Hz, major rotomer), 2.35 (t, 2H, J = 7.0 Hz, minor rotomer), 2.22 (t, 2H, J = 7.0 Hz, major rotomer), 1.19 
(t, 3H, J = 7.5 Hz, minor rotomer), 1.13 (t, 3H, J = 7.5 Hz, major rotomer). 
13C-NMR (CDCl3, 125 MHz): δ 154.50, 88.44, 74.95, 26.58, 12.93, 12.40. 
 
 
Synthesized by General Protocol C. 92% yield. 
1H-NMR (CDCl3, 500 MHz): δ 6.28 (q, 1H. J = 1.5 Hz, vinyl CH), 5.9 (bs, 1H, NH), 2.88 (d, 3H, J = 5.0 
Hz, NCH3), 2.62 (dq, 2H, J = 1.5 Hz, 7.5 Hz, allylic CH2), 1.11 (t, 3H, J = 7.5 Hz, -CH3). 
13C-NMR (CDCl3, 125 MHz): δ 166.14, 127.91, 115.56, 40.94, 26.39, 14.67. 
HRMS (ESI-TOF) calcd for C6H11NOI (M+H)+: 239.9885, found: 239.9885. 
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Synthesized by General Protocols D, E, F, and H. 7.4% yield over 4 steps. 
1H-NMR (2:1 CDCl3:CD3OD, 500 MHz): δ 6.81 (d, 1H, J = 1.0 Hz, vinyl CH), 6.67 (d, 1H, J = 1.0 Hz, 
vinyl CH), 3.92 (s, 3H), 3.09 (dq, 2H, J = 7.0, 0.5 Hz, allylic CH2), 2.64 (d, 3H, J = 1.5 Hz, allylic CH3), 
1.26 (t, 3H, J = 7.5 Hz, CH3).  
13C-NMR (CDCl3, 125 MHz): δ 181.33, 175.31, 162.29, 161.90, 155.57, 151.68, 140.24, 138.50, 127.15, 
125.27, 118.83, 115.06, 33.98, 27.88, 21.83, 13.55. 
HRMS (ESI-TOF) calcd for C16H15N2O4 (M+H)+: 299.1032, found: 299.1034. 
 
 
Synthesized by General Protocol A. 92% yield. 
1H-NMR (CDCl3, 500 MHz): δ 6.04 (bs, 1H, major rotomer NH), 5.89 (bs, 1H, minor rotomer), 2.99 (d, 
3H, J = 5.0 Hz, minor rotomer), 2.81 (d, 3H, J = 5.0 Hz, major rotomer), 2.33 (t, 2H, J = 7.0 Hz, minor 
rotomer), 2.22 (t, 2H, J = 7.0 Hz, major rotomer), 1.59 (sext, 2H, J = 7.0 Hz, minor rotomer), 1.54 (sext, 
2H, J = 7.0 Hz, major rotomer), 0.99 (t, 3H, J = 7.5 Hz, minor rotomer), 0.96 (t, 3H, J = 7.5 Hz, major 
rotomer). 
13C-NMR (CDCl3, 125 MHz): δ 54.47 (major), 87.18 (major), 75.76 (major), 29.87 (minor), 26.58 
(major), 21.43 (major), 20.97 (minor), 20.65 (major), 13.60 (major).  
HRMS (ESI) calcd for C7H12NO (M+H)+: 126.0919, found: 126.0920. 
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Synthesized by General Protocol C. 96% yield. 
1H-NMR (CDCl3, 500 MHz): δ 6.40 (bs, 1H, NH), 6.30 (s, 1H, vinyl CH), 2.82 (d, 3H, J = 5.0 Hz, 
NCH3), 2.53 (t, 2H, J = 7.0 Hz, allylic CH2), 1.54 (sext, 2H, J = 7.5 Hz), 0.86 (t, 3H, J = 7.5 Hz).  
13C-NMR (CDCl3, 125 MHz): δ 165.86, 128.49, 114.01, 49.03, 26.30, 22.52, 12.82.  
HRMS (ESI-TOF) calcd for C7H13NOI (M+H)+: 254.0042, found: 254.0045. 
 
 
Synthesized by General Protocols D, E, F, and H. 3.4% yield over 4 steps. 
1H-NMR (CDCl3, 500 MHz): δ 6.80 (s, 1H, vinyl CH), 6.68 (d, 1H, J = 1.0 Hz, vinyl CH), 3.93 (s, 3H), 
2.98 (t, 2H, J = 7.5 Hz, allylic CH2), 2.62 (d, 3H, J = 1.0 Hz, allylic CH3), 1.61 (q, 2H, J = 7.5 Hz), 1.03 
(t, 3H, J = 7.5 Hz, CH(CH3)2). 
HRMS (ESI-TOF) calcd for C17H17N2O4 (M+H)+: 313.1188, found: 313.1189. 
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To an oven-dried Schlenk flask was added 1-tetradecyne (0.748 g, 3.85 mmol) and THF (10 mL). 
Chilled to -78 ºC. Added n-BuLi (2.7 mL, 4.32 mmol) dropwise then stirred for 10 minutes. Added ethyl 
chloroformate (0.56 mL, 5.86 mmol) then allowed the reaction to warm to RT. The solvent was 
evaporated and the residue was purified by silica gel chromatography. Product was collected as a 
colorless oil (1.01 g, 3.79 mmol, 98.5% yield). 
1H-NMR (CDCl3, 500 MHz): δ 4.19 (q, 2H, J = 7.5 Hz), 2.30 (t, 2H, J = 7.5 Hz), 1.56 (pent, 2H, J = 7.5 
Hz), 1.37 (bpent, 2H, J = 8.0 Hz), 1.29 (t, 3H, J = 7.5 Hz), 1.28-1.21 (m, 16H), 0.86 (t, 3H, J = 7.0 Hz). 
13C-NMR (CDCl3, 125 MHz): δ 154.06, 89.66, 73.33, 61.91, 32.10, 29.82, 29.81, 29.77, 29.60, 29.53, 
29.21, 29.04, 27.73, 22.87, 14.29, 14.21.  
 
 
Synthesized by General Protocol A. 66% yield. 
1H-NMR (CDCl3, 500 MHz): δ 6.42 (bs, 1H, major rotomer NH), 6.24 (bs, 1H, minor rotomer NH), 2.93 
(d, 3H, J = 5.0 Hz, minor rotomer NCH3), 2.75 (d, 3H, J = 5.0 Hz, major rotomer NCH3), 2.29 (t, 2H, J = 
7.0 Hz, minor rotomer allylic CH2), 2.18 (t, 2H, J = 7.0 Hz, J = 7.0 Hz, major rotomer allylic CH2), 1.50 
(pent, 2H, J = 7.0 Hz, minor rotomer), 1.45 (pent, 2H, J = 7.5 Hz, major rotomer), 1.29 (bpent, 2H, J = 
7.5 Hz, major rotomer), 1.25-1.13 (m, 16H), 0.79 (t, 3H, J = 7.0 Hz). 
13C-NMR (CDCl3, 125 MHz): δ 157.35 (minor), 154.47 (major), 94.59 (minor), 87.17 (major), 75.50 
(major), 73.14 (minor), 31.92 (major), 29.66 (major), 29.64 (2C, major), 29.48 (major), 29.36 (major), 
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29.10 (major), 28.90 (major), 27.83 (major), 26.43 (major), 22.69 (major), 18.57 (major), 14.11 (major). 
20jun11-9-293-1-u500 
 
 
 
Synthesized by General Protocol C. 100% yield. 
1H-NMR (CDCl3, 500 MHz): δ 6.27 (s, 1H, vinyl CH), 5.74 (bs, 1H, NH), 2.89 (d, 3H, J = 4.5 Hz), 2.59 
(t, 2H, J = 7.5 Hz), 1.56 (bt, 2H, J = 7.0), 1.33-1.22 (m, 18H), 0.88 (t, 3H, J = 7.0 Hz). 
13C-NMR (CDCl3, 125 MHz): δ 165.96, 128.50, 114.45, 47.23, 32.07, 29.81, 29.80, 29.77, 29.66, 29.51, 
29.50, 29.36, 28.44, 26.36, 22.84, 14.29.  
 
 
Synthesized by General Protocols D, E, F, and H. 7.0% yield over 4 steps. 
1H-NMR (2:1 CDCl3:CD3OD, 500 MHz): δ 6.78 (s, vinyl CH), 6.67 (d, 1H, J = 1.0 Hz, vinyl CH), 3.91 
(s, 3H), 3.03 (t, J = 8.0 Hz), 2.64 (d, 3H, J = 1.0 Hz, allylic CH3), 1.58 (p, 2H, J = 7.5 Hz), 1.44 (p, 2H, J 
= 7.5 Hz), 1.27-1.4 (m, 16H), 0.89 (t, 3H, J = 7.5 Hz).  
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13C-NMR (d-TFA, 125 MHz): δ 182.13, 176.16, 166.58 (bs), 163.92 (bs), 160.66, 141.89, 139.75, 128.19 
(bs), 126.92, 125.93, 120.93, 38.25, 37.45, 33.96, 32.05, 31.63 (2C), 31.57, 31.52, 31.41, 31.36, 31.15, 
24.53, 23.41, 14.85. 
 
 
Synthesized by General Protocols D, E, F, and H. 6.2% yield over 4 steps. 
1H-NMR (2:1 CDCl3:CD3OD, 500 MHz): δ 6.78 (d, 1H, J = 1.0 Hz, vinyl CH), 6.70 (s, 1H, vinyl CH), 
3.92 (s, 3H), 3.09 (qd, 2H, J = 7.5, 1.0 Hz), 2.64 (d, 3H, J = 1.0 Hz, allylic CH3), 1.26 (t, 3H, J = 7.5 Hz, 
CH(CH3)2). 
 
 
Synthesized by General Protocols D, E, F, and H. 11% yield over 4 steps. 
1H-NMR (CDCl3, 500 MHz): δ 9.48 (bs, 1H, NH), 6.79 (d, 1H, J = 1.5 Hz, vinyl CH), 6.69 (s, 1H, vinyl 
CH), 3.93 (s, 3H), 3.00 (t, 2H, J = 7.5 Hz) 2.61 (d, 3H, J = 1.0 Hz, allylic CH3), 1.62 (sext, 2H, J = 7.5 
Hz), 1.04 (t, 3H, J = 7.5 Hz). 
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HRMS (ESI-TOF) calcd for C17H17N2O4 (M+H)+: 313.1188, found: 313.1187. 
 
 
Synthesized by General Protocols D, E, F, and H. 20% yield over 4 steps. 
1H-NMR (2:1 CDCl3:CD3OD, 500 MHz): δ 6.78 (s, vinyl CH), 6.67 (s, 1H), 3.92 (s, 3H), 3.03 (t, J = 7.5 
Hz), 2.64 (d, 3H, J = 1.0 Hz, allylic CH3), 1.58 (p, 2H, J = 7.5 Hz), 1.44 (p, 2H, J = 7.5 Hz), 1.27-1.4 (m, 
16H), 0.89 (t, 3H, J = 7.5 Hz). 
13C-NMR (d-TFA, 125 MHz): δ 182.21, 176.18, 166.64, 166.55, 165.56, 158.87, 141.347, 140.27, 
128.14, 127.13, 126.09, 120.54, 37.93, 36.73, 33.95, 31.84, 31.61 (2H), 31.54, 31.42, 31.38, 31.34, 31.13, 
24.50 24.37, 14.79. 
 
 
Synthesized by General Protocols D, E, F, and H. 17% yield over 4 steps. 
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1H-NMR (CDCl3, 500 MHz): δ 10.28 (bs, 1H), 6.83 (s, 1H, vinyl CH), 6.75 (s, 1H, vinyl CH), 3.93 (s, 
3H), 3.07 (dq, 2H, J = 7.5 Hz, 1.0 Hz), 3.04 (dq, 2H, J = 7.5 Hz, 1.0 Hz), 1.25 (t, 3H, J = 7.5 Hz), 1.24 (t, 
3H, J = 7.5 Hz). 
13C-NMR (2:1 CDCl3:CD3OD, 125 MHz): δ 181.29, 175.34, 162.29, 162.15, 157.28, 155.52, 140.00, 
138.78, 33.96, 27.90, 27.27, 13.62, 13.34. 
 
 
Synthesized by General Protocol A. 68% yield. 
13C-NMR (CDCl3, 125 MHz): δ 153.76 (major), 89.96 (major), 75.94 (major), 43.21 (minor), 39.66 
(major), 32.77 (minor), 31.51 (major), 21.43 (major), 20.96 (minor), 20.67 (major), 20.14 (major), 19.83 
(minor), 13.8 (major), 13.8 (minor), 13.6 (major), 13.6 (minor).  
HRMS (ESI) calcd for C10H15NO (M+H)+: 168.1388, found: 168.1382. 
 
 
Synthesized by General Protocol C. 98% yield. 
1H-NMR (CDCl3, 500 MHz): δ 6.26 (s, 1H, vinyl CH), 3.25 (q, 2H, J = 7.0 Hz), 2.51 (t, 2H, J = 7.5 Hz), 
1.54 (sext, 2H, J = 7.5 Hz), 1.48 (pent, 2H, J = 7.5 Hz), 1.32 (sext, 2H, J = 8.0 Hz), 0.86 (t, 3H, J = 7.0 
Hz), 0.85 (t, 3H, J = 7.5 Hz).  
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13C-NMR (CDCl3, 125 MHz): δ 165.13, 128.87, 113.51, 49.01, 39.36, 31.54, 22.51, 20.27, 13.81, 12.83. 
HRMS (ESI-TOF) calcd for C10H19NOI (M+H)+: 296.0511, found: 296.0503. 
 
 
Synthesized by General Protocols D, E, F, and H. 6.3% yield over 4 steps. 
1H-NMR (CDCl3, 500 MHz): δ 9.46 (s, 1H, NH), 6.77 (s, 1H, vinyl CH), 6.67 (d, 1H, J = 1.0 Hz, vinyl 
CH), 4.50 (m, 2H), 2.97 (t, 2H, J = 7.5 Hz, allylic CH2), 2.61 (d, 3H, J = 1.0 Hz, allylic CH3), 1.69 (pent, 
2H, J = 8.0 Hz), 1.60 (sext, 2H, J = 7.5 Hz), 1.47 (sext, 2H, J = 8.0 Hz), 1.03 (t, 3H, J = 7.5 Hz, CH3), 
0.99 (t, 3H, J = 7.5 Hz, CH3). 
13C-NMR (CDCl3, 125 MHz): δ 181.73, 175.37, 161.47, 160.91, 153.23, 151.31, 139.49, 137.78, 128.40, 
127.82, 119.67, 114.98, 46.35, 39.15, 31.40, 23.14, 22.40, 20.40, 14.28, 13.93. 
HRMS (ESI-TOF) calcd for C20H23N2O4 (M+H)+: 355.1658, found: 355.1655. 
 
 
Synthesized by General Protocols D, E, F, and H. 6.7% yield over 4 steps. 
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1H-NMR (CDCl3, 500 MHz): δ 9.52 (s, 1H, NH), 6.77 (d, 1H, J = 1.0 Hz, vinyl CH), 6.68 (s, 1H, vinyl 
CH), 4.52-4.49 (m, 2H), 2.99 (t, 2H, J = 7.5 Hz, allylic CH2), 2.59 (d, 3H, J = 1.0 Hz, allylic CH3), 1.68 
(pent, 2H, J = 7.5 Hz), 1.61 (sext, 2H, J = 8.0 Hz, CH2CH2CH3), 1.47 (sext, 2H, J = 8.0 Hz, 
CH2CH2CH3), 1.04 (t, 3H, J = 7.5 Hz, CH3), 1.00 (t, 3H, J = 7.5 Hz, CH3). 
13C-NMR (CDCl3, 125 MHz): δ 181.67, 175.28, 161.28, 160.96, 155.41, 149.27, 138.84, 138.25, 128.69, 
127.59, 120.12, 114.40, 46.20, 36.30, 31.40, 23.53, 22.88, 20.39, 14.13, 13.92.  
HRMS (ESI-TOF) calcd for C20H23N2O4 (M+H)+: 355.1658, found: 355.1658. 
 
 
Synthesized by General Protocols D, E, F, and H. 13% yield over 4 steps. 
1H-NMR (CDCl3, 500 MHz): δ 9.67 (s, 1H, NH), 6.77 (s, 1H, vinyl CH), 6.68 (s, 1H, vinyl CH), 4.49 (m, 
2H), 2.98 (t, 2H, J = 7.0 Hz, allylic CH2), 2.95 (t, 2H, J = 7.0 Hz, allylic CH3), 1.69 (pent, 2H, J = 8.5 Hz, 
CH), 1.72-1.65 (m, 2H), 1.65-1.55 (m, 4H), 1.47 (sext, 2H, J = 7.5 Hz), 1.03 (t, 3H, J = 7.0 Hz), 1.03 (t, 
3H, J = 7.5 Hz), 1.00 (t, 3H, J = 7.5 Hz, CH3). 
13C-NMR (CDCl3, 125 MHz): δ 181.70, 175.33, 161.47, 160.79, 155.34, 153.19, 139.15, 138.01, 127.93, 
127.62, 120.10, 114.69, 46.31, 37.09, 36.23, 31.41, 23.25, 22.98, 20.40, 14.28, 14.14, 13.93. 
HRMS (ESI-TOF) calcd for C22H27N2O4 (M+H)+: 383.1971, found: 383.1969. 
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Synthesized by General Protocol A. 83% yield. 
1H-NMR (CDCl3, 500 MHz): δ 6.25 (bs, 1H), 3.35 (pent, 2H, J = 7.0 Hz, minor rotomer NCH2), 3.23 
(pent, 2H, J = 7.5 Hz, major rotomer), 1.95 (s, 3H, minor rotomer), 1.85 (s, 3H, major rotomer), 1.12 (t, 
3H, J = 7.5 Hz, minor rotomer), 1.08 (t, 3H, J = 7.0 Hz, major rotomer).  
13C-NMR (CDCl3, 125 MHz): δ 153.58 (major), 82.80 (major), 75.05 (major), 38.20 (minor), 34.66 
 (major), 15.91 (minor), 14.51 (major), 3.93 (minor), 3.59 (major).  
HRMS (ESI) calcd for C6H10NO (M+H)+: 112.0762, found: 112.0764. 
 
 
Synthesized by General Protocol C. 98% yield. 
1H-NMR (CDCl3, 500 MHz): δ 6.28 (bs, 1H, NH), 6.22 (s, 1H, vinyl CH), 3.30 (pent, 2H, J = 7.5 Hz, 
NCH2), 2.59 (s, 3H, allylic CH3), 1.12 (s, 3H). 
13C-NMR (CDCl3, 125 MHz): δ 164.85, 129.28, 105.58, 35.75, 34.45, 14.74. 
HRMS (ESI-TOF) calcd for C6H11NOI (M+H)+: 139.9885, found: 139.9884. 
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Synthesized by General Protocols D, E, F, and H. 13% yield over 4 steps. 
1H-NMR (2:1 CDCl3:CD3OD, 500 MHz): δ 6.76 (d, 1H, J = 1.0 Hz, vinyl CH), 6.67 (d, 1H, J = 1.0 Hz, 
vinyl CH), 4.51 (q, 2H, J = 8.0 Hz), 2.36 (m, 6H, allylic CH3), 1.45 (t, 3H, J = 7.0 Hz).  
 
 
Synthesized by General Protocol A. 71% yield. 
1H-NMR (CDCl3, 500 MHz): δ 5.99 (bs, 1H), 3.31 (q, 2H, J = 7.0 Hz, minor rotomer NCH2), 3.20 (q, 
2H, J = 7.5 Hz, major rotomer NCH2), 1.98 (s, 3H, minor rotomer allylic CH3), 1.89 (s, 3H, major 
rotomer allylic CH3), 1.50 (sext, 2H, J = 7.5 Hz), 0.89 (t, 3H, J = 7.5 Hz). 
13C-NMR (CDCl3, 125 MHz): δ 153.71 (major), 89.96 (major), 75.13 (major), 45.15 (minor), 41.57 
(major), 23.92 (minor), 22.69 (major), 11.39 (major), 11.18 (minor), 3.69 (major). 
 
 
Synthesized by General Protocol C. 98% yield. 
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1H-NMR (CDCl3, 500 MHz): δ 6.23 (d, 1H. J = 1.5 Hz, vinyl CH), 6.22 (bs, 1H, NH), 3.23 (d, 2H, J = 
7.0 Hz, NCH2), 2.60 (d, 3H, J = 1.5 Hz, allylic CH3), 1.53 (sext, 2H, J = 7.0 Hz), 0.90 (t, 3H, 7.5 Hz). 
13C-NMR (CDCl3, 125 MHz): δ 164.98, 129.47, 105.47, 41.34, 35.76, 22.77, 11.61. 
HRMS (ESI-TOF) calcd for C7H13NOI (M+H)+: 254.0042, found: 254.0044. 
 
 
Synthesized by General Protocols D, E, F, and H. 13% yield over 4 steps. 
1H-NMR (CDCl3, 500 MHz): δ 6.77 (d, 1H, J = 1.0 Hz, vinyl CH), 6.68 (d, 1H, J = 1.5 Hz, vinyl CH), 
4.60 (m, 2H), 2.62 (d, 3H, J = 1.5 Hz, allylic CH3), 2.60 (d, 3H, J = 1.0 Hz, allylic CH3), 1.73 (sext, 2H, J 
= 8.0 Hz, CH), 1.04 (t, 3H, J = 7.5 Hz).  
13C-NMR (CDCl3, 125 MHz): δ 181.48, 175.09, 161.87, 161.75, 151.69, 149.97, 139.36, 138.58, 127.43, 
127.21, 119.48, 114.79, 22.87, 22.20, 21.81, 10.72. 
 
 
Synthesized by General Protocol A. 78% yield. 
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1H-NMR (CDCl3, 500 MHz): δ 6.01 (bs, 1H), 3.34 (q, 2H, J = 7.0 Hz, minor rotomer NCH2), 3.23 (q, 
2H, J = 6.0 Hz, major rotomer NCH2), 1.98 (s, 3H, minor rotomer allylic CH3), 1.89 (s, 3H, major 
rotomer allylic CH3), 1.46 (pent, 2H, J = 7.0 Hz), 1.31 (sext, 2H J = 7.5 Hz), 0.88 (t, 3H, J = 7.5 Hz). 
13C-NMR (CDCl3, 125 MHz): δ 153.71 (major), 89.96 (major), 75.13 (major), 45.15 (minor), 41.57 
(major), 23.92 (minor), 22.69 (major), 11.39 (major), 11.18 (minor), 3.69 (major). 
 
 
Synthesized by General Protocol C. 97% yield. 
1H-NMR (CDCl3, 500 MHz): δ 6.23 (d, 1H. J = 1.5 Hz, vinyl CH), 3.26 (q, 2H, J = 7.0 Hz, NCH2), 2.59 
(d, 3H, J = 1.5 Hz, allylic CH3), 1.48 (p, 2H, J = 7.5 Hz), 1.32 (sext, 2H, J = 7.5 Hz), 0.87 (t, 3H, J = 7.5 
Hz). 
13C-NMR (CDCl3, 125 MHz): δ 164.93, 129.47, 105.41, 39.35, 35.75, 31.55, 20.26, 13.83.  
HRMS (ESI-TOF) calcd for C8H15NOI (M+H)+: 268.0198, found: 268.0197. 
 
 
Synthesized by General Protocols D, E, F, and H. 9.9% yield over 4 steps. 
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1H-NMR (CDCl3, 500 MHz): δ 9.54 (bs, 1H), 6.77 (q, 1H, J = 1.0 Hz, vinyl CH), 6.68 (q, 1H, J = 1.0 Hz, 
vinyl CH), 4.53-4.50 (m, 2H), 2.62 (d, 3H, J = 1.0 Hz, allylic CH3), 2.60 (d, 3H, J = 1.0 Hz, allylic CH3), 
1.68 (pent, 2H, J = 7.5 Hz), 1.47 (sext, 2H, J = 7.5 Hz), 1.00 (t, 3H, J = 7.5 Hz). 
HRMS (ESI-TOF) calcd for C17H17N2O4 (M+H)+: 313.1188, found: 313.1190. 
 
 
Synthesized by General Protocol A. 86% yield. 
HRMS (ESI) calcd for C9H16NO (M+H)+: 154.1232, found: 154.1231. 
 
 
Synthesized by General Protocol C. 81% yield. 
1H-NMR (CDCl3, 500 MHz): δ 6.22 (d, 1H. J = 1.5 Hz, vinyl CH), 5.77 (bs, 1H, NH), 3.32 (q, 2H, J = 
7.0 Hz, NCH2), 2.64 (d, 3H, J = 1.5 Hz, allylic CH3), 1.55 (pent, 2H, J = 7.0 Hz), 1.35-1.30 (m, 4H), 0.89 
(t, 3H, J = 7.0 Hz) 
HRMS (ESI-TOF) calcd for C9H17NOI (M+H)+: 282.0355, found: 282.0356. 
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Synthesized by General Protocols D, E, F, and H. 11% yield over 4 steps. 
1H-NMR (2:1 CDCl3:CD3OD, 500 MHz): δ 6.76 (d, 1H, J = 1.0 Hz, vinyl CH), 6.67 (d, 1H, J = 1.5 Hz, 
vinyl CH), 4.48-4.43 (m, 2H), 2.63 (d, 3H, J = 1.5 Hz, allylic CH3), 2.63 (d, 3H, J = 1.0 Hz, allylic CH3), 
1.77 (pent, 2H, J = 7.5 Hz), 1.48-1.40 (m, 4H), 0.95 (t, 3H, J = 7.0 Hz). 
13C-NMR (2:1 CDCl3:CD3OD, 125 MHz): δ 181.47, 175.05, 161.83, 161.68, 151.66, 149.89, 139.31, 
138.53, 127.40, 127.19, 119.45, 114.75, 46.52, 28.82, 28.48, 22.87, 22.07, 21.81, 13.58. 
HRMS (ESI-TOF) calcd for C19H21N2O4 (M+H)+: 341.1501, found: 341.1496. 
 
 
Synthesized by General Protocol A. 79% yield. 
1H-NMR (CDCl3, 500 MHz): δ 5.85 (bs, 1H, major rotomer NH), 3.35 (q, 2H, J = 7.0 Hz, minor 
rotomer), 3.23 (q, 2H, J = 7.0 Hz, major rotomer), 2.00 (s, 3H, minor rotomer), 1.91 (s, 3H, major 
rotomer), 1.48 (pent, 2H, J = 7.0 Hz), 1.33-1.23 (m, 6H), 0.86 (t, 3H, J = 7.0 Hz). 
HRMS (ESI) calcd for C10H18NO (M+H)+: 168.1388, found: 168.1391. 
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Synthesized by General Protocol C. 98% yield. 
1H-NMR (CDCl3, 500 MHz): δ 6.22 (q, 1H. J = 1.5 Hz, vinyl CH), 5.73 (bs, 1H, NH), 3.32 (q, 2H, J = 
7.0 Hz), 2.64 (d, 3H, J = 1.5 Hz, allylic CH3), 1.55 (pent, 2H, J = 7.0 Hz), 1.38-1.27 (m, 6H), 0.88 (t, 3H, 
J = 7.0 Hz). 
HRMS (ESI-TOF) calcd for C10H19NOI (M+H)+: 296.0511, found: 296.0510. 
 
 
Synthesized by General Protocols D, E, F, and H. 12% yield over 4 steps. 
1H-NMR (2:1 CDCl3:CD3OD, 500 MHz): δ 6.76 (s, 1H), 6.67 (s, 1H), 4.45 (m, 2H), 2.63 (d, 3H, J = 1.0 
Hz, allylic CH3), 2.63 (d, 3H, J = 1.0 Hz, allylic CH3), 1.76 (pent, 2H, J = 7.5 Hz), 1.46 (pent, 2H, J = 7.0 
Hz), 1.40-1.34 (m, 4H), 0.92 (t, 3H, J = 7.0 Hz). 
13C-NMR (2:1 CDCl3:CD3OD, 125 MHz): δ 181.46, 175.04, 161.82, 161.66, 151.65, 149.88, 139.30, 
138.53, 127.40, 127.20, 119.44, 114.74, 46.57, 31.18, 28.76, 26.36, 22.87, 22.35, 21.81, 13.58.  
HRMS (ESI-TOF) calcd for C20H23N2O5 (M+H)+: 355.1658, found: 355.1660. 
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Synthesized by General Protocol A. 55% yield. 
1H-NMR (CDCl3, 500 MHz): δ 5.95 (bs, 1H, NH), 3.34 (q, 2H, J = 7.0 Hz, minor rotomer NCH2), 3.22 
(dt, 2H, J = 7.0 Hz, major rotomer), 1.98 (s, 3H, minor rotomer), 1.89 (s, 3H, major rotomer), 1.47 (pent, 
2H, J = 7.5 Hz), 1.30-1.20 (m, 8H), 0.84 (t, 3H, J = 7.0 Hz). 
13C-NMR (CDCl3, 125 MHz): δ 156.51 (minor), 153.65 (major), 89.75 (minor), 82.97 (major), 75.14 
(major), 72.80 (minor), 43.44 (minor), 39.93, (major), 31.84 (major), 30.67 (minor), 29.44 (major), 29.04 
(major), 28.97 (minor), 26.94 (major), 26.59 (minor), 22.69 (major).  
 
 
Synthesized by General Protocol C. 86% yield. 
1H-NMR (CDCl3, 500 MHz): δ 6.24 (q, 1H. J = 1.5 Hz, vinyl CH), 5.73 (bs, 1H, NH), 3.33 (q, 2H, J = 
6.5 Hz),  2.65 (d, 3H, J = 1.5 Hz, allylic CH3), 1.55 (pent, 2H, J = 7.0 Hz), 1.38-1.23 (m, 8H), 0.88 (t, 3H, 
J = 7.0 Hz). 
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Synthesized by General Protocols D, E, F, and H. 10% yield over 4 steps. 
1H-NMR (2:1 CDCl3:CD3OD, 500 MHz): δ 6.76 (q, 1H, J = 1.5 Hz, vinyl CH), 6.66 (q, 1H, J = 1.0 Hz, 
vinyl CH), 4.47-4.44 (m, 2H), 2.63 (d, 3H, J = 1.0 Hz, allylic CH3), 2.63 (d, 3H, J = 1.0 Hz, allylic CH3), 
1.77 (bpent, 2H, J = 8.0 Hz), 1.46 (bpent, 2H, J = 8.0 Hz), 1.42-1.26 (m, 6H), 0.90 (t, 3H, J = 7.0 Hz). 
 
 
Synthesized by General Protocol A. 72% yield. 
1H-NMR (CDCl3, 500 MHz): δ 5.72 (bs, 1H, major rotomer NH), 5.64 (bs, 1H, minor rotomer NH), 3.37 
(q, 2H, J = 7.0 Hz, minor rotomer NCH2), 3.26 (q, 2H, J = 7.0 Hz, major rotomer NCH2), 2.01 (d, 3H, J = 
1.0 Hz,  minor rotomer allylic CH3), 1.93 (d, 3H, J = 1.0 Hz, major rotomer allylic CH3), 1.50 (pent, 2H, J 
= 7.0 Hz), 1.34-1.20 (m, 18H), 0.87 (t, 3H, J = 7.0 Hz).  
13C-NMR (CDCl3, 125 MHz): δ 153.61 (major), 82.73 (major), 75.05 (major), 43.36 (minor), 39.81 
(major), 31.92 (major), 30.55 (minor), 29.66 (major), 29.64 (major), 29.61(major), 29.56 (major), 29.37 
(major), 29.31 (2C, major), 26.90 (major), 26.53 (minor), 22.69 (major), 14.12 (major), 3.95 (minor), 3.62 
(major).  
 
 
Synthesized by General Protocol C. 98% yield. 
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1H-NMR (CDCl3, 500 MHz): δ 6.22 (q, 1H. J = 1.5 Hz, vinyl CH), 5.93 (bs, 1H, NH), 3.29 (q, 2H, J = 
6.0 Hz), 2.62 (d, 3H, J = 1.5 Hz, NCH3), 1.52 (pent, 2H, J = 7.5 Hz), 1.35-1.20 (m, 18H), 0.85 (t, 3H, J = 
7.0 Hz).  
13C-NMR (CDCl3, 125 MHz): δ 164.97, 129.73, 105.42, 39.74, 35.80, 32.07,29.80, 29.79, 29.74, 29.71, 
29.59, 29.50, 29.46, 27.20, 22.84, 14.27. 
 
 
Synthesized by General Protocols D, E, F, and H. 15% yield over 4 steps. 
1H-NMR (CDCl3, 500 MHz): δ 10.3 (bs, 1H, NH), 6.75 (d, 1H, J = 1.0 Hz, vinyl CH), 6.68 (s, 1H, vinyl 
CH), 4.48 (t, 2H, J = 8.0 Hz, NCH2), 2.61 (d, 3H, J = 0.5 Hz, allylic CH3), 2.59 (d, 3H, J = 1.0 Hz, allylic 
CH3), 1.69 (pent, 2H, J = 7.5 Hz, NCH2CH2-), 1.42 (pent, 2H, J = 7.5 Hz, NCH2CH2CH2-), 1.38-1.18 (m, 
16H), 0.86 (t, 3H, J = 7.0 Hz, -CH2CH3). 
13C-NMR (CDCl3, 125 MHz): δ 181.78, 175.27, 161.27, 130.99, 151.38, 149.30, 139.13, 137.98, 128.64, 
128.40, 119.69, 114.66, 46.50, 32.12, 29.87, 29.85, 29.81, 29.80, 29.55, 29.44, 29.39, 27.14, 23.55, 22.88, 
22.44, 14.32. 
HRMS (ESI-TOF) calcd for C26H35N2O4 (M+H)+: 439.2597, found: 439.2595. 
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Synthesized by General Protocol A. 73% yield. 
HRMS (ESI) calcd for C9H16NO (M+H)+: 154.1232, found: 154.1233. 
 
 
Synthesized by General Protocol C. 95% yield. 
1H-NMR (CDCl3, 500 MHz): δ 6.22 (q, 1H, J = 1.5 Hz, vinyl CH), 5.82 (bs, 1H, NH), 3.33 (dq, 2H, J = 
7.5, 1.0 Hz), 2.63 (d, 3H, J = 1.5 Hz, allylic CH3), 1.64 (sept, 1H, J = 6.5 Hz), 1.43 (q, 2H, J = 7.0 Hz), 
0.91 (d, 6H, J = 6.5 Hz).  
HRMS (ESI-TOF) calcd for C9H17NOI (M+H)+: 282.0355, found: 282.0351. 
 
 
Synthesized by General Protocols D, E, F, and H. 12% yield over 4 steps. 
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1H-NMR (2:1 CDCl3:CD3OD, 500 MHz): δ 6.76 (q, 1H, J = 1.0 Hz, vinyl CH), 6.67 (q, 1H, J = 1.5 Hz, 
vinyl CH), 4.52-4.49 (m, 2H), 2.64 (d, 3H, J = 1.0 Hz, allylic CH3), 2.63 (d, 3H, J = 1.0 Hz, allylic CH3), 
1.81 (sept, 1H, J = 7.0 Hz, CH), 1.68-1.63 (m, 2H, CH2CH2CH), 1.03 (d, 6H, J = 6.5 Hz, CH(CH3)2).  
13C-NMR (2:1 CDCl3:CD3OD, 125 MHz): δ 181.48, 175.02, 161.83, 161.65, 151.69, 149.89, 139.30, 
138.50, 127.42, 127.23, 119.52, 114.77, 45.45, 37.28, 26.49, 22.89, 22.02, 21.83.  
HRMS (ESI-TOF) calcd for C19H21N2O4 (M+H)+: 341.1501, found: 341.1507. 
 
 
Synthesized by General Protocol A. 25% yield. 
1H-NMR (CDCl3, 500 MHz): δ 5.75 (bs, 1H, major rotomer NH), 3.17 (d, 2H, J = 7.0 Hz, minor rotomer 
NCH2), 3.09 (d, 2H, J = 6.5 Hz, major rotomer NCH2), 2.01 (s, 3H, minor rotomer allylic CH3), 1.94 (s, 
3H, major rotomer allylic CH3), 0.93 (s, 9H, minor rotomer), 0.92 (s, 9H, major rotomer). 
HRMS (ESI) calcd for C9H16NO (M+H)+: 154.1232, found: 154.1233. 
 
 
Synthesized by General Protocol C. 96% yield. 
1H-NMR (CDCl3, 500 MHz): δ 6.29 (q, 1H. J = 1.5 Hz, vinyl CH), 5.78 (bs, 1H, NH), 3.16 (d, 2H, J = 
6.0 Hz), 2.66 (d, 3H, J = 1.0 Hz), 0.96 (s, 9H).  
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HRMS (ESI-TOF) calcd for C9H17NOI (M+H)+: 282.0355, found: 282.0354. 
 
 
Synthesized by General Protocols D, E, F, and H. 10% yield over 4 steps. 
1H-NMR (2:1 CDCl3:CD3OD, 500 MHz): δ 6.75 (d, 1H, J = 1.0 Hz, vinyl CH), 6.67 (d, 1H, J = 1.0 Hz, 
vinyl CH), 4.95 (bs, 1H), 4.86 (bs, 1H), 2.64 (s, 6H, allylic CH3), 0.87 (s, 9H, (CH3)3). 
13C-NMR (CDCl3, 125 MHz): δ 181.20, 176.32, 162.40, 149.55, 141.41, 139.05, 127.31, 127.19, 119.33, 
114.87, 51.10, 34.31, 27.58, 22.80, 21.67. 
HRMS (ESI-TOF) calcd for C19H21N2O4 (M+H)+: 341.1501, found: 341.1498. 
 
 
Synthesized by General Protocol A. 76% yield. 
1H-NMR (CDCl3, 500 MHz): δ 6.00 (bs, 1H, minor rotomer NH), 5.83 (bs, 1H, major rotomer NH), 3.37-
3.32 (m, 2H, minor rotomer NCH2), 3.27-3.23 (m, 2H, major rotomer NCH2), 1.99 (s, 3H, minor rotomer 
allylic CH3), 1.89 (s, 3H, major rotomer allylic CH3), 1.45-1.42 (m, 2H, minor rotomer), 1.41-1.38 (m, 
2H, major rotomer), 0.91 (s, 9H, minor rotomer), 0.89 (s, 9H, major rotomer).  
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HRMS (ESI) calcd for C10H18NO (M+H)+: 168.1388, found: 168.1387. 
 
 
Synthesized by General Protocol C. 93% yield. 
1H-NMR (CDCl3, 500 MHz): δ 6.20 (q, 1H, J = 1.5 Hz, vinyl CH), 5.60 (bs, 1H, NH), 3.37-3.33 (m, 2H), 
2.65 (d, 3H, J = 1.5 Hz, NCH3), 1.48-1.45 (m, 2H), 0.94 (s, 9H).  
HRMS (ESI-TOF) calcd for C10H19NOI (M+H)+: 296.0511, found: 296.0513. 
 
 
Synthesized by General Protocols D, E, F, and H. 17% yield over 4 steps. 
1H-NMR (2:1 CDCl3:CD3OD, 500 MHz): δ 6.75 (d, 1H, J = 1.0 Hz, vinyl CH), 6.66 (d, 1H, J = 1.0 Hz, 
vinyl CH), 4.57-4.53 (m, 2H), 2.63 (d, 3H, J = 1.0 Hz, allylic CH3), 2.62 (d, 3H, J = 1.0 Hz, allylic CH3), 
1.66 (m, 2H, CH2CH2C(CH3)3, 1.07 (s, 9H, C(CH3)3).  
13C-NMR (2:1 CDCl3:CD3OD, 125 MHz): δ 181.46, 174.98, 161.81, 161.60, 151.64, 149.82, 139.35, 
138.45, 127.38, 127.21, 119.53, 114.74, 43.73, 41.45, 29.97, 28.87, 22.88, 21.81. 
HRMS (ESI-TOF) calcd for C20H23N2O4 (M+H)+: 355.1658, found: 355.1664. 
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Synthesized by General Protocol A. 65% yield. 
1H-NMR (CDCl3, 500 MHz): δ 6.27 (bs, 1H, major rotomer NH), 6.02 (bs, 1H, minor rotomer NH), 3.46 
(t, 2H, J = 6.0 Hz), 3.38 (q, 2H, J = 6.5 Hz), 3.34 (s, 3H), 1.92 (s, 3H), 1.77 (pent, 2H, J = 6.0 Hz). 
13C-NMR (CDCl3, 125 MHz): δ 156.37 (minor), 153.62 (major), 89.82 (minor), 82.95 (major), 75.00 
(major), 72.58 (minor), 71.28 (major), 70.45 (minor), 58.77 (major), 41.34 (minor), 38.04 (major), 30.15 
(minor), 28.87 (major), 3.97 (minor), 3.64 (major).  
 
 
Synthesized by General Protocol C. 96% yield. 
1H-NMR (CDCl3, 500 MHz): δ 6.26 (bs, 1H, NH), 6.21 (d, 1H. J = 1.0 Hz, vinyl CH), 3.49 (t, 2H, J = 6.0 
Hz), 3.42 (q, 2H, J = 6.5 Hz), 3.34 (s, 3H), 2.64 (d, 3H, J = 1.5 Hz), 1.81 (pent, 2H, J = 6.0 Hz). 
13C-NMR (CDCl3, 125 MHz): δ 164.90, 129.40, 105.51, 71.65, 58.93, 38.02, 35.78, 29.07. 
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Synthesized by General Protocols D, E, G, and H. 
1H-NMR (2:1 CDCl3:CD3OD, 500 MHz): δ 6.76 (d, 1H, J = 1.0 Hz, vinyl CH), 6.65 (d, 1H, J = 1.0 Hz, 
vinyl CH), 4.58 (t, 2H, J = 7.5 Hz), 3.70 (t, 2H, J = 6.0 Hz), 2.63 (d, 3H, J = 1.0 Hz, allylic CH3), 2.63 (d, 
3H, J = 1.0 Hz, allylic CH3), 2.06-2.01 (m, 2H). 
HRMS (ESI-TOF) calcd for C17H17N2O5 (M+H)+: 329.1137, found: 329.1129. 
 
Molecular Modeling of DNQ in NQO1 
DNQ (or derivative) was built and a 10 Å water layer was built around the molecule.  The 
DNQ structure was then energy minimized using MOE with a MMFF94x forcefield using gas 
phase calculations and a cutoff of 0.01.  Charges were then fixed using an MMFF94 forcefield.  
The NQO1 structure was downloaded from the PDB (2F1O).  One of the homodimers was 
extracted and protonated.  DNQ was then modeled into the protein active site, using the site of 
dicoumarol to identify the active site.  It was docked using the Dock program in MOE which 
uses Triangle Matching for the placement of the small molecule and London dG for rescoring of 
the placement of the small molecule.  The top 30 configurations were then visually inspected to 
ensure that the molecule was within the active site and pi stacking with the FAD molecule.  
Using LigX, the best configuration was protonated and energy minimized to obtain the 
calculated binding energies. 
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